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CD8 T lymphocytes are a crucial component of the adaptive immune system and 
mediate control of infections and malignancy, but also autoimmunity and allograft 
rejection. Given their central role in the immune system, CD8 T cell responses 
are tightly regulated by costimulatory signals and cytokines. Strategies targeting 
signals that are critical for T cell activation have been employed in a 
transplantation setting to impede alloreactive T cell responses and prevent graft 
rejection. The goal of my thesis is to understand how costimulatory signals and 
inflammation regulate alloreactive CD8 T cell responses and how to target these 
pathways to develop more effective tools to prevent graft rejection.  
Costimulation blockade is an effective approach to prolong allograft survival in 
murine and non-human primate models of transplantation and is an attractive 
alternative to immunosuppressants. I describe a novel murine anti-CD40 
monoclonal antibody that prolongs skin allograft survival across major 
histocompatibility barriers and attenuates alloreactive CD8 T cell responses. I 
find that the pro-apoptotic proteins Fas and Bim function concurrently to regulate 
peripheral tolerance induction to allografts. Activation of the innate immune 
system by endogenous moIecules released during surgery or infections in 
transplant recipients can modulate T cell responses. However, the direct impact 
of inflammation on alloreactive CD8 T cell responses is not clear. Using a T cell 
receptor (TCR) transgenic mouse modeI, I demonstrate that inflammatory stimuli 




differentially regulate donor-reactive CD8 T cell responses by generating distinct 
cytokine milieus. Finally I demonstrate the role of pro-inflammatory cytokines 
stem cell factor (SCF), granulocyte-macrophage colony-stimulating factor (GM-
CSF) and interleukin-3 (IL-3) in improving human B cell development in 
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Rationale and thesis outline 
 
 
T lymphocytes of the adaptive immune system protect the host from 
infections with pathogens and malignancies. An important feature of the immune 
system is the ability to differentiate ‘self’ from ‘non-self’ or ‘altered self’. 
Mechanisms such as negative selection of self-reactive thymocytes are in place 
to ensure that no immune response is mounted to the host’s own tissues. 
Dysregulation of these mechanisms can result in autoimmunity and hence, 
aberrant activation of T cells needs to be prevented. In the context of infections, 
an uncontrolled T cell response can result in immunopathology and tissue 
damage. T cell responses are therefore carefully regulated. 
In the context of organ transplantation graft-reactive T cell responses need 
to be suppressed to facilitate transplant survival. Organ transplantation is the 
only treatment option available for end stage organ failure, but successful organ 
survival requires chronic immune suppression in order to prevent allograft 
rejection. CD8 T cells are crucial mediators of acute rejection and kill target cells 
directly by secreting cytotoxic proteins perforins and granzymes. Understanding 
how CD8 T cells are activated in the context of transplantation will aid in the 
development of therapies to dampen their responses.  
The goal of my thesis research is to examine how costimulation and 
inflammation impact alloreactive CD8 T cell responses. Costimulation blockade 
therapies have shown success in prolonging allograft survival in rodent and non-




skin graft model of transplant rejection, I investigated the role of CD40-CD154 
costimulation in generating alloreactive CD8 T cell responses across major 
histocompatibility barriers. Inflammation resulting from tissue damage during 
organ procurement and surgery as well as infections in the peri-transplant period 
can impact graft survival. Using a TCR transgenic model to study alloreactive 
CD8 T cells in vivo, I examined the impact of two inflammatory agents LPS and 
poly(I:C) on alloreactive CD8 T cell responses. Finally, I studied how cytokines 
influence B cell development and antibody responses using a humanized mouse 
model. 
The following introduction will provide a background on the topics that are 
relevant for this thesis. Although the focus of the thesis is transplantation 
immunology, I have referenced some studies in the fields of viral infection, 
cancer immunity and vaccines since knowledge obtained from these studies has 
directly helped transplantation research. I have provided a brief overview of 
signals required for CD8 T cell activation to set the stage for subsequent topics. I 
have then described the mechanisms of graft rejection, the strategies employed 
by researchers and clinicians to improve graft survival, and the hurdles in 
achieving transplantation tolerance. I have ended with an overview of humanized 
mice and their advantages and limitations in studying human immunity.   
 






 CD8 T cell activation requires antigen processing and presentation by 
antigen presenting cells (APCs). Dendritic cells (DCs), macrophages and B cells 
are the professional APCs of the immune system. DCs sample antigen in the 
local environment and migrate to draining lymph nodes where they present the 
processed antigen to naïve CD8 T cells to stimulate their activation. Upon 
activation, naïve CD8 T cells undergo proliferation and differentiate into effector 
cells or cytotoxic T cells (CTLs) that kill infected cells through secretion of 
perforins and granzymes. Effector CD8 T cells also produce cytokines such as 
IFN-γ and TNF-α. Following elimination of the invading pathogen, effector CD8 T 
cells undergo contraction where 90-95% of the antigen-specific cells die and the 
remaining cells survive to become long-lived memory CD8 T cells (Kaech and 
Cui, 2012). Memory CD8 T cells are highly sensitive to restimulation and the 
memory or secondary T cell response is faster than the primary T cell response 
(Russ et al., 2012).  
Optimal CD8 T cell activation requires 3 signals. The first signal is the 
interaction between the T cell receptor (TCR) and cognate MHC-peptide complex 
on the antigen-presenting cell. The second signal is delivered by costimulatory 
and coinhibitory molecules on the APC and the balance between these 
costimulatory and coinhibitory signals determines the outcome of the CD8 T cell-
APC interaction. The third signal is a cytokine signal. CD8 T cell activation by the 
integration of these three signals drives their differentiation to fully functional 




 CD8 T cells recognize foreign peptides derived from pathogens or tumors 
in the context of self-MHC class I. In the context of tissue transplantation, CD8 T 
cells can recognize foreign peptides in the context of foreign MHC, a process 
termed allorecognition (Afzali et al., 2008), which I have described in a 
subsequent section. Classical MHC class I antigen presentation involves 
peptides that are generated in the cytosol upon degradation of proteins by the 
proteasome. These peptides are translocated into the endoplasmic reticulum 
(ER) by transporter associated with antigen processing (TAP) where they may 
undergo further trimming by aminopeptidases to generate 8-10 amino acid long 
peptides that are then loaded onto MHC class I molecules. The peptide-MHC 
complex is transported to the cell surface through the Golgi complex and exocytic 
vesicles. This pathway thus allows CD8 T cells to respond to infected or 
neoplastic cells displaying foreign or modified self-peptides respectively (Blum et 
al., 2013). Alternatively, APCs may capture exogenous antigen by endocytosis 
and present it on MHC class I to CD8 T cells, a process known as cross-
presentation. This mechanism is important for pathogens that do not directly 
infect the APC. DCs are the main cross-presenting APCs in vivo. There are two 
pathways for cross-presentation of exogenous antigens: cytosolic and vacuolar 
(Joffre et al., 2012). In the cytosolic pathway, antigen is transferred to the cytosol 
where it is processed by the classical MHC I antigen presentation machinery. 




where the antigen is cleaved by endosomal proteases and loaded onto MHC-I 
directly within the endosome.  
 The α:β heterodimeric TCR associates with the CD3 complex consisting of 
CD3γ, CD3δ and two CD3ε chains along with a homodimer of ζ chains to form 
the T cell receptor complex. The T cell receptor complex has ITAMs 
(immunoreceptor tyrosine-based activation motifs) that are phosphorylated by 
Src kinases Lck and Fyn. The co-receptor CD8 binds MHC-I and clusters with 
the TCR complex to facilitate phosphorylation of the ITAMs and subsequent 
signaling into the cell. The signal transduction cascade results in the activation of 
transcription factors NF-κB, NFAT and AP-1 that stimulate transcription of genes 
involved in T cell proliferation and differentiation (Smith-Garvin et al., 2009).  
 
CD8 T cell activation: signal 2 (costimulation) 
 
 
The recognition of cognate MHC-peptide complexes by the T cell receptor 
triggers TCR signaling, but the cumulative effect of costimulatory and coinhibitory 
signals regulates T cell function and fate. Most costimulatory and coinhibitory 
molecules belong to the CD28 family or the tumor necrosis factor receptor 
(TNFR) family (Ford, 2016). Since the focus of my thesis is alloreactive T cells, I 
have described in this section the costimulatory and coinhibitory molecules that 





CD28 was the first costimulatory molecule identified and was shown to augment 
proliferation and IL-2 production by T cells after TCR stimulation thus amplifying 
the response (June et al., 1987). CD28 is constitutively expressed on T cells and 
binds B7 molecules B7-1 or CD80 (Linsley et al., 1990) and B7-2 or CD86 
(Azuma et al., 1993; Hathcock et al., 1993) expressed on the surface of APCs. 
The expression of B7 molecules is upregulated when the APC senses pathogen 
associated molecular patterns (PAMPs) through innate immune receptors. 
Ligation of CD28 with B7 molecules activates several signaling pathways and 
delivers a positive signal for T cell survival and growth. The coinhibitory receptor 
CTLA4 (cytotoxic T lymphocyte-associated antigen 4) was subsequently 
identified (Linsley et al., 1991). CTLA4 is induced on T cells upon activation, 
binds CD80 and CD86 with higher affinity than CD28 and negatively regulates T 
cell responses. After the CD28-B7 interaction was characterized, the ‘two signal’ 
model of T cell activation was accepted, which entailed that both signal 1 (the 
specific signal between TCR and peptide-MHC complex) and signal 2 (the non-
specific signal between CD28 and B7) are required for T cell proliferation and 
function (June et al., 1994). 
CD40/CD154 
CD40, a TNFR family member, was first identified on bladder carcinoma cells 
and found to be expressed on B cells (Paulie et al., 1985). The CD40 ligand 
(CD154) was identified on activated CD4 helper T cells and its interaction with 




et al., 1992). Subsequent studies defined roles for the CD40-CD154 signal in 
promoting T cell immunity (Caux et al., 1994; Cella et al., 1996). CD40 is 
constitutively expressed on B cells, macrophages and DCs and expression is 
inducible on parenchymal cells such as epithelia, endothelia, fibroblasts and 
keratinocytes upon inflammation (Larsen and Pearson, 1997). CD154, the ligand 
for CD40, is expressed predominantly on activated CD4 T cells, although 
expression has also been demonstrated on activated B cells, smooth muscle 
cells, DCs and platelets (Ma and Clark, 2009). Ligation of CD154 on activated 
CD4 T cells with CD40 on APCs promotes APC maturation by increasing 
expression of CD80, CD86, MHC class I and II and production of cytokines. 
Moreover, CD40 signaling into DCs increases DC life span by promoting 
upregulation of the anti-apoptotic factor Bcl-xL in an NF-κB dependent manner 
(Wong et al., 1997). Activated DCs can then effectively prime naïve CD8 T cells. 
Some studies have reported CD154 expression on activated CD8 T cells (Han et 
al., 2007; Hernandez et al., 2007; Wong et al., 2008). In the absence of CD4 T 
cells, interaction between CD8 T cell expressed CD154 and DC expressed CD40 
contributes to the generation of a maximal primary CD8 T cell response 
(Hernandez et al., 2007).  
OX40/OX40L 
Originally identified as a T cell activation marker, OX40 was discovered to have 
costimulatory function (Calderhead et al., 1993). OX40 is a member of the TNFR 




Although TCR signaling is sufficient to induce OX40 expression, CD28-B7 
interactions enhance and sustain its expression (Walker et al., 1999). OX40L is 
expressed on APCs upon CD40 stimulation or activation of Toll-like receptors 
(TLRs) (Godfrey et al., 1994). OX40 signaling directly promotes proliferation and 
survival of CD8 T cells after antigen encounter and generation and maintenance 
of memory CD8 T cells (Croft et al., 2009).    
LFA-1/ICAM-1 and VLA-4/VCAM-1 
The expression of the integrin αLβ2 or LFA-1 (lymphocyte function-associated 
antigen 1) on T cells is crucial for cell arrest and migration on surfaces 
expressing its ligand ICAM-1 (intercellular adhesion molecule 1) and for forming 
immunological synapses with APCs reducing the amount of antigen necessary 
for T cell activation (Hogg et al., 2011). TCR stimulation activates LFA-1, which in 
turn enhances CD8 T cell responses by triggering Erk1/2 signaling (Li et al., 
2009). LFA-1 signaling is critical for effective memory CD8 T cell responses (Cox 
et al., 2013; Scholer et al., 2008). 
VCAM-1 (vascular cell adhesion molecule 1) is expressed on endothelial cells at 
low levels and upregulated upon inflammation. T cell activation increases 
expression of α4β1 integrin or VLA-4 (very late antigen 4) that promotes T cell 
migration to sites of inflammation as well as interactions with proteins of the 
extracellular matrix that can enhance TCR signaling. VLA-4 also contributes to 





ICOS (inducible costimulatory molecule), a CD28 family member, is inducibly 
expressed on T cells upon activation and has overlapping functions with CD28 in 
regulating CD8 T cell proliferation and function (Nurieva et al., 2009). 
4-1BB/4-1BBL  
4-1BB, a TNFR superfamily member, is inducibly expressed upon T cell 
activation and CD28 signaling and its interaction with 4-1BBL promotes CD8 T 
cell survival by upregulating anti-apoptotic proteins Bcl-xL and Bfl-1 (Lee et al., 
2002) and downregulating pro-apoptotic protein Bim (Sabbagh et al., 2008). This 
interaction also promotes CD8 T cell proliferation and amplifies CTL responses in 
vivo (Shuford et al., 1997).  
CD27/CD70 
CD27, a TNFR superfamily member, is constitutively expressed on naïve CD4 
and CD8 T cells (Nolte et al., 2009). Although TCR stimulation elevates CD27 
expression, CD27 is downregulated after T cells undergo multiple rounds of 
division and differentiate to effector cells. CD70 is transiently expressed on 
activated T cells and DCs following TCR stimulation and CD40/TLR signaling 
respectively. CD27/CD70 interactions promote effector and memory T cell 
generation by inducing proliferation and survival of T cells and are critical for the 
quality of memory CD8 T cell responses (Nolte et al., 2009)  
TIM family members 
The TIM (T cell immunoglobulin mucin) family member TIM-1 is expressed on 




upon interaction with its ligand TIM-4 on APCs (de Souza et al., 2005; Meyers et 
al., 2005). TIM-3 is a coinhibitory molecule expressed on activated CD4 T cells 
and interacts with its ligand galectin-9 to inhibit T cell proliferation and cytokine 
production (Sabatos et al., 2003).  
PD-1/PD-L1 
PD-1 (programmed death 1), a member of the CD28 family, is expressed on 
activated T cells and functions in the effector phase of an immune response to 
negatively regulate the response. The ligand PD-L1 is widely expressed in 
peripheral tissues whereas expression of the ligand PD-L2 is restricted to DCs 
and monocytes and can be induced on other cell types depending on the local 
microenvironment. PD-1 has a higher binding affinity for PD-L2. Ligation of PD-1 
with its ligands reduces the magnitude of an ongoing T cell response 
(Buchbinder and Desai, 2016). Elevated and sustained expression of PD-1 is a 
hallmark of T cell ‘exhaustion’, a state characterized by progressive loss of T cell 
effector function and proliferative potential, resulting from persistent exposure to 
antigen and inflammation observed in chronic infections and cancer (Wherry and 
Kurachi, 2015). PD-1 blockers nivolumab and pembrolizumab have shown 
therapeutic benefits in many cancer patients by reinvigorating the anti-tumor T 
cell response (Buchbinder and Desai, 2016).  
Costimulatory and coinhibitory molecules regulate specific aspects of T cell 




cells and primary or recall responses and contribute to the quality of the 
response. 
 
CD8 T cell activation: signal 3 (cytokines) 
 
Although signal 1 (TCR stimulation) and signal 2 (costimulation) can 
initiate proliferation of naïve CD8 T cells, they are not sufficient to develop 
optimal effector function and formation of an effective memory population. In vitro 
experiments demonstrated that IL-12 (Curtsinger et al., 1999) and type I 
interferons (Curtsinger et al., 2005) provide a signal directly to CD8 T cells to 
stimulate clonal expansion and differentiation to effector CD8 T cells. Using the 
adoptive transfer of antigen-specific T cells deficient in receptors for IL-12 and 
IFNα/β into wild type mice, several investigators reported the requirement for 
these two cytokines in generating optimal CD8 T cell responses to viral, bacterial 
and parasitic pathogens as well as tumors and transplants (Curtsinger and 
Mescher, 2010). These studies also illustrated that these cytokines are important 
for generating optimal memory CD8 T cells. The ‘three signal’ model of T cell 
activation is widely accepted and includes signal 3 as a cytokine signal with IL-12 
and type I IFN being signal 3 for CD8 T cells. IL-1 is thought to be the signal 3 
cytokine for the activation of naïve CD4 T cells (Curtsinger and Mescher, 2010).  
 Conceptually, signal 3 cytokines could promote accumulation of effector 
CD8 T cells by increasing survival or proliferation during the expansion phase of 




type I IFN extend the division of CD8 T cells in response to IL-2 by sustaining the 
expression of the high affinity IL-2 receptor CD25 (Starbeck-Miller et al., 2014). 
Gene expression analysis of CD8 T cells stimulated with signal 1+2 or signal 
1+2+3 revealed significant changes between the two groups that included genes 
involved in CD8 T cell proliferation, survival, function, migration as well as fate 
determining transcription factors T-bet and Eomes (Starbeck-Miller et al., 2014). 
Histone deacetylase inhibitors mimicked the effects of IL-12 and type I IFN 
signaling indicating that signal 3 cytokines sustain gene expression by promoting 
histone acetylation (Agarwal et al., 2009). CD4 T cells provide help to CD8 T 
cells by stimulating DCs to produce signal 3 cytokines.  
 
Innate immunity: cross-talk with adaptive immunity 
 
The innate immune system forms the first line of defense against 
infections and responds rapidly to invading pathogens. Cells are well-equipped 
with molecules that serve as sensors of conserved structures of pathogens 
termed ‘pathogen associated molecular patterns’ or PAMPs. These sensors, 
known as ‘pattern recognition receptors’ or PRRs are germline-encoded and 
upon sensing PAMPs, transduce signals that communicate to the cells the 
presence of a pathogen and trigger the production of interferons and 






Pattern recognition receptors  
Based on protein domain homology, PRRs are grouped into 5 families (Brubaker 
et al., 2015). 
Toll-like receptors (TLRs) 
TLRs are the best-characterized family of pattern recognition receptors and 
contain the TIR (Toll/interleukin-1 receptor) domain (Brubaker et al., 2015). They 
are transmembrane proteins located either on the cell surface where they sense 
extracellular pathogens or on endosomal membranes where they sense 
pathogens within the endosome. There are 10 known TLRs in humans (TLR1-
TLR10) and 12 known TLRs in mice (TLR1-TLR9 and TLR11-TLR13). Cell 
surface TLRs include TLR1, TLR2, TLR4, TLR5, TLR6 and human TLR10 and 
endosomal TLRs include TLR3, TLR7, TLR8, TLR9 and mouse TLR11, TLR12 
and TLR13 (Kawasaki and Kawai, 2014). TLR2 heterodimerizes with TLR1 or 
TLR6 to recognize distinct lipopeptides, peptidoglycan, lipoteichoic acids, 
zymosan and mannan. TLR4 recognizes bacterial lipopolysaccharide as well as 
several endogenous molecules released by stressed cells known as DAMPs 
(damage-associated molecular patterns) (Poltorak et al., 1998). TLR5 binds 
flagellin from flagellated bacteria (Hayashi et al., 2001). TLR3 and TLR7 
recognize viral nucleic acids double-stranded RNA (dsRNA) and single-stranded 
RNA (ssRNA) respectively (Alexopoulou et al., 2001; Hemmi et al., 2002). TLR9 
predominantly recognizes unmethylated CpG DNA motifs that are not common in 




viral and bacterial RNA (Heil et al., 2004; Oldenburg et al., 2012). TLR11 and 
TLR12 recognize profilin from Toxoplasma gondii (Koblansky et al., 2013; 
Yarovinsky et al., 2005).  
C type lectin receptors (CLRs) 
CLRs contain the C-type lectin-like domain and are soluble or transmembrane 
proteins. They recognize fucose, mannose and glucan carbohydrate structures of 
diverse pathogens (Geijtenbeek and Gringhuis, 2009) CLR signaling activates 
NF-κB and regulates TLR induced gene transcription.   
RIG-I-like receptors (RLRs) 
RLRs are cytosolic RNA sensors containing a DExD/H-box helicase core (Wu 
and Chen, 2014). These receptors differentiate ‘non-self’ from ‘self’ RNA by 
detecting 5’ triphosphate RNA, long double stranded RNA and viral genome 
specific sequences such as the poly-uridine region of hepatitis C virus. RIG-I 
(retinoic acid-inducible gene I), MDA5 (melanoma differentiation-associated 
protein 5) and LGP2 (laboratory of genetics and physiology 2) are the three 
known members of this family. dsRNA sensing by RIG-I and MDA-5 is 
responsible for IFN production in response to viral infection (Yoneyama et al., 
2004). 
NOD-like receptors (NLRs) 
NLRs are intracellular sensors characterized by a nucleotide-binding 




caspase-1 to stimulate production of inflammatory mediators such as IL-1β 
(Chen et al., 2009a). 
AIM2-like receptors (ALRs) 
ALRs are intracellular DNA sensors containing a pyrin domain for protein-protein 
interactions and a HIN-200 DNA-binding domain. AIM2 (absent in melanoma 2) 
and IFI16 (interferon gamma inducible protein 16) are the known ALRs. These 
sensors are a component of inflammasomes, cytosolic multiprotein complexes 
that trigger production of IL-1β and IL-18 and a form of inflammatory cell death 
known as pyroptosis (Vanaja et al., 2015). 
 
LPS and poly(I:C) 
LPS and poly(I:C) are recognized by distinct cellular receptors (Fig. 1.1). 
TLR4 signaling upon LPS binding involves a multireceptor complex including the 
proteins LBP (LPS binding protein) (Tobias et al., 1986), CD14 (Wright et al., 
1990) and MD2 (O'Neill et al., 2013). Upon LPS transfer to TLR4-bound MD2, 
TLR4 dimerizes and initiates a signal transduction cascade that requires adaptor 
proteins. The sorting adaptor TIRAP (TIR-containing adaptor protein) recruits the 
signaling adaptor MyD88 (myeloid differentiation primary response gene 88) to 
trigger signaling culminating in the activation of transcription factors NF-κB and 
AP-1 and the resultant transcription of proinflammatory cytokine genes. Once 
MyD88 signaling is initiated, TLR4 is endocytosed with the help of CD14. The 




adaptor TRIF (TIR domain-containing adaptor inducing IFNβ) to trigger signaling 
culminating in the activation of transcription factors NF-κB and IRF3/IRF7 and 
transcription of type I interferon genes. Recently it was found that the murine 
non-canonical inflammasome caspase-11 directly binds intracellular LPS (Shi et 
al., 2014). When LPS reaches high concentrations in endotoxemia, its aberrant 
localization to cytosol activates caspase-11 that mediates pyroptotic cell death 
(Hagar et al., 2013).   
Poly(I:C) is a synthetic dsRNA analog that binds TLR3 within endosomes 
and signals through the adaptor TRIF to activate NF-κB and IRF3/IRF7. Poly(I:C) 
is also recognized by RIG-I or MDA-5 depending on its length. MDA5 prefers 
long fragments (>4 kb) whereas RIG-I prefers enzyme digested shorter 
fragments (~300bp) (Kato et al., 2008). Both RNA sensors use the adaptor 
protein MAVS (mitochondrial antiviral-signaling protein) to initiate a signaling 
cascade that results in NF-κB and IRF3 activation and subsequent type I IFN 
production. Poly(I:C) is also recognized by the serine/threonine kinase PKR 
(protein kinase R) that suppresses the initiation of translation by phosphorylating 
eukaryotic initiation factor 2 and inhibits viral replication (Balachandran et al., 
2000). Moreover, a triad of helicases DDX1, DDX21 and DHX36 was shown to 
bind poly(I:C) in the cytosol and use the TRIF pathway to stimulate type I IFN 
production (Zhang et al., 2011b). 
 




 The innate and adaptive immune systems work in a co-ordinated fashion 
to protect the host from pathogens. PRR signaling regulates the adaptive 
immune response at multiple stages of the response.  
PRR signaling on DCs initiates DC maturation and migration to lymph 
nodes. TLR stimulation of immature DCs reduces the expression of the 
inflammatory chemokine receptor CCR6 and increases expression of lymphoid 
chemokine receptor CCR7 that enables DC migration from tissues to draining 
lymph nodes. (Dieu et al., 1998; Sallusto et al., 1998). TLR signaling through 
MyD88 increases expression of costimulatory molecules CD80 and CD86 and 
MHC-II on DCs and production of cytokines thereby facilitating efficient priming of 
naïve T cells (Pasare and Medzhitov, 2004; Schnare et al., 2001). As DCs 
mature, they lose their phagocytic potential. TLR4 stimulation with LPS was 
reported to transiently enhance antigen capture and subsequent cross-
presentation if antigen was delivered at the same time as LPS (West et al., 
2004). However, pre-treatment with LPS or poly(I:C) downregulated antigen 





Fig. 1.1. LPS and poly(I:C) are recognized by distinct receptors. 
 
 
Fig. 1.1. LPS and poly(I:C) are recognized by distinct receptors. LPS from Gram 
negative bacterial membrane binds to CD14/TLR4/MD2 complex and signals through 
the adaptor MyD88 to activate NF-κB and transcription of inflammatory cytokine genes. 
Endocytosed LPS signals through the adaptor TRIF to phosphorylate and activate 
IRF3/IRF7 and transcription of type I interferon genes. Poly(I:C), a viral dsRNA mimetic, 
binds the endosomal receptor TLR3 and signals through TRIF. The triad comprising 
DDX1, DDX21 and DHX36 helicases sense poly(I:C) in the cytoplasm and use the TRIF 
pathway. Cytosolic MDA5 uses the adaptor MAVS and signals through TRIF to stimulate 
transcription of type I interferon genes. The cytoplasmic sensor PKR upon recognizing 










































CD4 T cells may differentiate into Th1, Th2, Th9, Th17, Th22 or Tfh cells 
depending on the cytokines they encounter which in turn depends on the kind of 
microbial infection that is sensed by PRRs (DuPage and Bluestone, 2016). Th1 
cells are induced upon intracellular bacterial and viral infection; Th2 and Th9 
cells are induced upon extracellular parasite infections and Th17 cells are 
induced upon fungal and extracellular bacterial infections. A seminal study 
showed that TLR4 stimulation of DCs relieves conventional CD4 T cells from 
Treg-mediated suppression in an IL-6 dependent manner (Pasare and 
Medzhitov, 2003). Besides regulating CD4 T cell differentiation and function, 
TLR ligands regulate CTL function as well as antibody responses. TLR3 and 
TLR9 ligands are potent stimulators of cytotoxic CD8 T cell responses (Jelinek et 
al., 2011). Because of the ability of TLR ligands to costimulate T as well as B cell 
responses, they are desirable adjuvants for peptide or soluble protein based 
vaccines (Dowling and Mansell, 2016).  
 Although PRR signaling promotes the generation of T cell responses, 
emerging evidence indicates that it can also inhibit responses. TLR2 and TLR4 
signaling has been associated with suppression of CD8 T cell responses. TLR4 
engagement abrogated TLR3 induced priming (Mandraju et al., 2014) and 
function (Bogunovic et al., 2011) of CD8 T cells by altering the recruitment of DC 
subsets to draining lymph nodes and promoting secretion of the suppressive 
cytokine IL-10 respectively. Moreover, LPS has been shown to induce IL-10-




derived suppressor cells (MDSCs) (De Wilde et al., 2009) that suppress CD8 T 
cell immunity. TLR2-TLR6 binding lipopeptides were recently shown to suppress 
T cell immunity by inducing MDSCs in an IL-6 dependent manner (Skabytska et 
al., 2014). IL-6 can also act directly on CD8 T cells to inhibit their function (Wu et 
al., 2015). Clinical and experimental sepsis inhibits T cell immunity by inducing 
apoptosis of naïve T cells and lymphopenia (Danahy et al., 2016).  
 
T cell apoptosis 
 
 
Apoptotic cell death is characterized by cell shrinkage, plasma membrane 
blebbing and formation of apoptotic bodies, chromatin condensation and DNA 
fragmentation (Elmore, 2007). Apoptosis of T and B lymphocytes is a tightly 
regulated process. Lymphocytes are deleted during development in the thymus 
and bone marrow due to unproductive rearrangements of genes that form the T 
and B cell receptors, inefficient recognition of self-ligands by the TCRs/BCRs 
(positive selection) and high affinity binding of developing lymphocytes to self-
ligands (negative selection).  Deletion of lymphocytes in the primary lymphoid 
organs serves to eliminate non-functional and potentially autoreactive cells and 
prevent autoimmunity. Clonal deletion of lymphocytes occurs in the periphery 
after an invading pathogen has been cleared from the system as the immune 
response wanes. Deletion at this stage is important to prevent immunopathology 
and establish homeostasis. Just as suboptimal death of lymphocytes is 




lymphoma depending on the context, uncontrolled death of lymphocytes can 
manifest as immunodeficiency that can be detrimental to the host. Hence, 
checkpoints exist in the life of lymphocytes to ensure that apoptosis occurs in a 
controlled manner. Two distinct pathways mediate apoptosis of T cells: extrinsic  
(death-receptor mediated) and intrinsic  (mitochondrial) (Krammer et al., 2007). 
These pathways are not mutually exclusive and members of one pathway can 
regulate the other. 
The extrinsic pathway is activated upon binding of death ligands to their 
cognate death receptors. The best-characterized death receptor/ligand pairs 
include Fas/FasL, TNFR1/TNF, DR3/Apo3L, DR4/Apo2L and DR5/Apo2L 
(Pobezinskaya and Liu, 2012). The death receptors belong to the TNF receptor 
superfamily and have an intracellular ‘death domain’ that transduces signals into 
the cell. Activation of the death receptor is followed by the formation of the death-
inducing signaling complex (DISC) that includes an adaptor protein and 
procaspase-8. Formation of the DISC triggers autoproteolytic activation of 
procaspase-8. The resulting caspase-8 is an initiator caspase that activates 
executioner caspases caspase-3 and caspase-7 resulting in apoptosis.  
The intrinsic pathway is activated by a variety of stimuli such as growth 
factor deprivation, cytotoxic drugs, irradiation and extracellular stresses and is 
mediated by Bcl-2 family members (Youle and Strasser, 2008). Bcl-2 family 
proteins are grouped into three classes: the pro-survival proteins Bcl-2, Bcl-xL, 




domain-only proteins such as Bim, Bik, Bad, Noxa and Puma that are regulators 
of anti-apoptotic proteins. Activation of Bim by death stimuli activates pro-
apoptotic proteins Bax and Bak that disrupt the outer mitochondrial membrane 
resulting in a loss of mitochondrial transmembrane potential and the release of 
cytochrome c. Cytochrome c binds Apaf-1 and procaspase-9 to form an 
apoptosome. Upon activation, the initiator caspase-9 activates executioner 
caspase-3, caspase-6 and caspase-7. Thus both extrinsic and intrinsic apoptotic 
pathways converge at the executioner caspases that cleave cellular substrates 
resulting in cell death. Anti-apoptotic proteins Bcl-2 and Bcl-xL repress Bax and 
Bak. BH3-only proteins relieve this repression by direct binding and inhibition of 
Bcl-2 and Bcl-xL.  
The death receptor Fas is involved in activation induced cell death (AICD), 
a form of death induced upon restimulation of the TCR (Green et al., 2003). Mice 
deficient in functional Fas (Faslpr mice) (Watanabe-Fukunaga et al., 1992) and 
functional FasL (Fasgld mice) (Takahashi et al., 1994) develop a 
lymphoproliferative disorder characteristic of humans with autoimmune 
lymphoproliferative syndrome caused by mutations in the Fas gene (Rieux-
Laucat et al., 1995). Likewise, deficiency of the mitochondrial apoptosis inducer 
Bim results in autoimmunity in mice (Bouillet et al., 1999). These results suggest 
that Fas and Bim play a role in negative selection and/or peripheral deletion of 
autoreactive T cells that escape negative selection. Bim is indispensable for T 




because of a dearth of cytokines occurring after the antigen is cleared (Pellegrini 
et al., 2003; Weant et al., 2008). On the other hand, Fas is necessary for 
contraction following LCMV but not HSV infection (Pellegrini et al., 2003; Weant 
et al., 2008). It has been proposed that the strength of the signal received 
through the TCR in the periphery determines the ensuing response and its 
contraction (Bouillet and O'Reilly, 2009). Mice with combined deficiency in Fas 
and Bim exhibit autoimmunity and blocks in contraction of antiviral immune 
responses larger than those of mice with single Fas or Bim deficiency suggesting 
the cooperation of these proteins in regulating death of autoreactive and viral 






When cells or tissues are transplanted between genetically different individuals of 
the same species, the immune system of the recipient recognizes the donor graft 
as ‘foreign’, a process termed as allorecognition. Alloantigens comprise both 
major and minor histocompatibility antigens. The major histocompatibility 
complex (MHC) of humans, located on chromosome 6, is known as the HLA 
complex. In mice, the MHC is located on chromosome 17 and known as the H-2 
complex. Minor histocompatibility antigens are proteins that are polymorphic and 
hence, may vary between the donor and recipient even if they are matched at the 




donor graft. Rejection is classified as hyperacute, acute and chronic based on 
the time it takes to reject the graft.   
 
Hyperacute rejection 
Hyperacute rejection develops within minutes to hours of organ transplantation 
(Moreau et al., 2013). This form of rejection is mediated by pre-existing 
antibodies that originate in the graft recipient from previous exposure to donor 
antigen through blood transfusions, previous transplantation or pregnancy. Pre-
formed antibodies bind alloantigen expressed on the endothelium of the donor 
graft vasculature triggering the complement cascade and stimulating endothelial 
cells to secrete von Willebrand procoagulant factor resulting in thrombosis, 
recruitment of neutrophils and macrophages, parenchymal injury and graft 
necrosis (Moreau et al., 2013) This form of rejection is now an uncommon event 
because of routine pretransplant checking for ABO compatibility and cross-
matching between donor cells and recipient sera for pre-formed donor-specific 
antibodies (Mulley and Kanellis, 2011). Hyperacute rejection can be modeled in 
rodents using passive transfer of high-titer antibodies to Rag-/- xenograft 
recipients (Ding et al., 2008) or high-titer antibodies with xenograft complement 








Acute rejection in graft recipients occurs between 1 week and several 
months after transplantation and results in rapid graft loss (Moreau et al., 2013). 
This form of rejection is mediated by donor-reactive T cells (cellular rejection) 
and/or B cells (humoral rejection).  
Upon activation by alloantigen presenting DCs, naïve CD4 T cells 
differentiate into Th1 and Th17 cells in the proinflammatory environment (Moreau 
et al., 2013). Similarly, naïve CD8 T cells are activated by DCs and differentiate 
into cytolytic effectors with help from CD4 T cells. The CTLs migrate to the graft 
where they recognize their allogeneic targets and induce apoptosis thereby 
mediating graft rejection. Besides aiding CTL differentiation, CD4 helper T cells 
secrete cytokines that stimulate B cells to trigger humoral rejection and 
recruitment and activation of other cell types such as macrophages and NK cells. 
 B cells, upon terminal differentiation to plasma cells, secrete 
alloantibodies that play an important role in acute rejection. Acute antibody-
mediated rejection (AMR) is dependent on complement activation and diagnostic 
features of AMR include donor-specific antibodies (DSA) in the serum and C4d 
deposition (Stegall et al., 2012). Immunoglobulin (Ig) knockout mice show 
delayed rejection of cardiac allografts and passive transfer of complement 
activating antibodies promotes acute rejection mediated by T cells (Wasowska et 




in Rag-/- allograft recipients by the passive transfer of sera containing extremely 
high-titer alloantibodies (Nozaki et al., 2007). 
 Other immune cell types contribute to acute graft rejection but are neither 
necessary nor sufficient to mediate rejection (LaRosa et al., 2007). NK cells may 
promote graft rejection by directly inducing apoptosis in the graft epithelial cells 
via the NKG2D receptor (Zhang et al., 2008), amplify intragraft inflammation by 
producing chemokines (Kondo et al., 2000), sensitize endothelial cells (ECs) to 
CTL attack by inducing upregulation of MHC-I and MHC-II on the ECs in an IFN-
γ dependent manner (Ayalon et al., 1998; McDouall et al., 1997) or directly 
mediate graft rejection upon maximal stimulation by IL-15 (Kroemer et al., 2008). 
Macrophages comprise a significant proportion of the graft infiltrate in rejecting 
grafts and promote tissue damage by producing inflammatory cytokines as well 
as effector molecules such as reactive oxygen and nitrogen species and may act 
as APCs to primed CD4 T cells (Wyburn et al., 2005). Neutrophils migrate into 
the grafts early after transplantation (Celli et al., 2011) and produce chemokines 
that recruit T cells to the graft (Morita et al., 2001). Eosinophils infiltrate into the 
graft and mediate tissue damage by releasing inflammatory effectors and cationic 









Chronic rejection is a gradual process occurring over months or years after 
transplantation (Moreau et al., 2013). With improvements in immunosuppressive 
medications lowering the risk of acute rejection, chronic rejection is now the 
leading cause of graft failure. The main feature of chronic rejection is progressive 
occlusion or intimal hyperplasia of blood vessels along with fibrosis of the graft 
tissue, processes that culminate in ischemia, cell death and graft failure (Chong 
et al., 2013). Several immunological and non-immunological factors such as 
multiple acute rejection episodes, immunosuppressant side effects, viral 
infection, hypertension and hyperlipidemia contribute to the pathogenesis of 
chronic rejection (Li and Yang, 2009). T cells and donor specific antibodies are 
the main immunological mediators of chronic rejection, although innate immune 
cells also play a role in the process. Alloantibodies activate endothelial cells to 
produce growth factors that promote the accumulation of extracellular matrix, a 
lesion of fibrosis. Endothelial cell activation also stimulates proliferation of 
smooth muscle cells and recruitment of inflammatory cells through release of 









Mechanisms of T cell allorecognition  
T cells, predominant mediators of acute graft rejection, can recognize 
alloantigens by 3 pathways: direct, indirect and semi-direct (Fig. 1.2). 
 
Direct allorecognition 
APCs from the donor are co-transferred with the graft during organ 
transplantation. These APCs, termed as ‘passenger leukocytes’ migrate out of 
the graft to the secondary lymphoid tissues where they activate recipient T cells 
specific for the alloantigen, a process termed ‘direct recognition’ (Talmage et al., 
1976). The principal passenger leukocytes capable of activating recipient T cells 
are DCs (Talmage et al., 1976). Approximately 1-10% of T cells in any individual 
are specific for foreign MHC-peptide complexes (Suchin et al., 2001; 
Veerapathran et al., 2011) whereas approximately 0.01% of the T cells recognize 
a foreign peptide bound to a self-MHC. Two models have been proposed to 
explain this unusually high precursor frequency of T cells with direct 
allospecificity. The peptide-centric model or the ‘binary complexes hypothesis’ 
postulates that foreign MHC structurally similar to self-MHC will bind an entire 
pool of foreign peptides that will activate recipient T cells with a wide range of 
specificities (Matzinger and Bevan, 1977). The MHC-centric model or the ‘high 
determinant density’ hypothesis postulates that TCRs will recognize foreign MHC 
with polymorphic amino acid residues in the TCR docking sites regardless of the 




APCs will activate high numbers of recipient T cells (Bevan, 1984). Direct 
recognition by CD8 T cells triggers a potent cytolytic response that destroys the 
graft. Studies have also showed that CD4 cells with direct allospecificity are 
sufficient to mediate acute rejection (Pietra et al., 2000). Since donor-derived 
APCs die over time, the direct pathway is believed to predominate during the 
early phase of acute rejection. 
 
Indirect allorecognition 
When allopeptides are presented to recipient T cells by recipient APCs in a self-
MHC restricted manner, the process is termed ‘indirect allorecognition’. In this 
scenario, the allopeptide may be derived from the foreign MHC molecule or a 
minor alloantigen. There are three possible mechanisms by which recipient APCs 
can acquire donor antigens. First, alloantigens from the graft may be shed into 
the circulation and engulfed by recipient APCs in secondary lymphoid tissue. 
Second, donor cells may be engulfed by recipient APCs in secondary lymphoid 
tissue. Third, recipient APCs may migrate to the graft, capture alloantigen and 
then migrate out to secondary lymphoid tissue. Although CD4 T cells are 
predominantly activated by allopeptides presented in the context of self-MHC II, 
CD8 T cells activated by cross-presentation can also contribute to graft rejection 
(Valujskikh et al., 2002). The requirement for antigen processing and 
presentation in the indirect pathway correlates with slower graft-reactive 




precursor frequency of T cells with indirect specificity is orders of magnitude less 
than T cells with direct specificity, the indirect pathway dominates in the later part 
of acute rejection after the passenger leukocytes have been eliminated and in 
chronic rejection.    
 
Semi-direct allorecognition 
Recipient APCs can acquire intact donor MHC-peptide complexes by direct cell-
to-cell contact (trogocytosis) (Joly and Hudrisier, 2003) or endocytosis of donor 
derived vesicles or exosomes (Thery et al., 2002), a process termed ‘cross-
dressing’  (Herrera et al., 2004). The process whereby recipient APCs acquire 
donor MHC-peptide complexes and activate CD8 T cells directly is referred to as 
semi-direct recognition. This mechanism allows the same recipient APC to 
activate CD8 T cells by semi-direct pathway and CD4 T cells by indirect pathway 
and thus, linked help to occur. The semi-direct pathway is now known to activate 
direct specificity CD8 T cells long after the passenger leukocytes have been 








Fig. 1.2. Mechanisms of allorecogntion. The direct pathway involves recognition of donor 
MHC-peptide complexes on donor APCs by recipient T cells. The indirect pathway 
involves uptake, processing and presentation of donor-derived alloantigen by recipient 
APCs to recipient T cells. The semi-direct pathway involves acquisition of donor MHC-
peptide complexes by recipient APCs and direct presentation to CD8 T cells. In this 
pathway, CD4 T cells recognize donor derived alloantigen presented on recipient MHC 

















Allogeneic MHC or  




Allogeneic MHC or  








Transplantation tolerance: why and how? 
 
Immunosuppressants: old and new 
Transplant recipients receive immunosuppressants in order to prevent 
graft rejection by the immune system. The first successful renal transplantation 
was performed in 1954 at the Peter Bent Brigham Hospital in Boston under the 
direction of Joseph Murray between identical twins in the absence of 
immunosuppression (Merrill et al., 1956). This event opened up the possibility of 
extending transplantation to non-identical twins and stimulated research into 
immunosuppressants. The first immunosuppressant identified was cortisone, a 
glucocorticosteroid, which was used in combination with sub-lethal doses of total 
body irradiation (TBI) in the 1950s (Sayegh and Carpenter, 2004). Bone marrow 
aplasia developing as a result of TBI made the patients extremely susceptible to 
infections and death. After Robert Schwartz and William Dameshek reported the 
efficacy of the antimetabolite 6-mercaptopurine (6-MP) in rabbits in 1959 
(Schwartz et al., 1959), variants of 6-MP were synthesized and screened and the 
candidate drug azathioprine was tested in clinical trials along with corticosteroids 
in 1962. This combination improved one-year allograft survival rate to 40-50%. 
The introduction of the depleting reagent anti-thymocyte globulin (ATG) in late 
1960s further increased the one-year allograft survival rate to 70% (van Sandwijk 
et al., 2013). The advent of the calcineurin inhibitor cyclosporine in early 1980s 
marked the beginning of an era in clinical transplantation increasing one-year 




Based on the mechanism of action, immunosuppressants are classified as 
glucocorticosteroids, antimetabolites, calcineurin inhibitors, mTOR inhibitors, 
depleting and non-depleting antibodies (van Sandwijk et al., 2013). 
Glucocorticosteroids cause complex changes in immune cell populations and 
inhibit synthesis of inflammatory mediators. Antimetabolites such as azathioprine 
and mycophenolate mofetil inhibit DNA synthesis. Mycophenolate mofetil, first 
used in early 1990s, inhibits lymphocyte proliferation by blocking purine synthesis 
via inhibition of inosine monophosphate dehydrogenase and is more selective 
than azathioprine (Allison and Eugui, 2005). Calcineurin inhibitors such as 
cyclosporine and tacrolimus inhibit calcineurin and thereby block translocation of 
the transcription factor NFAT into the nucleus and expression of cytokine genes. 
mTOR inhibitor rapamycin (Sirolimus) blocks signal transduction by IL-2 and 
other cytokines by inhibiting the mTOR complex and has anti-proliferative effects 
on T and B cells. ATG and OKT3 are T cell depleting immunoglobulins. 
Alemtuzumab (Campath) is another depleting antibody that targets CD52 
expressed on T, B and NK cells. Non-depleting antibodies in clinical use in 
transplantation include basliximab that targets the IL-2 receptor alpha chain 
CD25.      
 Induction regimens for transplant recipients involve drugs with the highest 
intensity of immunosuppression since the risk for graft rejection is the highest in 
the early post-operative period (van Sandwijk et al., 2013). Lymphocyte depleting 




Maintenance regimens involve drugs with lower intensity of immunosuppression 
and lower toxicity and are given throughout the patient’s life to prevent acute and 
chronic rejection (van Sandwijk et al., 2013). Calcineurin and mTOR inhibitors, 
antimetabolites along with corticosteroids are the preferred maintenance 
immunosuppressants. Despite strict adherence to immunosuppressive regimens, 
patients are at a risk of acute or chronic allograft rejection (Heemann and Lutz, 
2013). The complications associated with the use of immunosuppressants such 
as toxicity and increased risk of infections and malignancy necessitate the 
development of safe and efficacious therapies (Christians et al., 2011; Gallagher 
et al., 2010; Jha, 2010). Achieving transplantation tolerance in the clinic is indeed 
the ‘Holy Grail’ for transplantation immunologists.  
 
Central and peripheral tolerance 
‘Immunologic tolerance’ is a state in which the immune system does not 
mount a response to a particular antigen in the absence of exogenous 
immunosuppression (Li et al., 2001). Self-tolerance is of utmost importance in 
order to prevent development of autoimmunity. There are two mechanisms of 
self-tolerance: central and peripheral. Central T cell tolerance is established in 
the thymus when developing T cells with high affinity for self-antigen/MHC 
complexes are eliminated (negative selection) (Hogquist et al., 2005). Since 
negative selection does not eliminate all autoreactive T cells, mechanisms must 




mechanisms include deletion, anergy and immunoregulation and constitute 
peripheral tolerance (Mueller, 2010). 
Spontaneous operational tolerance has been observed in liver and renal 
transplant patients where they maintain normal graft function after being weaned 
off immunosuppression, although this is a rare event (Benitez et al., 2013; Sagoo 
et al., 2010) The concept of ‘actively acquired tolerance’ was first introduced by 
Peter Medawar’s group in early 1950s when they observed that injecting 
allogeneic tissue into mouse fetuses made the adult mice tolerant to skin grafts 
from the original donor strain (Billingham et al., 1953). This observation opened 
up the possibility of inducing tolerance to a foreign antigen by exposing the 
immature or developing immune system to the antigen. Transplantation 
immunologists have tried to induce tolerance to allografts based on the principle 
that strategies/therapies to induce and maintain transplantation tolerance will 
exploit the natural mechanisms of self-tolerance. Central tolerance induction 
approaches in animal models involve direct introduction of allogeneic cells into 
the thymus accompanied by anti-lymphocyte depleting serum (Odorico et al., 
1993) or creation of mixed hematopoietic chimerism by injecting T cell depleted 
syngeneic and allogeneic bone marrow into irradiated hosts (Ildstad and Sachs, 
1984). Deletion of the donor antigen specific T cells in the thymus by apoptosis is 
the major mechanism operating in central tolerance. Peripheral tolerance 
induction is more complex with multiple mechanisms operating simultaneously. 




activation, termed as ‘costimulation blockade’, is an effective means of inducing 
peripheral tolerance to allografts. Deletion, anergy and immunoregulation are the 
major mechanisms that constitute peripheral tolerance.  
Deletion 
Several studies in MHC-mismatched transplantation have indicated a 
requirement for T cell apoptosis by costimulation blockade therapies for 
successful peripheral tolerance induction. Both extrinsic and intrinsic apoptotic 
pathways play a role in peripheral tolerance induction. The resistance of IL-2 
deficient mice to tolerance induction by costimulation blockade was ascribed to 
the failure of T cells to undergo Fas-mediated AICD (Dai et al., 1998; Wells et al., 
1999). Moreover, costimulation blockade-induced deletion of alloreactive CD4 T 
cells was significantly impaired in lpr mice that lack functional Fas (Wekerle et al., 
2001). Bcl-xL transgenic mice were also resistant to tolerance induction (Wells et 
al., 1999) and impaired costimulation blockade induced alloreactive CD4 T cell 
deletion (Wekerle et al., 2001) However, other studies revealed that tolerance 
induction can occur when either apoptotic pathway is dysfunctional suggesting 
that there may be a redundancy in the execution of T cell apoptosis upon 
costimulation blockade treatment (Li et al., 1999; Wagener et al., 2000). Since 
the frequency of alloreactive T cells in the periphery may be as high as 1 in 20 T 
cells (Suchin et al., 2001), apoptotic deletion may aid in controlling this extremely 
large pool of cells capable of mediating rapid graft destruction. Li et al. proposed 




alloreactive T cell pool to a level at which other mechanisms of tolerance, such 
as anergy and immunoregulation can operate to control the otherwise potent 
alloresponse (Li et al., 2001).  
Anergy 
Gustav Nossal and Beverley Pike first described ‘clonal anergy’ as functional 
inactivation of B cells after injecting mice with tolerogenic doses of antigen 
(Nossal and Pike, 1980). Ronald Schwartz has defined anergy as a state in 
which ‘a lymphocyte is intrinsically functionally inactivated following antigen 
encounter, but remains alive for an extended period of time in the 
hyporesponsive state’ (Schwartz, 2003). In the context of transplantation 
tolerance, TCR activation in the absence of costimulation results in 
hyporesponsiveness of T cells to proliferate and produce cytokines such as IL-2 
upon in vitro restimulation. Costimulation blockade induced CD4 T cell anergy 
characterized by reduced ability to proliferate and produce cytokines upon in vitro 
restimulation and inability to reject a graft when transferred into another recipient 
(Phillips et al., 2006; Quezada et al., 2005; Quezada et al., 2003). Recently, CD4 
and CD8 T cell anergy has been demonstrated in mice treated with a tolerogenic 
anti-CD3 antibody (Baas et al., 2016; Besancon et al., 2017). CD8 anergy was 
characterized by reduced proliferation, IFN-γ production and donor-






Regulatory T cells are indispensable for the maintenance of self-tolerance and 
have an important role in peripheral tolerance induction. These cells suppress 
self-reactive and foreign antigen specific effector T cell responses. Richard 
Gershon first described a T cell subset capable of suppressing immune 
responses and mediating tolerance induction (Gershon and Kondo, 1970, 1971). 
However it was Shimon Sakaguchi and his group who established the identity of 
suppressor cells as regulatory T cells (Tregs), a distinct T cell lineage 
characterized as CD4+ CD25+ T cells in mice (Sakaguchi et al., 1995) and later 
by the transcription factor Foxp3 (Hori et al., 2003). Tregs are known to mediate 
immunosuppression by secreting anti-inflammatory cytokines IL-10, IL-35, TGFβ, 
releasing exosomes carrying miRNAs that silence T cell response genes, 
modulating APC maturation and function through CTLA4, directly inducing T cell 
apoptosis, suppressing IL-2 consumption by effector T cells or suppressing 
metabolism (Schmidt et al., 2012; Vaikunthanathan et al., 2017). Operationally 
tolerant liver recipients have an increased frequency of Tregs in peripheral blood 
compared to patients on immunosuppression (Li et al., 2004). In animal models 
of transplantation, Tregs play a vital role in the induction and maintenance of 
tolerance to allografts (Ferrer et al., 2014; Quezada et al., 2005; Walsh et al., 
2004). Scientists are now exploiting the tolerogenic potential of Tregs to develop 
Treg cell-based therapies for tolerance induction in the clinic. I have discussed 






Given the central role of costimulation in the optimal generation of T cell 
responses, blocking costimulatory signals therapeutically is a logical approach to 
prevent graft rejection mediated by T cells. I have described in brief some of the 
costimulatory pathways that have been targeted and shown success in animal 
models of transplant rejection.  
CD28/B7 
The first successful costimulation blockade reagent developed was CTLA4-Ig, a 
fusion protein consisting of the extracellular domain of CTLA4 and IgG (Linsley et 
al., 1991). CTLA4-Ig blocks B7 signaling and inhibits alloreactive T cell 
responses as well as T-dependent B cell antibody production. CTLA4-Ig 
(abatacept) showed significant activity in rheumatoid arthritis patients (Kremer et 
al., 2005) and was the first costimulation blockade agent to be approved by the 
FDA in 2005. Since abatacept did not show efficacy in non-human primate (NHP) 
transplant models (Levisetti et al., 1997), a high variant with increased affinity 
and avidity towards both B7 molecules CD80 and CD86 called belatacept was 
developed that showed better outcomes than abatacept (Larsen et al., 2005). 
Belatacept was approved by the FDA in 2011 and has shown improved renal 
function in kidney recipients compared to the current standard of care calcineurin 
inhibitor cyclosporine, although belatacept was associated with higher incidence 
and severity of acute rejection (Durrbach et al., 2016; Vincenti et al., 2010; 




Tregs by inhibiting CD28 (Golovina et al., 2008) and CTLA4 signaling (Sojka et 
al., 2009), which has been shown to be important for Treg homeostasis and 
function. It was recently reported that long-term belatacept-treated kidney 
transplant patients exhibit reduced Treg suppressor function compared to healthy 
individuals and it may be a result of epigenetic regulation of Foxp3 locus (Alvarez 
Salazar et al., 2017). Antibodies selectively targeting CD28 have been developed 
in order to maintain CTLA4 signaling and have shown superior outcomes in NHP 
transplant models relative to belatacept (Liu et al., 2014; Ville et al., 2016). 
CD40/CD154  
CD40/CD154 pathway has a tremendous potential for tolerance induction due to 
its critical impact on both T cell activation and generation of antibody responses. 
Antibodies targeting CD154 showed great outcomes in murine and NHP 
transplant models (Pinelli and Ford, 2015); however their clinical translation was 
precluded by the unanticipated development of thromboembolic complications in 
early clinical trials (Kawai et al., 2000). The prothrombotic effect of the antibody 
was thought to be associated with the expression of CD154 on platelets and 
destablization of platelet plugs by anti-CD154 and/or the crosslinking of the Fc 
receptor FcγRIIa on platelets by anti-CD154-soluble CD154 immune complexes 
(André et al., 2002; Robles-Carrillo et al., 2010). After the clinical trials with the 
anti-CD154 antibodies were halted, researchers directed their efforts towards 
developing Fc-silent anti-CD154 antibodies and reagents targeting the receptor 




2013) and CD40 targeting antibodies (Adams et al., 2005; Aoyagi et al., 2009; 
Badell et al., 2012; Cordoba et al., 2015; Gilson et al., 2009; Haanstra et al., 
2003; Lowe et al., 2012; Oura et al., 2012; Page et al., 2012; Pearson et al., 
2002) have shown efficacy in murine and NHP transplant models with currently 
the CD40 antagonists ASKP1240 in phase 2a (NCT01780844) and CFZ533 in 
phase1/phase 2 (NCT02217410) clinical trials for use in kidney transplant 
recipients. 
Our lab employs a two-component costimulation blockade protocol consisting of 
donor specific transfusion (DST) and anti-CD154 mAb (Clone MR1). Historically, 
living donor kidney recipients have been treated with whole blood transfusions 
from the donor (DST) in addition to immunosuppressants and patients receiving 
DST have shown better outcomes than patients receiving immunosuppressants 
alone (Marti et al., 2006). Tolerance induction by DST/anti-CD154 costimulation 
blockade involves all three mechanisms of peripheral tolerance, namely deletion, 
anergy and immunoregulation.   
OX40/OX40L 
The finding that OX40 stimulation abrogates the suppressor function of Tregs 
and prevents induction of Tregs from conventional CD4 T cells is of immense 
importance for tolerance induction (Vu et al., 2007). Although OX40 blockade as 
a monotherapy did not induce tolerance to murine allografts, it prolonged allograft 
survival by inhibiting accumulation of CD4 and CD8 T cells in the draining lymph 




2013b; Kinnear et al., 2010). Moreover, OX40 blockade inhibited CD28/CD154 
independent rejection and in wild type mice, synergized with CD28/CD154 
blockade to induce long-term skin allograft acceptance (Demirci et al., 2004). 
Studies in NHP models will reveal the robustness of OX40 blockade and 
determine if these agents go to clinical trials for transplantation.  
LFA-1/ICAM-1 and VLA-4/VCAM-1 
Antibodies targeting LFA-1 and VLA-4 have shown efficacy in both murine and 
NHP models of transplantation (Kean et al., 2017). These reagents are of 
particular interest because they prevent CD28/CD154 blockade resistant 
rejection by memory alloreactive T cells by impairing T cell trafficking and graft 
infiltration and/or memory recall effector function (Badell et al., 2010; Kitchens et 
al., 2012; Setoguchi et al., 2011). FDA approved anti-LFA-1 antibody efalizumab 
for psoriasis was tested in clinical trials for islet and renal transplantation (Posselt 
et al., 2010; Turgeon et al., 2010; Vincenti et al., 2007). However, it was taken off 
the market because of the development of progressive multifocal 
leucoencephalopathy (PML), a central nervous system (CNS) infection caused 
by JC polyoma virus, in some patients (Carson et al., 2009). Anti-VLA-4 antibody 
natalizumab, which was FDA approved for multiple sclerosis and Crohn’s 
disease, is also associated with PML development. The incidence of PML 
development, owing to these antibodies causing CD4 T lymphopenia and altered 
trafficking of T cells into the CNS, has dampened interest in targeting these 




Other costimulatory pathways targeted include ICOS/ICOS-L (Harada et al., 
2003; Kosuge et al., 2003; Lo et al., 2015; Ozkaynak et al., 2001), 4-1BB/4-1BBL 
(Cho et al., 2004; Wang et al., 2003) and CD27/CD70 (Demirci et al., 2004), 
LFA-3/CD2 (Lo et al., 2013; Weaver et al., 2009a), TIM-1 (Ueno et al., 2008) and 
TIM-4 (Yeung et al., 2013). Targeting these pathways has shown variable 
success in different transplant models. Reagents targeting these costimulatory 
molecules may work better as combination therapies and need to be tested with 
CD28 and CD154 pathway blockers.  
 
Alternative approaches to tolerance induction 
Blocking co-inhibitory pathways 
Blocking the co-inhibitory receptor PD-1 or its ligand PD-L1 accelerated acute 
graft rejection (Ito et al., 2005) and prevented induction (Wang et al., 2007) and 
maintenance (Koehn et al., 2008) of tolerance by CD28/CD154 blockade by 
increasing the accumulation of IFN-γ secreting effector CD8 T cells and 
decreasing graft infiltration of Tregs. Stimulating PD-1 might aid in inducing 
tolerance along with blocking costimulation; however no PD-1 agonists are 
available. Similarly, activating CTLA4 is desirable in the context of transplantation 
but is precluded by the lack of availability of CTLA4 agonists. Agonistic antibody 
against the newly identified co-inhibitory molecule PD-1H (VISTA) protected mice 
from graft versus host disease (GvHD) by arresting donor alloreactive T cell 




2015). Targeting the coinhibitory molecule BTLA prolonged murine allograft 
survival when combined with CTLA4-Ig, but the mechanism of the anti-BTLA 
antibody was not clearly defined in these studies (Truong et al., 2007a; Truong et 
al., 2007b). While blocking the coinhibitory receptor TIM-3 accelerated graft 
rejection by increasing frequencies of alloreactive effector T cells and attenuating 
iTreg generation (Boenisch et al., 2010), activating TIM-3 by treatment with the 
ligand galectin-9 combined with rapamycin induced tolerance to allografts (Cai et 
al., 2013).  
Establishment of mixed chimerism 
Mixed chimerism is a state in which donor and recipient cells co-exist after 
allogeneic bone marrow transplantation. More than 1% donor cells of total cells 
should be detectable in the recipient’s blood to be considered ‘mixed chimerism’. 
Donor-specific T cells get eliminated in the thymus by clonal deletion (negative 
selection) because the donor antigens originating from the donor bone marrow 
are now ‘self’ for the recipient. Conditioning treatments are necessary for donor 
bone marrow acceptance. Non-myeloablative conditioning regimens include 
immunosuppressants (depleting antibodies, costimulation blockade) and thymic 
or total body irradiation at low doses to prevent eradication of all recipient bone 
marrow (Ruiz et al., 2013). Three groups have reported induction of mixed 
chimerism and operational tolerance in renal transplant patients using distinct 
conditioning regimens (Kawai et al., 2008; Kawai et al., 2013; Leventhal et al., 




Regulatory T cell infusion 
Cell-based therapies have become popular over the past decade because they 
permit tolerance induction without the adverse effects of pharmacological 
immunosuppression. Considering the prominent role of Tregs in the induction 
and maintenance of tolerance, several laboratories have explored ways to utilize 
these cells to prolong graft survival in the clinic. Tregs may be obtained directly 
from the recipient peripheral blood and expanded ex vivo followed by autologous 
transfer; they may be obtained from umbilical cord blood followed by ex vivo 
expansion; they may be induced in vitro from naïve T cells (iTregs) under specific 
tissue culture conditions or they may be induced in vitro by allogeneic stimulation 
or polyclonal activation (Tang and Bluestone, 2013). Several clinical trials are 
ongoing with Tregs in solid organ transplantation and treatment of GvHD 
following hematopoietic stem cell transplantation (Romano et al., 2016). Overall, 
Tregs seem to be well tolerated even at high doses; their efficacy will become 
clear when results from these trials are published. A recent study employed a 
new approach to generate antigen-specific Tregs. Using the synthetic fusion 
protein chimeric antigen receptor (CAR) technology, the authors generated HLA-
A2 specific CAR Tregs and showed their potency in a human skin xenograft 
transfer model (Boardman et al., 2017).  
Myeloid suppressor cell infusion 
Several kinds of suppressor cells of the myeloid lineage have been identified and 




DCs), originally described as regulatory DCs (DCregs), are immature DCs that 
express low levels of MHC-II and costimulatory molecules. Tol-DCs promote 
tolerance induction by various mechanisms, including T cell deletion and anergy, 
induction of Tregs and production of immunosuppressive factors (Li and Shi, 
2015; Riquelme et al., 2012). Regulatory macrophages (Mregs) suppress 
proliferation and induce apoptosis of activated T cells (Riquelme et al., 2012). 
Myeloid derived suppressor cells (MDSCs) are immature cells of the monocytic 
(mMDSCs) and granulocytic (gMDSCs) origin. They express arginase-1 and 
iNOS (inducible nitric oxide synthase), produce reactive oxygen species and 
peroxynitrite and mediate immunosuppression by inhibiting T cell proliferation 
and function, inducing T cell apoptosis and supporting Treg induction and 
proliferation (Gabrilovich and Nagaraj, 2009). The ONE Study, a collaborative 
effort to test and compare these myeloid derived cell-based therapies in renal 
transplantation in patients, should reveal which of these populations is effective 
at promoting tolerance induction (Geissler, 2012). 
Mesenchymal stem cell infusion 
Mesenchymal stem cells are a heterogenous population found in the bone 
marrow and connective tissue. These cells are known to mediate 
immunosuppression by increasing the numbers of Tregs and tol-DCs and 
impairing alloreactive T cell homing (Scalea et al., 2016). Clinical trials using 




that infusing MSCs may facilitate reduction of pharmacological 
immunosuppression (Mudrabettu et al., 2015; Peng et al., 2013). 
Apoptotic cell infusion 
Phagocytosis of apoptotic cells by APCs may reduce APC maturation and 
stimulate secretion of immunosuppressive factors thereby inducing Tregs and 
inhibiting T cell function (Griffith and Ferguson, 2011). Intravenous transfusion of 
UV-B- or γ-irradiation treated early apoptotic cells before transplantation prolongs 
allograft survival in mouse transplant models (Morelli and Larregina, 2016). 
Although apoptotic cell therapy has not been clinically tested for solid organ 
transplantation, infusing allogeneic early apoptotic cells prior to HLA-matched 
hematopoietic stem cell transplantation reduced the severity of GvHD in a clinical 
trial (Mevorach et al., 2014). 
Infusion of exosomes  
Exosomes are extracellular vesicles formed by the inward budding of endosomal 
membranes and are secreted by many cell types. Intravenous delivery of donor-
derived exosomes purified from peripheral blood (Song et al., 2016) or bone 
marrow derived DC culture supernatants (Peche et al., 2003) prolonged allograft 
survival and induced tolerance when combined with short-term 
immunosuppression (Peche et al., 2006) in rodent models of transplantation by 
inhibiting alloreactive T cell responses. Exosomes purified from syngeneic Tregs 




trials in cancer have shown safety of exosomes (Viaud et al., 2010), testing in 
organ transplantation may not be far off. 
Another approach that employs strategically exposing the recipient to 
donor antigens before transplantation is the delivery of donor splenocytes cross-
linked with ethylenecarbodiimide (ECDI) (Luo et al., 2008). This approach 
induced donor-specific tolerance to murine allografts via multiple mechanisms, 
including clonal deletion, anergy and immunoregulation (Kheradmand et al., 
2012).  
 
Barriers to transplantation tolerance 
 
Although tolerance induction is possible in rodents using the strategies I 
described in the previous section, several barriers have been recognized that 
may prevent tolerance induction and abrogate tolerance once it has been 
established. Since rodents are housed in specific pathogen-free environments in 
laboratory settings, they are not exposed to the environmental antigens that 
humans are exposed to on a daily basis, making it difficult to identify precisely 
the factors that prevent tolerance in clinical settings. However, knowledge gained 
from patient studies and the creation of elegant mouse models has made it 
feasible to conduct mechanistic studies in the laboratory. I have described some 
of the hurdles in transplantation tolerance reported in the literature. 
 




In the context of solid organ transplantation, antigen-independent injury occurs to 
the graft before and during transplantation (Mori et al., 2014). Organ damage 
occurs during brain death of the donor as well as during cold storage of the organ 
prior to transplantation. After the organ is transplanted, subsequent damage 
occurs due to restoration of blood flow, known as ischemia reperfusion injury 
(IRI). These processes cause localized activation of the innate immune system 
and inflammation in the graft known as ‘sterile inflammation’. Intracellular and 
extracellular molecules that are normally sequestered become exposed to the 
immune system upon necrotic cell death and trigger sterile inflammation. These 
endogenous triggers of inflammation are called damage associated molecular 
patterns (DAMPs). Intracellular DAMPs include nuclear proteins such as HMGB1 
and cellular chaperones such as heat shock proteins; extracellular DAMPs 
include low molecular weight form of the extracellular matrix component 
hyaluronan and acute phase protein haptoglobin. Many of these DAMPs are 
recognized by TLR4 and TLR2 and are associated with acute and chronic 
rejection in clinical transplantation as well as mouse transplant models (Mori et 
al., 2014). Functional polymorphisms in TLR4 that reduce TLR4 signaling are 
associated with improved graft outcomes in patients undergoing lung and kidney 
transplantation (Ducloux et al., 2005; Fekete et al., 2006; Palmer et al., 2003). 
Moreover, genetic deficiency or knockdown of TLR4 or the adaptors MyD88 and 




2006; Zhang et al., 2010; Zhang et al., 2012) illustrating the significant barrier 
that innate immune signaling represents to tolerance induction. 
 
Infections 
Certain infections in the peri-transplant period are known to interfere with 
tolerance induction in mouse models. PAMPs from the infecting microbes bind 
their PRRs on the recipient’s cells and stimulate production of inflammatory 
cytokines that induce APC maturation and trigger alloimmunity overriding the 
effects of tolerance induction therapies. Bacterial infections such as Listeria 
monocytogenes (Wang et al., 2008), and Staphylococcus aureus (Ahmed et al., 
2011) and viral infections such as LCMV and Pichinde (Turgeon et al., 2000) in 
the peri-transplant period prevent tolerance induction by costimulation blockade. 
Our lab and others have demonstrated that injecting mice with PAMPs such as 
LPS, Pam3CysK4, poly(I:C) and CpG on the day of transplantation prevents long-
term acceptance of allografts (Chen et al., 2006; Thornley et al., 2006b). Once 
tolerance is induced, it is difficult to breach in mouse models of transplantation 
(Alegre et al., 2014). Listeria infection can abrogate established tolerance in 
some graft recipients although it requires 15-fold higher dose of Listeria to 
reverse tolerance compared to the dose required to prevent induction of 
tolerance (Wang et al., 2010). In a patient study of kidney transplant recipients 
who were operationally tolerant, 30% of the patients rejected their grafts after a 




bacterial and viral infections relative to the ones who maintained their tolerance 
(Brouard et al., 2012). 
 
Memory alloreactive T cells 
Memory alloreactive T cells may develop in an individual as a result of prior 
exposure to alloantigens or through microbial infections (heterologous immunity). 
Memory T cells have a low activation threshold and hence can be stimulated by 
low doses of antigen and limited costimulation and hence are resistant to 
costimulation blockade protocols of tolerance induction. Both CD4 and CD8 
memory T cells contribute to allograft rejection. Memory alloreactive CD4 T cells 
provide help to alloreactive B cells to generate alloantibodies and to alloreactive 
effector CD8 T cells that then drive allograft rejection (Chen et al., 2004). 
Memory alloreactive CD8 T cells directly mediate costimulation blockade-
resistant graft rejection (Su et al., 2014). Studies investigating the impact of 
alloreactive memory T cells on transplant rejection are based on generating 
cross-reactive memory T cells by infection of the recipient, priming the recipient 
to donor antigen or adoptive transfer of donor-antigen primed memory T cells 
(Benichou et al., 2017). Using these strategies, studies have demonstrated that 
memory alloreactive T cells present a formidable barrier to tolerance induction by 
costimulation blockade and hematopoietic chimerism (Adams et al., 2003; Brehm 
et al., 2003; Pantenburg et al., 2002). NHPs with higher frequencies of 




compared to those with lower frequencies of memory T cells (Nadazdin et al., 
2011). As a result of exposure to environmental antigens, humans have cross-
reactive memory T cells despite no previous exposure to alloantigens. The 
frequency of donor-reactive memory T cells was shown to correlate with the risk 
of developing acute rejection episodes post kidney transplantation (Heeger et al., 
1999). Recently, an ‘incognito’ form of immune memory was described where 
memory T cells specific for a non-MHC antigen prevent tolerance induction to an 
allograft provided the presentation of the non-MHC antigen is linked to the 
alloantigen (Nelsen et al., 2017). 
 
Memory alloreactive B cells and alloantibodies 
Similar to memory alloreactive T cells, memory alloreactive B cells and donor-
specific antibodies may arise in the recipient as a result of previous exposure to 
alloantigens or through infections. Memory alloreactive B cells and alloantibodies 
prevent costimulation blockade-induced tolerance by promoting T cell 
alloimmunity (Burns and Chong, 2011; Burns et al., 2009). 
 
Homeostatic proliferation 
Homeostatic proliferation refers to the proliferation of residual non-depleted 
lymphocytes following lymphodepletion. T cell depleting agents ATG and 
alemtuzumab skew the repopulating T cells to allo-specific effector memory 




studies in mouse models have revealed that T cells undergoing homeostatic 
proliferation developed memory phenotype and function and rendered the mice 
resistant to costimulation blockade induced tolerance to allografts (Wu et al., 
2003). Transient lymphopenia was also sufficient to abrogate established 
tolerance (Iida et al., 2013).  
 
Pre-existing autoimmunity 
Patients with T cell autoreactivity may have a higher risk of post-transplant graft 
injury (Burlingham et al., 2007; Jurcevic et al., 2001; Kalache et al., 2011). It has 
been demonstrated in mouse transplant models that pre-sensitization to 
autoantigen prevents costimulation blockade mediated tolerance induction to 
allografts expressing the autoantigen (Kalache et al., 2014). In this scenario, 
memory autoreactive T cells provided help to activate and expand alloreactive 
effector T cells that rejected the graft. The authors did not find cross-reactivity 
between autoreactive and alloreactive T cells indicating that heterologous 
immunity was not the mechanism. Treating recurrent autoimmunity by depleting 





Animal models are used as surrogates of human biology due to the 
logistical and ethical restrictions of working with cell and tissue samples from 




such as mice and rats are widely used mammalian model systems due to their 
small size, ease of maintenance and handling, short reproductive cycle, sharing 
of genomic and physiological properties with humans, and ability to be readily 
manipulated genetically. Despite the vast amount of basic biology obtained from 
mouse studies, there are limitations to mouse models when investigating human 
biology. Several components of mouse biological systems are incongruent with 
those of humans, particularly their immune system. For example, there are many 
differences in innate immune molecules, including the lack of a functional TLR10 
in mice and the expression of TLR11, TLR12, and TLR13 in mice that are not 
present in the human genome (Zschaler et al., 2014). Furthermore, many drugs 
and pathogens are species specific. The nature and pathogenesis of immune 
responses mounted against pathogens that can infect only human cells may 
markedly differ from that of murine infectious agents or human infectious agents 
that have been murine-adapted (Shultz et al., 2007). These issues underscore 
the need for better small animal models that can more faithfully recapitulate 
human biological systems. 
Humanized mice have begun to fill this gap and have become important 
preclinical tools for biomedical research. Humanized mice, also known as human 
immune system mice, are immunodeficient mice that have been engrafted with 
hematopoietic cells and tissues of human origin to produce a functional human 
immune system.	There has been a continuous improvement of immunodeficient 




2012). The key breakthrough was the development of immunodeficient mice 
bearing mutations in the IL-2 receptor common gamma chain (IL2rgnull) in the 
early 2000s. The common gamma chain constitutes an important component of 
receptors for IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 and is indispensable for high 
affinity binding and signaling of these cytokines. When combined with either the 
protein kinase DNA-activated catalytic polypeptide mutation (Prkdcscid or scid) or 
with recombination activating gene (Rag) 1 or 2 (Rag1null or Rag2null) mutations, 
these mice lack adaptive immunity and exhibit severe deficiencies of innate 
immunity, including absence of murine natural killer (NK) cells.  
 Three strains of immunodeficient IL2rgnull mice are widely used today: 
NSG (NOD.Cg-PrkdcscidIl2rgtm1Wjl) (Ito et al., 2002), NOG (NOD.Cg-
PrkdcscidIl2rgtm1Sug) (Shultz et al., 2005) and BRG (C;129S4-Rag2tm1FlvIl2rgtm1Flv) 
(Traggiai et al., 2004). NOG mice have a truncated cytoplasmic domain of the 
gamma chain that binds cytokines but lacks the signaling domain, whereas NSG 
and BRG mice completely lack the gamma chain. When engrafted with human 
cells, tissues, and immune systems, the biological responses in humanized 
IL2rgnull mice more faithfully recapitulate those seen in humans than in any 
previous models of humanized mice. 
 There are three general approaches to engraft human immune systems 
into immunodeficient IL2rgnull mice. The first model, known as Hu-PBL-SCID, is 
created by injection of human peripheral blood leukocytes (PBLs) (Mosier et al., 




of the first week. This model is excellent for studying human T cell function in 
vivo but has only a short experimental window due to the development of lethal 
xenogeneic graft-versus-host disease (GVHD), usually within 4–8 weeks. 
However, this experimental window can be extended using NSG recipients 
lacking murine MHC class I or II (King et al., 2009). The second model, known as 
Hu-SRC-SCID, encompasses the intravenous or intrafemoral injection of human 
severe combined immunodeficiency (SCID) repopulating cells, that is, human 
CD34+ hematopoietic stem cells (HSCs) derived from bone marrow, umbilical 
cord blood, fetal liver, or G-CSF–mobilized peripheral blood. This model (also 
referred to as HSC-engrafted) supports engraftment of a complete human 
immune system. Although B, T, myeloid, and antigen-presenting cells are 
present in the peripheral hematopoietic tissues, granulocytes, platelets, and red 
blood cells (RBCs) that are generated in the bone marrow are observed at only 
very low levels in the blood. In addition, the human T cells are educated in the 
mouse thymus and are thus H2-, not HLA-restricted (Watanabe et al., 2009). The 
third model is the bone marrow/liver/thymus (BLT) model that is established by 
transplantation of human fetal liver and thymus under the kidney capsule and i.v. 
injection of autologous fetal liver HSCs (Lan et al., 2006; Melkus et al., 2006). As 
in the Hu-SRC-SCID model, all lineages of human hematopoietic cells develop. 
However, BLT mice also develop a robust mucosal human immune system, and 
the human T cells are educated on an autologous human thymus and are HLA-




the mice develop a wasting GVHD-like syndrome that limits the time window for 
experimentation. Each model has its advantages and limitations, and therefore it 
is important for researchers to select a model appropriate for their specific 
biological questions. 
 There are several limitations associated with these humanized mouse 
models (Shultz et al., 2012). Residual mouse immune system precludes 
complete human cell engraftment. Functional responses of human immune cells 
are impaired due to the differences between human and mouse cytokines. 
Humoral responses are limited because of impaired class switching and affinity 
maturation and poorly organized secondary lymphoid structures. Several 
modifications have been made to the existing strains by knocking out specific 
mouse genes or knocking in or transgenically expressing specific human genes 
to overcome these limitations. The result is an improved array of humanized mice 
with higher human immune cell engraftment levels and enhanced functionality 
(Shultz et al., 2012). These improved humanized mouse models are now being 
used to study many human biological responses and diseases and are 
increasingly employed as preclinical tools to evaluate drugs and identify 
underlying mechanisms in a broad array of diseases. In particular, humanized 
mice are playing an increasing role in the study of human-specific infectious 
agents such as HIV and are widely used as preclinical models in cancer biology. 
Moreover, humanized mice are being increasingly utilized as translational models 



















A novel murine anti-CD40 monoclonal 














The CD40-CD154 pathway regulates key aspects of immune system activation, 
and blockade of this pathway with antibodies targeting CD154 has been used to 
induce transplantation tolerance and suppress autoimmune disease. The efficacy 
of anti-CD154 antibody in prevention of allograft rejection and suppression of 
autoimmunity in murine and non-human primate models accelerated efforts to 
develop this strategy for clinical use. However, clinical trials with anti-CD154 
antibody resulted in thromboembolic complications in patients and limited clinical 
application. To develop an alternative approach to anti-CD154 antibody, recent 
efforts have focused on targeting its receptor, CD40. In this study I evaluated the 
effects of a novel murine antagonistic, non-depleting antibody targeting CD40 on 
alloreactive immune responses. Costimulation blockade consisting of donor 
splenocytes (DST) and anti-CD40 mAb significantly prolonged skin graft survival 
in the stringent BALB/c to B6 MHC mismatch model with an efficacy similar to 
anti-CD154 mAb. Moreover DST/anti-CD40 treatment attenuated donor-specific 
antibody production and alloreactive CD8 T cell responses as shown by inhibition 
of expansion, decreased cytokine production and decreased killing of allogeneic 
targets. However tolerance induced by anti-CD40 antibody was abrogated by 
induction of systemic inflammation with bacterial lipopolysaccharide, as 
previously described with strategies targeting CD154. These results demonstrate 




of transplantation tolerance and support the application of anti-CD40 antibodies 





Contemporary immunosuppressive medications, particularly those that 
rely on calcineurin inhibitors, are highly effective at reducing acute rejection 
rates, but improvement of long term allograft survival has been modest (Webber 
and Vincenti, 2016). Costimulation blockade is a potential calcineurin-inhibitor 
free approach that has emerged as one of the most promising methods for 
induction of transplantation tolerance in the absence of chronic 
immunosuppression (Kinnear et al., 2013a). Studies in mouse and non-human 
primates (NHP) have demonstrated the effectiveness of costimulation blockade 
therapies to diminish alloreactive T cell responses and improve graft survival 
(Ford, 2016; Shiao et al., 2005). Costimulation blockade strategies targeting 
human-specific molecules have been successfully modeled in humanized mice, 
preventing the rejection of human stem cell derived pancreatic endoderm (Szot 
et al., 2015). Several costimulatory molecules including CD80, CD86, CD28, 
CD154, ICOS, OX-40, 4-1BB, LFA-3, LFA-1 and TIM-1 have been targeted as 
monotherapies or combination therapies and have shown some degree of 
success in transplant models (Demirci et al., 2004; Kitchens et al., 2012; Larsen 
et al., 1996; Ozkaynak et al., 2001; Ueno et al., 2008; Wang et al., 2003; Weaver 




CD40-CD154 interactions have been extensively studied in the context of 
alloimmunity and transplantation. After the clinical trials with the anti-CD154 
antibodies were halted, researchers directed their efforts towards developing Fc-
silent anti-CD154 antibodies and reagents targeting the receptor CD40. As an 
alternative to targeting CD154, recent efforts have focused on CD40 for the 
induction of transplantation tolerance (Pinelli and Ford, 2015). Early studies 
showed that mice genetically deficient in CD40 were amenable to tolerance 
induction to islet and cardiac, but not skin allografts, from CD40 deficient donors 
(Nathan et al., 2004; Phillips et al., 2003). A murine anti-CD40 antibody with 
intact Fc binding activity (7E1-G2b) had comparable efficacy to anti-CD154 in 
promoting allogeneic bone marrow chimerism and skin graft survival (Gilson et 
al., 2009). Several investigators have developed and tested anti-CD40 antibodies 
in NHP models and shown significant efficacy in kidney, liver, bone marrow and 
islet transplantation either alone or in combination with CD28 pathway blockers 
(Adams et al., 2005; Aoyagi et al., 2009; Badell et al., 2012; Cordoba et al., 2015; 
Haanstra et al., 2003; Lowe et al., 2012; Oura et al., 2012; Page et al., 2012; 
Pearson et al., 2002). The promising results achieved in these murine and NHP 
models paved the way for anit-CD40 reagents to be tested in human subjects 
(Goldwater et al., 2013).  
Understanding the mechanism of action for anti-CD40 antibodies and how 
they compare to anti-CD154 antibodies is critical. In this chapter, I describe 




non-depleting, fully antagonistic anti-CD40 monoclonal antibody. Anti-CD40 mAb 
in combination with DST was as effective in prolonging survival of fully 
mismatched skin allografts as anti-CD154 mAb. DST/anti-CD40 treatment 
attenuated the generation of alloantibodies and IFN-γ producing effector/memory 
CD8 T cells, and impaired the expansion of alloreactive CD8 T cells. 
Inflammation induced by bacterial lipopolysaccharide (LPS) precipitated allograft 
rejection despite DST/anti-CD40 costimulation blockade. My findings suggest 
that reagents targeted towards CD40 are attractive candidates for translation in 
clinical transplantation.  
 
Materials and Methods 
 
Generation and characterization of the anti-CD40 mAb 
Wistar rats were immunized with recombinant mouse CD40/hFc (R&D Systems) 
in alum adjuvant in the footpad and boosted i.p and/or i.v. Sera positive animals 
were sacrificed and hybridomas were created by fusion with the mouse myeloma 
cell line Sp2/0 (ATCC). Hybridomas that exhibited selective molecular and 
cellular CD40 binding and capable of blocking molecular CD40-CD40L 
interaction were subcloned, grown in serum-free medium and purified. The 
antagonistic and agonistic activity of purified mAbs was assessed using 
proliferation assays. Briefly, mouse splenocytes (4x104 cells) cultured with 
recombinant mouse IL-4 were treated with varying concentrations of mAb alone 
(agonism) or for 1 hour prior to stimulation with 100 ng/ml of MegaMouse CD40L 




3[H]-thymidine incorporation. Anti-mouse CD40 clones FGK4.5 and 3/23 were 
used as full agonist and partial/weak agonist controls, respectively. The Vgene 
sequence of the sole clone exhibiting pure antagonistic activity was recovered 
and engineered onto a mouse IgG2a Fc containing mutations to abrogate Fcg 
receptor binding.  
 
Animals 
C57BL/6J (H2b), BALB/cJ (H2d), CBA/J (H2k) and B6.129(Cg)-
Foxp3tm3(DTR/GFP)Ayr/J mice were obtained from The Jackson Laboratory. (CBA/J X 
KB5.CBA) F1 CD8+ TCR-transgenic mice were bred at the animal facility of 
University of Massachusetts Medical School. The TCR transgene is expressed in 
CBA (H2k) mice by CD8 T cells and specifically recognizes native H-2Kb 
(Iwakoshi et al., 2001). All animals were housed in a specific pathogen free 
facility in microisolator cages and given autoclaved food. All experiments were 
performed in accordance with the guidelines of the Institutional Animal Care and 
Use Committee of the University of Massachusetts Medical School.  
 
Generation of CD8+ KB5 TCR-transgenic synchimeric mice 
To generate KB5 TCR transgenic hematopoietic chimeras, male CBA/J non-
transgenic mice at 4-5 weeks of age were treated with 200cGy whole body 
gamma irradiation and injected intravenously (i.v.) with 0.5 X 106 bone marrow 




chimerism was allowed to develop for 8 weeks post bone marrow transfer. The 
resulting ‘synchimeras’ were used in experiments between 12-16 weeks of age.  
 
Flow cytometry, antibodies and intracellular cytokine staining 
At the specified times, mice were sacrificed by cervical dislocation. Single cell 
suspensions of splenocytes were prepared by grinding spleens between glass 
microscope slides. Erythrocytes were lysed with 0.84% ammonium chloride. 
Single cell suspensions were stained with the antibodies: CD16/CD32 (2.4G2), 
CD3 (145-2C11), CD4 (RM4-5), CD8α (53-6.7), CD44 (IM7), B220 (RA3-6B2), 
CD19 (1D3), CD11c (HL3), CD11b (M1/70), F4/80 (BM8), Ig (multiple 
adsorption), IFN-γ (XMG1.2) or isotype controls purchased from BD Biosciences, 
Ebioscience or BioLegend. For intracellular cytokine staining, 2 x 106 RBC lysed 
splenocytes from recipient mice were incubated with 1 x 106 LPS matured, 
irradiated syngeneic or allogeneic splenocytes in complete RPMI and monensin 
(eBioscience) for 4 hrs at 37°C and assessed for intracellular IFN-γ production as 
described previously (Brehm et al., 2007). Samples were run on LSR II flow 
cytometer (BD Biosciences). At least 300000 events were collected. Data were 
analyzed using FlowJo software (Tree Star). 
 
VPD450 labeling and adoptive transfer 
Splenocytes were harvested from KB5 transgenic mice, RBC lysed and 




(BD Biosciences) for 12 mins at 37°C.  Cells were washed twice in PBS + 10% 
FBS, and splenocytes comprising 2 X 106 labeled DES+ CD8+ T cells 
resuspended in PBS were injected i.v. into non-transgenic CBA mice.   
 
In vivo cytotoxicity assay 
Splenocytes were harvested from B6 and CBA mice, RBC lysed, resuspended in 
PBS and labeled with 2.6 µM and 0.2 µM CFSE (Sigma) respectively for 4 mins 
at 37°C. Cells were washed twice in PBS + 10% FBS and combined in equal 
proportions. 20 X 106 cells were adoptively transferred intravenously into the 
indicated recipient B6 mice. Spleens from recipient mice were harvested 3 hours 
later and the survival of each CFSE labeled population was assessed by flow 
cytometry. Specific lysis was calculated as: [1-(ratio immune/ratio naive)] X 100, 
where the ratio = % allogeneic population/% syngeneic population.  
 
Skin transplantation and tolerance induction 
Skin grafts were obtained from the flanks of BALB/c mice and transplanted onto 
the dorsal flanks of B6 mice on day 0. The recipient B6 mice were given a DST of 
10 x 106 BALB/c splenocytes i.v. on day -7 and 0.5 mg of anti-CD154 mAb, clone 
MR1 (BioXCell) or 1 mg of the anti-CD40 mAb or its isotype control i.p. on days -
7, -4, 0 and +4 relative to transplantation. 0.5 mg of CLTA4-Ig (BioXCell) was 
injected i.p. on days 0, 2, 4 and 6 where specified. Recipient mice were injected 




where indicated. Diphtheria toxin (DT) obtained from List Biological Laboratories, 
Inc. was given i.p. daily from day -8 to day -2 at a dose of 100 ng per mouse.  
 
Measurement of alloantibodies 
Alloantibody levels were measured by flow cytometry as described previously 
(Leenaerts et al., 1990). Briefly, B6 mice were bled two weeks after skin 
transplantation and plasma was isolated by centrifugation. BALB/c splenocytes 
were used as allogeneic target cells. 1 x 106 BALB/c splenocytes were 
resuspended in 100ul PBS, incubated with Fc block™ and then incubated with 
100 ul of B6 plasma diluted 1:10, 1:100 and 1:1000 for 30 mins at 4°C. Cells 
were washed twice to remove excess plasma and incubated with PE-conjugated 
polyclonal anti-mouse Ig for 20 mins at 4°C. B cells stained with anti-CD19 and 
anti-B220 were excluded by gating and mean fluorescence intensity (MFI) of the 




Statistical analyses were performed using GraphPad PRISM software. Allograft 
survival curves were generated by the Kaplan-Meier method and compared by 
the log-rank test. Three or more means were compared using one-way ANOVA 
and Tukey’s multiple comparisons test. p values < 0.05 were considered 







Characterization of the anti-CD40 monoclonal antibody 
 
The chimeric anti-CD40 monoclonal antibody with mutated mouse Fc regions 
was tested for specificity of binding to mouse CD40, inhibition of CD40L binding 
to CD40 and antagonistic activity. The anti-CD40 mAb bound to plate-bound 
recombinant murine CD40-hFc fusion protein with an EC50 of 0.07 nM whereas 
binding to the control RANK-hFc fusion protein was negative (Fig. 2.1A). In 
addition anti-CD40 mAb  bound to B6 splenocytes with an EC50 of 0.42 ± 0.08 
nM with no binding to Cd40-/- splenocytes observed (Fig. 2.1B). Next we tested 
the ability of the anti-CD40 mAb to block binding of soluble CD154 to plate bound 
CD40. The anti-CD40 mAb blocked MegaMouseCD40L-FLAG from binding to 
plate bound recombinant mouse CD40/hFc (10 ng/well) by ELISA (IC50 of 
0.25nM). Anti-mouse CD40 clone 3/23 was used as a positive control (Fig. 2.1C). 
Finally, we tested the anti-CD40 mAb for the ability to antagonize proliferation of 
mouse B cells induced by MegaCD40L, a soluble construct of two artificially 
linked CD40L molecules. FGK4.5, a complete CD40 agonist, induced maximal 
proliferation of B cells (Fig. 2.1D). The anti-CD40 mAb completely inhibited cell 
proliferation, whereas 3/23 showed partial agonistic effects (Fig. 2.1D).  These 
data demonstrate that the anti-CD40 mAb is a fully antagonistic antibody.  
 
 





Fig. 2.1. Anti-CD40 mAb is a fully antagonistic antibody. (A) The anti-CD40 mAb was 
tested for binding to plate-bound recombinant CD40-hFc and RANK-hFc fusion proteins. 
(B) The anti-CD40 mAb was tested for binding to WT B6 and Cd40-/- splenocytes. (C) 
Anti-CD40 mAb and control 3/23 antibody were tested for blocking soluble CD154 
binding to plate-bound CD40. (D) The anti-CD40 mAb and control antibodies FGK4.5 
































































































Anti-CD40 mAb combined with DST prolongs skin allograft survival 
 
 A two-element protocol comprising DST and anti-CD154 mAb has been 
shown to prolong the survival of murine skin, islet and cardiac allografts 
(Kishimoto et al., 2004; Markees et al., 1997; Parker et al., 1995). Considering 
the complete antagonistic nature of the anti-CD40 mAb (Fig. 2.1), I hypothesized 
that the anti-CD40 mAb will work efficiently in costimulation blockade therapies 
aimed at prolonging survival of allogeneic tissues in mice. I therefore tested 
DST/anti-CD40 combination therapy in the stringent BALB/c to B6 mouse model 
of skin transplantation (Fig. 2.2A). Untreated mice reject skin grafts between 10-
15 days in this model (Iwakoshi et al., 2000). Mice that received DST/isotype 
control treatment rapidly rejected skin grafts with a median survival time (MST) of 
12 days (Fig. 2.2B). DST/anti-CD40 treatment, on the other hand, significantly 
prolonged allograft survival over the duration of the experiment similar to 










Fig. 2.2. Anti-CD40 mAb is equivalent to anti-CD154 mAb at prolonging allograft 
survival. (A) C57BL/6 mice were grafted with BALB/c skin on day 0 and treated with a 
DST of 10 x 106 BALB/c splenocytes i.v. on day -7 and 0.5 mg of anti-CD154 mAb or 1 
mg of anti-CD40 mAb or its isotype control i.p. on days -7, -4, 0 and +4 where indicated. 
Graft survival curves are shown in (B). Data are representative of three independent 
experiments. *p<0.05, **p<0.01, ****p<0.0001. 
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Next I tested the impact of these treatments on alloreactive B cell and T cell 
function. Mice were bled two weeks post skin transplantation and the plasma 
levels of alloantibodies were determined. Untreated/naive mice were used as 
negative controls. Mice that received DST/isotype control treatment had high 
levels of circulating alloantibodies (Fig. 2.3A). Anti-CD40 mAb, similar to anti-
CD154 mAb, blunted the alloantibody levels to the extent of untreated mice (Fig. 
2.3A). Next I investigated the ability of alloreactive CD8 T cells to produce IFN-γ 
upon ex vivo allogeneic (BALB/c) stimulation 6 weeks post skin transplantation. 
In agreement with our previous studies, DST/anti-CD154 treatment resulted in a 
low frequency of IFN-γ producing alloreactive effector/memory CD8 T cells (Fig. 
2.3B) (Brehm et al., 2007; Thornley et al., 2006a). Mice that received 
DST/isotype control had significantly higher levels of IFN-γ+ CD8 T cells, 
whereas DST/anti-CD40 treatment reduced the frequency of IFN-γ producers 
(Fig. 2.3B). These results indicate that anti-CD40 mAb in combination with DST 
inhibits alloantibody production by B cells and generates low levels of IFN-γ 







Fig. 2.3 Anti-CD40 mAb combined with DST reduces the generation of graft-
reactive antibodies and IFN-γ producing effector/memory CD8 T cells. 
 
Fig. 2.3. Anti-CD40 mAb combined with DST reduces the generation of graft-reactive 
antibodies and IFN-γ producing effector/memory CD8 T cells. C57BL/6 mice were 
treated as in Fig. 2.2A. (A) Alloantibodies in the plasma of the mice were measured by 
flow cytometry 2 weeks post-transplantation. Plasma from untreated mice served as 
negative control for the alloantibody assay. (B) Splenocytes were harvested from mice 6 
weeks post-transplantation and stained for intracellular IFN-γ upon allogeneic BALB/c 
stimulation. The percentages and numbers of IFN-γ producing CD8+ T cells are shown. 















































































































Anti-CD40 mAb combined with DST inhibits alloreactive CD8 T cell 
expansion and function 
 
 
 I next evaluated the effects of anti-CD40 mAb treatment on alloreactive 
CD8 T cell function, levels, and phenotype. I assessed the cytotoxic potential of 
alloreactive CD8 T cells in C57BL/6 mice using an in vivo cytotoxicity assay. 
Recipient mice were administered allogeneic (H2k) CBA DST along with a single 
dose of anti-CD154, anti-CD40 or the isotype control Ab and tested for their 
ability to reject allogeneic CBA splenocytes 3 days later. NK cells from B6 mice 
do not reject CBA splenocytes in vivo and the rejection observed is entirely a 
result of CD8 T cell cytotoxicity (Brehm et al., 2005). Untreated mice did not 
reject allogeneic cells since they have not acquired cytolytic capability in the 3 
hour time frame of this assay (Fig. 2.4). Mice in the DST/isotype control group 
demonstrated 81% killing of allogeneic CBA targets confirming alloreactive CD8 
T cell cytotoxic functionality. Anti-CD40 mAb, similar to anti-CD154 mAb, 
reduced the cytolysis to background levels. The results of the in vivo cytotoxicity 
assay suggested two possibilities: blocking CD40-CD154 interactions 1) inhibits 
cytotoxicity of CD8 T cells on a per cell basis and/or 2) depletes alloreactive CD8 
T cells effectively reducing the net cytotoxicity of the remainder cells.  
To determine if DST/anti-CD40 treatment results in deletion of alloreactive 
CD8 T cells, I utilized a TCR transgenic mouse model on the H-2k background 









Fig. 2.4. DST/anti-CD40 mAb treatment inhibits cytolysis of allogeneic target cells. 
C57BL/6 mice were treated on day 0 with a DST of 10 x 106 CBA splenocytes i.v. and 
0.5 mg of anti-CD154 mAb or 1 mg of anti-CD40 mAb or its isotype control i.p as 
indicated. On day 3, CFSE labeled CBA (H2k) and C57BL/6 (H2b) splenocytes were 
transferred intravenously at equal proportions into the mice, and the survival of each 
population was determined 3 hours later. Survival of the CBA splenocytes is shown in 
the representative histograms and the graph shows percent specific lysis of CBA 




































































Chimeras generated from these mice, called ‘KB5 chimeras’ have 2-12% 
alloreactive CD8 T cells in the circulation that can be recognized by the 
clonotypic antibody DES (Iwakoshi et al., 2001). KB5 chimeric mice were injected 
with a DST from B6 (H-2b) mice and a single dose of anti-CD154, anti-CD40 or 
the isotype control Ab. The frequency of alloreactive DES+ CD8 T cells was then 
monitored in the blood. DES+ CD8 T cells in all mice that received DST 
underwent an early attrition (Table 2.1). This finding suggests that the DST 
component of costimulation blockade is responsible for this early death of 
alloreactive CD8 T cells. This phase of cell death was followed by a rapid 
expansion in the DST/isotype control group by day 3 suggesting a rapid burst of 
proliferation. Expansion of DES+ CD8 T cells was however blunted in the 
DST/anti-CD40 and DST/anti-CD154 groups and significantly lower numbers 
were found in the spleens of these mice (Table 2.1, Fig. 2.5A). The inhibition of 
expansion of alloreactive CD8 T cells observed in the DST/anti-CD40 group 
between 48 and 72 hours (Table 2.1) suggested these cells are refractory to 
proliferation. To determine the proliferative potential of alloreactive CD8 T cells 
with each treatment, 2 X 106 VPD450 labeled DES+ CD8 T cells were adoptively 
transferred into non-transgenic CBA mice that were then injected with B6 DST 
and anti-CD154, anti-CD40 or the isotype control Ab after 24 hours. Mice were 
sacrificed on day 3 post-treatment for proliferation analysis of VPD450 labeled 




Table 2.1. DST/anti-CD40 treatment inhibits expansion of alloreactive CD8 T 














- 6 6.33±0.86 7.88±1.54a 7.27±1.10b 6.257±1.15 
DST/anti-CD40 10 7.05±0.35 0.94±0.06 1.79±0.56 1.62±0.19 
DST/isotype control 10 6.06±0.73 0.52±0.07 6.07±1.12b 2.6±0.33 
DST/anti-CD154 7 6.71±0.79 0.69±0.34 1.24±0.27 1.26±0.15 
 
KB5 chimeras were administered the indicated treatment and bled at the indicated times. 
The values indicate the percentage of DES+ CD8 T cells in the blood (gated on 
lymphocytes) and are expressed as mean ± SEM. Data are cumulative of two 
independent experiments.  a p<0.0001 vs all other groups, b p<0.05 vs DST/anti-CD40 


























Fig. 2.5. DST/anti-CD40 mAb treatment inhibits alloreactive CD8+ T cell 
expansion and function. 
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Fig. 2.5. DST/anti-CD40 mAb treatment inhibits alloreactive CD8+ T cell expansion and 
function.  (A) KB5 chimeric mice were treated on day 0 with a DST of 10 x 106 C57BL/6 
splenocytes i.v. and 0.5 mg of anti-CD154 mAb or 1 mg of anti-CD40 mAb or its isotype 
control i.p and sacrificed on day 3. The numbers of DES+ CD8+ T cells in the spleen are 
shown. Data are representative of 2 experiments. (B) 2 x 106 VPD450 labeled DES+ CD8 
T cells were transferred intravenously to non-transgenic CBA mice that further received 
the indicated treatments. Mice were sacrificed on day 3 and DES+ CD8 T cells from the 
spleen were assessed for VPD450 dilution. Representative VPD450 profiles and 
proliferation indices for each treatment group are shown. (C) Mice treated as in (A) were 
sacrificed on day 3. Representative flow plots for CD44hi DES+ CD8 T cells and CD44 
MFI are shown. Data are representative of 2 independent experiments. (D) Mice treated 
as in (A) were sacrificed on day 3 and splenocytes were stained for intracellular IFN-γ 
upon allogeneic B6 stimulation. The top panel shows representative flow plots of IFN-γ 
staining on DES+ CD8 T cells. The bottom panel shows percentages and numbers of 
IFN-γ producing DES+ CD8 T cells. All data are cumulative of 2 independent 






Cells in all mice that received DST underwent multiple cycles of divisions; 
however, anti-CD40 and anti-CD154 treatments resulted in modest delay in cell 
division (Fig. 2.5B). These data suggest that anti-CD40 mAb induces abortive 
expansion of DES+ CD8 T cells to alloantigen challenge, a process where cells 
proliferate but then undergo cell death impairing the net accumulation of cells. 
I next assessed if anti-CD40 mAb reduces activation and function of DES+ 
CD8 T cells. I first quantified the expression of the activation marker CD44 on 
DES+ CD8 T cells in the spleen on day 3. I found that a majority of DES+ CD8 T 
cells in the mice that received DST were CD44hi (DST/isotype control group: 79.5 
± 2.4%, DST/anti-CD40 group: 77.1 ± 1.8%, DST/anti-CD154 group: 74.8 ± 
1.1%). CD44 expression in the three groups was comparable indicating that anti-
CD40 mAb treatment does not inhibit alloreactive CD8 T cell activation (Fig. 
2.5C). However, a significantly lower percentage of DES+ CD8 T cells in the 
DST/anti-CD40 group produced IFN-γ following ex vivo restimulation with 
allogeneic C57BL/6 cells relative to DST/isotype control group (Fig. 2.5D).  
Interestingly, DST/anti-CD154 treated mice showed a significantly lower 
percentage of IFN-γ producing effector DES+ CD8 T cells compared to DST/anti-
CD40 treatment. The total number of IFN-γ+ DES+ CD8 T cells was significantly 
lower in both DST/anti-CD40 and DST/anti-CD154 groups relative to DST/isotype 
control (Fig. 2.5D). Together, these data indicate that blocking CD40 in mice 
limits the magnitude of the alloresponse as well as the function of alloreactive 









 Productive activation and function of T cells requires priming by antigen-
presenting cells. I tested the hypothesis that the anti-CD40 mAb acts by 
depleting CD40 expressing antigen-presenting cells thus causing a deficiency of 
cells required to prime alloreactive T cells and mediate graft rejection. I 
administered CBA DST and a single dose of anti-CD40, isotype control or anti-
CD154 mAb to C57BL/6 mice. Mice were sacrificed 24 hours later and numbers 
of B cells, dendritic cells and macrophages were determined in the spleen. 
Spleens of the mice from each treatment group showed comparable numbers of 
each of the cell types indicating that the anti-CD40 mAb does not deplete CD40 
expressing cells (Fig. 2.6).  
 




Regulatory T cells play a vital role in the induction and maintenance of 
tolerance to allografts (Ferrer et al., 2014; Walsh et al., 2004). Depletion of CD4+ 
CD25+ Tregs by the anti-CD25 mAb PC61 prevented tolerance induction by 





Fig. 2.6. Anti-CD40 mAb does not deplete CD40 expressing cells.  
 
 
Fig. 2.6. Anti-CD40 mAb does not deplete CD40 expressing cells. C57BL/6 mice were 
treated with a DST of 10 x 106 CBA splenocytes i.v. and 0.5 mg of anti-CD154 mAb or 1 
mg of anti-CD40 mAb or its isotype control i.p and sacrificed 24 hours later. The 
numbers of B220+ CD19+ B cells (A), CD11c+ dendritic cells (B) and CD11b+ 














































































However, PC61 can potentially deplete activated CD4 and CD8 T cells that have 
transiently upregulated CD25 confounding interpretations of results obtained with 
this depletion. To circumvent this problem, I employed B6.Foxp3DTR mice in order 
to test the role of CD4+ Foxp3+ Tregs in prolonging allograft survival by the 
DST/anti-CD40 therapy. These mice express DTR-EGFP genes knocked-in into 
the Foxp3 locus and maintain expression of the endogenous Foxp3 gene intact 
(Kim et al., 2007). Injection of diphtheria toxin to these mice specifically ablates 
Foxp3+ cells. B6.Foxp3DTR mice and B6 mice were injected with DT daily from 
day -8 to day -2 relative to BALB/c skin transplantation on day 0 (Fig. 2.7A). Mice 
were bled before DT treatment and on day -1 to estimate Treg levels. DT 
treatment caused over 97% depletion of CD4+ CD25+ Foxp3+ Tregs in the blood 
of B6.Foxp3DTR mice (Fig. 2.7B). Tregs rebounded to 70% of their original levels 
in blood on day +8. B6.Foxp3DTR mice that received DST/anti-CD40/PBS 
demonstrated prolonged skin allograft survival (MST of 35 days) indicating that 
they don’t have an intrinsic resistance to tolerance induction (Fig. 2.7C). 
Confirming earlier observations, Treg depletion by DT in DST/anti-CD154 treated 
B6.Foxp3DTR recipients precipitated allograft rejection (MST of 13 days). DT 
administration induced a similar rejection of skin allografts in B6.Foxp3DTR mice 
treated with DST/anti-CD40 (MST of 11 days). WT C57BL/6 mice treated with 
DST/anti-CD40/DT exhibited prolonged allograft survival indicating that DT, by 





Fig. 2.7. CD4+ Foxp3+ Tregs are necessary for tolerance induction by DST/anti-
CD40 mAb treatment. 
 
 
Fig. 2.7. CD4+ Foxp3+ Tregs are necessary for tolerance induction by DST/anti-CD40 
mAb treatment. (A) B6 or B6.Foxp3DTR mice were grafted with BALB/c skin on day 0 and 
treated with a DST of 10 x 106 BALB/c splenocytes i.v. on day -7 and 0.5 mg of anti-
CD154 mAb or 1 mg of anti-CD40 mAb or its isotype control i.p. on days -7, -4, 0 and +4 
where indicated. 100 ng of diphtheria toxin or PBS was administered daily from day -8 to 
day -2 where indicated. (B) B6.Foxp3DTR mice that received diphtheria toxin were bled 
on days -8, -1 and +8. Representative flow plots and graphs showing the frequency of 
C25+ Foxp3(GFP)+ of total CD4+ T cells. (C) Graft survival curves are shown. Data are 
cumulative of two independent experiments. ***p<0.001, ****p<0.0001. 
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These data demonstrate that the tolerogenic properties of DST/anti-CD40 
therapy are dependent on Foxp3+ Tregs.  
 
 




Previous studies have shown that inflammation resulting from viral infections like 
LCMV and Pichinde virus and bacterial infections like Listeria monocytogenes 
and Staphylococcus aureus prevents costimulation blockade mediated tolerance 
induction (Ahmed et al., 2011; Wang et al., 2008; Welsh et al., 2000). Studies 
have reported that TLR (Toll like receptor) agonists LPS, poly(I:C), Pam3CysK4 
and CpG prevent anti-CD154 mAb mediated long-term allograft acceptance 
(Chen et al., 2006; Thornley et al., 2006a). I questioned if DST/anti-CD40 
induced tolerance is susceptible to inflammatory stimuli. LPS was administered 
to mice that received DST and anti-CD154 or anti-CD40 mAb on day -7 relative 
to skin (Fig. 2.8A). Confirming previous observations, LPS treatment resulted in 
acute allograft rejection in the DST/anti-CD154 group (MST = 14.5 days, Fig. 
2.8B). B6 mice in the DST/anti-CD40/LPS group also rejected skin allografts with 






Fig. 2.8. LPS prevents DST/anti-CD40 mediated tolerance induction.  
 
Fig. 2.9. LPS prevents DST/anti-CD40 mediated tolerance induction. (A) C57BL/6 mice 
were grafted with BALB/c skin on day 0 and treated with a DST of 10 x 106 BALB/c 
splenocytes i.v. on day -7 and 0.5 mg of anti-CD154 mAb or 1 mg of anti-CD40 mAb or 
its isotype control i.p. on days -7, -4, 0 and +4 where indicated. 50 ug LPS was injected 
on day -7 relative to transplantation. Graft survival curves are shown in (B). Data are 
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To determine if LPS activated alloreactive B cells during costimulation blockade 
with anti-CD40 mAb, alloantibodies were measured in treated mice. However, I 
found that LPS treatment did not increase alloantibody levels compared to 
DST/anti-CD40 treatment alone (Fig. 2.9A). Previously our lab had shown that 
CD8 T cells were necessary for LPS to shorten skin allograft survival induced by 
DST/anti-CD154 (Thornley et al., 2006b). Indeed, the percentage and numbers 
of CD8 T cells secreting IFN-γ in response to allogeneic (BALB/c) stimulation 
were higher in mice treated with DST/anti-CD154/LPS relative to mice treated 
with DST/anti-CD154 alone although the difference was not statistically 
significant (Fig. 2.9B). Similarly higher frequencies of IFN-γ producing CD8 T 
cells were observed in mice treated with DST/anti-CD40/LPS suggesting a 
prominent role of alloreactive CD8 T cells in LPS mediated allograft rejection 






Fig. 2.9. LPS challenge increases levels of donor-reactive IFN-γ producing CD8 
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Fig. 2.9. LPS challenge increases levels of donor-reactive IFN-γ producing CD8 T cells, 
but not alloantibodies in response to DST/anti-CD40. C57BL/6 mice were treated as in 
Fig. 2.8A. (A) Alloantibodies in the plasma of the mice were measured by flow cytometry 
2 weeks post-transplantation. Plasma from untreated mice served as negative control for 
the alloantibody assay. (B) Splenocytes were harvested from the mice 6 weeks post-
transplantation and stained for intracellular IFN-γ upon allogeneic BALB/c stimulation. 
The percentages and numbers of IFN-γ producing CD8+ T cells are shown. Data are 

















CD40-CD154 interactions play a critical role in the regulation of the 
immune response and hence are being actively targeted in transplantation, 
autoimmunity and cancer. After a brief hiatus following the unexpected 
development of thromboembolism in patients receiving anti-CD154 reagents in 
clinical trials for renal transplantation (Kawai et al., 2000), the CD40-CD154 
pathway has enjoyed a resurgence with the development and success of anti-
CD40 antibodies in experimental models of transplantation. However, the modes 
of action of these antibodies in vivo at the molecular and cellular level are not 
clear. CD40 targeting antibodies possessing variable attributes like isotype, 
target epitope, agonistic potential, serum half-life and cellular depletion have 
prolonged allograft survival in non-human primates (Adams et al., 2005; Aoyagi 
et al., 2009; Badell et al., 2012; Cordoba et al., 2015; Haanstra et al., 2003; Lowe 
et al., 2012; Oura et al., 2012; Page et al., 2012; Pearson et al., 2002). 
Conceptually, an ideal CD40 antibody candidate for clinical translation in 
transplantation would 1) be an antagonist 2) have a long serum half-life 3) not 
deplete CD40 expressing APCs thereby preserving protective immunity to 
pathogens 4) be non-immunogenic. Knowledge of the mechanisms by which 
anti-CD40 antibodies prolong graft survival will help investigators design better 
reagents for clinical translation. In this study, I described a novel murine anti-
CD40 mAb and compared its effects on skin allograft survival and donor-reactive 




CD40 mAb is as effective as anti-CD154 mAb in the induction of transplantation 
tolerance and suppression of alloimmunity. 
 CD154 has four known receptors: the classical receptor CD40 and the 
integrins Mac-1 (Wolf et al., 2011), αIIbβ3 (André et al., 2002) and α5β1 (Leveille et 
al., 2007). The contribution of each of these interactions to the development of an 
alloresponse needs to be elucidated to gain a complete understanding of the 
mechanism of action of anti-CD154 antibodies. The current paradigm is that anti-
CD154 antibodies inhibit the binding of CD154 on activated CD4 T cells to CD40 
on APCs preventing APC maturation resulting in diminished expansion and 
differentiation of alloreactive T cells (Ford, 2016). αIIbβ3 is expressed only on 
platelets and its binding to soluble CD154 was shown to be necessary for 
stability of arterial thrombi (André et al., 2002). The CD154 - αIIbβ3 interaction is 
thus important for thrombosis with no known role in alloimmunity. Mac-1 and α5β1 
are expressed on innate immune cells like monocytes, macrophages and 
neutrophils and play a role in cellular adhesion and migration. Studies by El-
Sawy and colleagues demonstrated that attenuating neutrophil-mediated tissue 
damage during reperfusion improved the efficacy of costimulation blockade to 
prevent cardiac allograft rejection suggesting a vital role of innate cells in 
transplant rejection (El-Sawy et al., 2005). Recently CD154 costimulation 
blockade was shown to reduce chemokine expression and intra-graft infiltration 
of neutrophils and CD8 T cells (Ferrer et al., 2012b).  It is conceivable that 




allograft and inhibition of these interactions by anti-CD154 antibody delays graft 
rejection. Earlier studies attributed the tolerogenic properties of the anti-CD154 
mAb (MR1) to Fc-mediated deletion of activated alloreactive T cells (Monk et al., 
2003). However, subsequent studies suggested that Fc-dependent functions of 
anti-CD154 mAb are not critical for induction of tolerance. An aglycosylated form 
of anti-CD154 exhibiting reduced binding to Fc receptors and complement was 
able to prolong skin allograft survival with similar efficacy as the glycosylated 
form (Daley et al., 2008). Moreover, an Fc-silent anti-CD154 domain antibody 
attenuated donor-reactive effector T cell responses, promoted generation of 
Foxp3+ induced Tregs (iTregs) and prolonged skin graft survival comparable to 
the Fc-intact antibody (Pinelli et al., 2013).  
The anti-CD40 mAb used in the studies described here has several point 
mutations in the mouse IgG2a Fc region to reduce antibody-dependent cell-
mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) 
and increase its serum half-life. Mouse IgG2a antibodies have a high activatory : 
inhibitory FcγR binding ratio and thus naturally possess ADCC and CDC effector 
functions (Beers et al., 2016). I confirmed that the Fc-modified antibody did not 
deplete CD40 expressing cells in vivo (Fig. 2.6). Coupled with DST, the anti-
CD40 mAb prolonged survival of allogeneic skin in a transplantation model of 
acute rejection with comparable efficacy to anti-CD154 mAb. In this model, acute 
rejection is primarily mediated by alloreactive T cells. Deletion, anergy and 




tolerance to allografts. Studies have demonstrated a requirement for deletion of 
alloreactive T cells in order to induce tolerance to allografts (Wells et al., 1999). 
Using the KB5 synchimera model, I investigated the effects of DST/anti-CD40 
treatment on donor-reactive CD8 T cells in detail. I observed that this treatment 
predominantly impacted the magnitude of the alloresponse with a smaller impact 
on alloreactive CD8 T cell functionality. It is possible that the skin infiltrating 
alloreactive CD8 T cells exhibit a more profound reduction in functionality 
compared to cells in the spleen. I acknowledge that the KB5 model is a model of 
direct allorecognition and does not fully recapitulate the endogenous 
alloresponse, which has features of both direct and indirect recognition. A recent 
study using an indirect model of allorecognition reported that alloreactive CD4 T 
cells undergo abortive expansion following DST/anti-CD154 treatment, but the 
residual cells retain the capacity to make IL-2, IFN-γ and TNF-α (Chai et al., 
2015). The functional impairment of alloreactive CD8 T cells following DST/anti-
CD154 or DST/anti-CD40 treatment suggest that CD4 and CD8 T cells might be 
differentially regulated by costimulation blockade. Further, my observation that 
DST/anti-CD154 treatment generates a significantly lower percentage of IFN-γ+ 
DES+ effector CD8 T cells relative to DST/anti-CD40 treatment raises the 
possibility of the involvement of other CD154 receptors in regulating IFN-γ 





Engagement of CD40 on DCs with CD154 on activated CD4 T cells 
‘licenses’ DCs by inducing upregulation of B7 molecules CD80 and CD86 as well 
as MHC-I and MHC-II on the DC surface besides promoting secretion of 
cytokines IL-12, IL-6 and TNF (Pinelli and Ford, 2015). Moreover, CD40 signaling 
into DCs promotes DC survival by upregulating expression of the anti-apoptotic 
protein Bcl-xL (Wong et al., 1997). DC-mediated triggering of T cell responses 
depends on both DC longevity and maturation. I found no significant change in 
DC numbers after anti-CD40 treatment (Fig. 2.6B) suggesting that the attenuated 
CD8 T cell responses in mice receiving these antibodies are not a result of 
reduced alloantigen-presenting DC survival. Ferrer et al. recently demonstrated 
reduced secretion of inflammatory cytokines IL-6 and IL-12 by DCs from mice 
treated with anti-CD154 mAb (Ferrer et al., 2012a). It is likely that DST/anti-CD40 
treatment has a similar effect of impairing the provision of ‘signal three’ for 
development of productive alloreactive T cell responses. An additional interaction 
likely to be inhibited by the anti-CD40 mAb is that between CD40 expressed on 
activated CD8 T cells and CD154 on activated CD4 T cells. Using genetic 
ablation of CD40 on different cell types, Liu et al. demonstrated that loss of CD40 
on CD8 T cells was sufficient to prolong allograft rejection and reduce the 
frequency of IFN-γ+ TNF+ double-cytokine producing alloreactive CD8 T cells (Liu 
et al., 2013). The exact contribution of blocking this interaction to prolonging graft 




The ability of donor-specific antibodies to mediate acute rejection and 
chronic rejection in clinic is becoming increasingly clear and is considered a 
major barrier to improving long-term outcomes (Djamali et al., 2014). Therapeutic 
modalities that control alloantibody production in presensitized transplant 
recipients and prevent de novo alloantibody generation are of great interest.  
Interaction of CD40 on activated B cells with CD154 on activated T helper cells is 
necessary for the generation of T-dependent antibody responses (Foy et al., 
1993). CD40 signaling in B cells is required for germinal center formation and 
progression, antibody isotype switching and affinity maturation (Elgueta et al., 
2009). Indeed, I found that inhibition of CD40-CD154 interactions by the anti-
CD40 or anti-CD154 mAb coupled with DST led to a drastic decrease in 
alloantibody levels in vivo (Fig. 2.3A). Thus, CD40 costimulation blockade limits T 
as well as B cell responses to the graft.  
Regulatory T cells are major players in the maintenance of self-tolerance 
as well as induced tolerance. I demonstrated a requirement for Foxp3+ Tregs 
during the induction phase of tolerance by the anti-CD40 mAb. Ferrer et al. 
showed that DST/anti-CD154 induces peripheral graft-reactive Tregs as early as 
7 days post DST and these iTregs infiltrate the graft and mediate 
immunosuppression. (Ferrer et al., 2011). Using diphtheria toxin to deplete 
Foxp3+ cells in B6.Foxp3DTR mice, I demonstrated over 95% depletion of CD4+ 
CD25+ Foxp3+ cells by day 7 post DST (Fig. 2.7B). I speculate that the DT 




number of iTregs resulting in skin graft rejection. My results demonstrate the 
dominant role of Foxp3+ Tregs in tolerance induction by CD40 costimulation 
blockade and that Foxp3- Tregs are not sufficient to induce tolerance.   
  Certain viral and bacterial infections in the peri-transplant period have 
been shown to override the tolerizing effects of anti-CD154 mAb by generating 
CTLs cross-reactive with the alloantigen or by promoting bystander activation of 
alloreactive T cells (Ahmed et al., 2011; Welsh et al., 2000). Our lab has 
previously demonstrated that LPS challenge in the pre-transplant period 
shortened DST/anti-CD154 mediated skin graft survival in a CD8 T cell 
dependent manner (Thornley et al., 2006b). LPS signaling through TLR4 
stimulated type I IFN secretion that prevented the deletion of alloreactive CD8 T 
cells (Thornley et al., 2007b). My present study reports that skin graft acceptance 
by DST/anti-CD40 is equally susceptible to LPS (Fig. 2.8B). I observed that LPS 
treatment did not increase alloantibody levels in the plasma, which is consistent 
with another report showing that another TLR agonist CpG does not restore 
alloantibody levels at doses that induce graft rejection (Chen et al., 2006). Higher 
levels of IFN-γ producing CD8 T cells were generated following LPS challenge 
(Fig. 2.9B) suggesting that LPS bypasses CD40 blockade to promote effector T 
cell responses. Although this study does not describe the mechanism by which 
LPS shortens graft survival, I speculate that LPS induces APC maturation 
resulting in increased costimulatory molecule expression and production of 




 In conclusion, I describe a novel, antagonistic, Fc-mutated non-depleting 
anti-CD40 mAb that prolongs fully mismatched skin graft survival and attenuates 
donor-reactive T and B cell responses when administered with DST. This study 
highlights that anti-CD154 mAb and anti-CD40 mAb has similar effects on skin 
allograft survival and cell-mediated and humoral responses and thus, these 
antibodies act predominantly by blocking the CD40-CD154 interaction. The role 
of CD154 interacting with its integrin receptors in the generation of alloresponses 
appears to be minimal, if any. In line with other studies, I have shown that 
depletion of APCs is not necessary to achieve prolonged graft survival by CD40 
targeting antibodies (Cordoba et al., 2015; Okimura et al., 2014). Finally, I show 
that tolerance induction by CD40 blockade is susceptible to inflammatory insults. 
I propose that therapies targeting multiple costimulatory pathways and the 
transfer of autologous ex-vivo expanded polyclonal or donor antigen-specific 
















 Proapoptotic proteins Fas and Bim 
concurrently regulate costimulation 








Apoptosis of CD8 T cells is an essential mechanism that maintains immune 
system homeostasis, prevents autoimmunity and reduces immunopathology. 
CD8 T cell death also occurs early during both the response to inflammation and 
the induction of peripheral tolerance to allografts by costimulation blockade 
therapy. T cell death is mediated by the extrinsic death receptor pathway and 
intrinsic or mitochondrial death pathway. Here I studied the effects of a combined 
deficiency of Fas (extrinsic) and Bim (intrinsic) on peripheral tolerance induction 
to allografts by costimulation blockade. Bcl2l11-/-Faslpr/lpr mice were resistant to 
tolerance induction by costimulation blockade targeting the CD40-CD154 
pathway. This result demonstrates that both extrinsic and intrinsic apoptosis 






Apoptosis is a critical mechanism regulating T cell homeostasis and is 
essential for T cell development, for suppression of autoreactive T cells, and for 
the contraction phase of an antigen-specific T cell response. The well described 
attrition of memory T cells occurring early after both viral infection and peripheral 
tolerance induction by costimulation blockade therapy also involves apoptosis of 
T cells. Death of alloreactive T cells is an important component for successful 




pathways (Li et al., 2001; Wells et al., 1999). Tolerance induction strategies 
targeting the CD28-B7 and CD40-CD154 costimulation pathways have been 
tested extensively in animal models of transplantation (Ford, 2016). 
Costimulation blockade utilizing the reagents CTLA4-Ig and anti-CD154 mAb 
extends survival of skin, islets, heart and kidney allografts in mice (Maltzman and 
Turka, 2013). (CTLA4-Ig + anti-CD154) induced tolerance to allografts in FasL 
deficient gld mice or Fas deficient lpr mice suggesting that the Fas-FasL pathway 
is not necessary for tolerance induction (Li et al., 1999; Trambley et al., 2001; 
Wagener et al., 2000). Moreover, Bim deficient mice were sensitive to tolerance 
induction by costimulation blockade (CTLA4-Fc + anti-CD154) indicating that the 
passive cell death pathway regulated by Bim is dispensable for peripheral 
tolerance induction (Lehnert et al., 2007).  
In the present study, I investigated the effects of a combined deficiency of 
Fas and Bim on costimulation blockade induced tolerance to skin allografts by 
generating mice lacking Bim and harboring the inactivating lpr mutation in Fas 
(Bcl2l11-/-Faslpr/lpr). Mice lacking Bim and bearing the lpr mutation in Fas have a 
block in the contraction of antigen-specific T cells in chronic and certain acute 
viral infections, dysregulated homeostatic proliferation and develop 
lymphadenopathy and autoimmunity (Bouillet and O'Reilly, 2009; Fortner et al., 
2010; Hughes et al., 2008; Hutcheson et al., 2008; Weant et al., 2008). My 
studies show that Bcl2l11-/-Faslpr/lpr mice were resistant to tolerance induction to 




mAb. These results indicate that Fas and Bim function concurrently to regulate 
peripheral tolerance induction by costimulation blockade. 
  
Materials and Methods    
 
Mice 
C57BL/6J (H2b), BALB/c (H2d) and CBA/J (H2k) mice were obtained from The 
Jackson Laboratory. Bcl2l11-/- and Bcl2l11-/-Faslpr/lpr mice were obtained from Dr. 
Roger Davis’s laboratory at University of Massachusetts Medical School, 
Worcester, MA. All animals were housed in a specific pathogen free facility in 
microisolator cages and given autoclaved food. All experiments were performed 
in accordance with the guidelines of the Institutional Animal Care and Use 
Committee of the University of Massachusetts Medical School. 
 
Transplantation 
Recipient mice of the specified strain were transplanted with complete MHC 
mismatched skin and treated with a tolerizing regimen of DST and anti-CD154 
mAb as described previously (Iwakoshi et al., 2000). Briefly, full thickness skin 
grafts were obtained from flanks of donor mice and transplanted onto the dorsal 
flanks of recipient mice on day 0. A DST of 1 x 107 donor splenocytes was 
injected i.v. on day -7 relative to skin transplantation on day 0. 0.5 mg anti-




relative to skin transplantation. Skin grafts were monitored for survival and graft 
rejection was defined as the first day when the entire graft was necrotic.  
 
Antibodies, flow cytometry and intracellular cytokine staining 
Leukocytes were stained for CD8α (53-6.7), CD4 (RM4-5), CD44 (IM7), IFNγ 
(XMG1.2). For intracellular cytokine staining, 2X106 RBC lysed splenocytes from 
recipient mice were incubated with 1X106 LPS matured, irradiated syngeneic 
(H2b) or allogeneic (H2d) stimulator cells for 4 hrs in complete RPMI and 
monensin (eBioscience) and assessed for intracellular IFNγ production as 
described previously (Brehm et al., 2007). Samples were analyzed on an LSRII 
flow cytometer (Becton Dickinson), and data were further analyzed using FlowJo 
(Tree Star).  
 
Statistics 
Statistical analyses were performed using GraphPad PRISM software. To 
compare 3 or more means, one-way ANOVA and Tukey’s multiple comparisons 
test were used. All error bars represent the Standard Error of the Mean (SEM). 
Allograft survival curves were plotted by the Kaplan-Meier method and compared 







Peripheral tolerance induction by costimulation blockade is dependent on 
Fas and Bim 
 
To determine the apoptotic pathways involved in allograft survival induced by 
costimulation blockade, WT C57BL/6J, Bcl2l11-/- and Bcl2l11-/-Faslpr/lpr mice were 
transplanted with MHC-mismatched BALB/c skins and treated with DST/anti-
CD154 mAb. WT C57BL/6J mice that were given no treatment rejected skin 
grafts rapidly with a median survival time (MST) of 12 days (Fig. 3.1A). In 
contrast, WT mice that received DST/anti-CD154 mAb treatment showed 
prolonged allograft survival, consistent with previous reports (Fig. 3.1A) (Markees 
et al., 1997). Bcl2l11-/- mice that received no treatment rejected grafts with 
kinetics similar to those of WT mice (MST=12 days) (Fig. 3.1A). Interestingly, 10 
out of 17 Bcl2l11-/- mice that received DST/anti-CD154 mAb rejected grafts 
(MST=13 days) (Fig. 3.1A), suggesting that Bim is partially necessary for 
tolerance induction. Skin allografts were rejected in Bcl2l11-/-Faslpr/lpr mice that 
received no treatment, as expected (MST=14 days) (Fig. 3.1A). All Bcl2l11-/-
Faslpr/lpr mice that were treated with DST/anti-CD154 mAb rejected their grafts 
with a MST of 15 days (Fig. 3.1A). These results suggest that loss of Fas 
function in addition to that of Bim completely prevents the increased survival of 





Fig. 3.1. Costimulation blockade induced tolerance to allografts is dependent on 




Fig. 3.1. Costimulation blockade induced tolerance to allografts is dependent on Bim and 
Fas.	 A) WT C57BL/6, Bcl2l11-/- and Bcl2l11-/-Faslpr/lpr mice were treated with BALB/c 
DST/anti-CD154 mAb and skin as described in the Materials and Methods. Skin allograft 
survival was then monitored for all groups. The graph shows skin graft survival curves. 
B) Splenocytes were harvested from the WT, Bcl2l11-/- and Bcl2l11-/-Faslpr/lpr mice 5 
weeks post-transplantation, stimulated with in vitro matured irradiated syngeneic (H2b) or 
allogeneic (H2d) splenocytes for 4 hours and stained for intracellular IFN-γ by flow 
cytometry. The bar graphs show percentages of IFN-γ producing CD8 T cells in 
response to syngeneic and allogeneic stimulation. The data are representative of two 
independent experiments with 2-5 mice per group. Percentages ± SEM are depicted. 
*p<0.05, **p<0.01, ****p<0.0001.  
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I next investigated the ability of alloreactive CD8+ T cells in each group of mice to 
produce IFN-γ in response to syngeneic (C57BL/6J) or allogeneic (BALB/c) 
stimulation. Consistent with our previous observation, DST/anti-CD154 treatment 
significantly reduced the frequency of donor-reactive IFN-γ producing 
effector/memory CD8+ T cells in WT mice correlating with increased survival of 
skin allografts in these mice (Fig. 3.1B) (Brehm et al., 2007). Donor-reactive IFN-
γ producing CD8+ T cell frequencies were lowered in Bcl2l11-/- mice treated with 
DST/anti-CD154 mAb despite the observation that 10 out of 17 of these mice 
rejected skin allografts (Fig. 3.1B). Bcl2l11-/-Faslpr/lpr mice were resistant to 
tolerance induction by DST/anti-CD154 mAb and high frequencies of IFN-γ 
producing CD8+ T cells were detectable in these mice comparable to those 
observed in untreated skin-grafted mice (Fig. 3.1B). Together, these data 
indicate that the deletion of alloreactive T cells and optimal extension of skin 
allograft survival in mice by costimulation blockade requires both Fas and Bim, 




T cell deletion is desirable in settings like autoimmunity and organ 
transplantation. Costimulation blockade is a non-lymphoablative therapy of 
inducing tolerance to donor tissues by inducing deletion or/and anergy of donor-
reactive T cells. Apoptosis of T cells infiltrating into allografts and xenografts was 




1995; Lau et al., 1996). However, studies suggest that activation induced cell 
death (AICD) of alloreactive T cells by Fas is not necessary for tolerance 
induction by costimulation blockade (Li et al., 1999; Trambley et al., 2001; 
Wagener et al., 2000). FasL deficient gld mice were tolerized to similar extent as 
WT mice by costimulation blockade consisting of anti-CD154 mAb and CTLA4-Ig 
in a C3H/HeJ to B6 skin graft model (Trambley et al., 2001). Also, Fas deficient 
B6.lpr mice were tolerized to DBA/2 islet and heart grafts by anti-CD154 
mAb/CTLA4-Ig (Li et al., 1999). Moreover, lpr mice injected with tumor necrosis 
factor-alpha (TNF-α) neutralizing antibody were tolerized to cardiac allografts by 
CTLA4-Ig suggesting that Fas and TNF receptor (TNFR) independent pathways 
contribute to alloantigen-driven T cell apoptosis (Wagener et al., 2000). The role 
of the mitochondrial or passive cell death pathway in the induction of tolerance is 
less clear. Bcl-xL transgenic mice showed partial resistance to tolerance 
induction by CTLA4-Ig or anti-CD154 mAb in a BALB/c to B6 model of 
vascularized cardiac allotransplantation suggesting that the passive cell death 
pathway is partially necessary for tolerance induction (Wells et al., 1999). 
However, Bcl-2 transgenic B6 mice were tolerized to BALB/c islet allografts as 
well as PVG rat islet xenografts by anti-CD154/CTLA4-Fc (Lehnert et al., 2007). 
Also, this study showed that Bim knockout mice were susceptible to tolerance 
induction to rat islet xenografts suggesting that the passive cell death pathway is 




be explained by differences in the transplanted tissue, the strains of mice and the 
costimulation blockade reagents and their dosages.   
 The two-element costimulation blockade protocol of DST/anti-CD154 mAb 
results in abortive expansion of alloreactive T cells (Iwakoshi et al., 2000). 
Tolerance induction by this protocol also requires deletion of mature alloreactive 
B cells (Li et al., 2007). In this study, I have shown in a stringent BALB/c to B6 
skin allograft model, that Bcl2l11-/- mice are partially resistant whereas Bcl2l11-/-
Faslpr/lpr mice are completely resistant to tolerance induction. I propose that the 
passive cell death pathway is the primary mechanism for tolerance induction with 
a small contribution by the death receptor pathway. Recent studies have shown 
that the anti-CD154 mAb inhibits dendritic cell expression of inflammatory 
cytokines that are required for productive T cell activation and expansion (Ferrer 
et al., 2012a). In Fas or FasL deficient mice, the passive death pathway activated 
by the lack of cytokines resulting from CD154 antagonism would mediate 
apoptosis of alloreactive T cells facilitating tolerance induction. In Bim deficient 
mice, some cell death would occur by AICD or mitochondrial apoptosis by an 
alternate BH3 protein such as Puma, Noxa or Bid resulting in partial susceptibility 
to tolerance induction. However, in mice lacking Fas and Bim, the inhibition of 
both extrinsic and intrinsic apoptosis completely prevents tolerance induction. 
These results highlight the concurrent function of multiple apoptotic pathways in 















Differential regulation of alloreactive CD8 T 









The innate immune system can be activated in patients undergoing solid organ 
transplantation by inflammation resulting from the release of endogenous danger 
molecules, infections occurring in peri-transplant period and translocation of 
microbiota. Inflammatory signals regulate the magnitude and functionality of 
antigen-specific T cell responses during challenge with viral and bacterial 
pathogens, but the direct impact of inflammation on the generation of alloreactive 
T cell responses has not been extensively studied. Understanding the role of 
inflammation on regulating the activation of alloreactive T cells will aid in the 
development of novel immune therapies to prolong allograft survival. I used the 
KB5 chimeras expressing allo-specific TCRs to study the response of alloreactive 
T cells in the presence of inflammatory signals. My results show that stimuli 
inducing different inflammatory profiles had significant effects on the size, 
phenotype and quality of the alloreactive CD8 T cell response as compared to 
stimulation with alloantigen alone. Inflammation induced by exposure to poly(I:C) 
increased the number of IFN-γ producing and cytolytic alloreactive effector CD8 T 
cells at the peak of the response. Inflammation induced upon LPS challenge 
increased the number of alloreactive CD8 T cells at the peak of the response; 
however their ability to produce IFN-γ and cytotoxic activity was decreased. 
Signaling through recipient TLR4 and IL-6 were necessary for this LPS mediated 
suppression of CD8 T cell function. LPS slowed the contraction phase of the 




relative to poly(I:C). These data indicate that inflammatory signals differentially 
regulated the kinetics and functionality of alloreactive CD8 T cell responses and 





Although the rates of acute rejection in clinical transplantation have fallen 
in recent years with the current immunosuppression regimens, there is an 
increasing need to develop effective solutions to acute rejection because of the 
increasing demand for organ grafts (Matas et al., 2014). Identification of the 
triggers that make grafts susceptible to acute rejection is essential for the 
development of novel strategies to prolong allograft survival. In addition to the 
direct and antigen dependent onslaught of the adaptive immune system on the 
graft, there are also antigen independent factors that predispose the graft to 
rejection by the immune system (Mori et al., 2014). The role of inflammation in 
triggering graft rejection is becoming increasingly clear. Broadly, there are three 
sources of inflammation in the context of transplantation. First, ischemia 
reperfusion injury results in localized activation of the innate immune system and 
‘sterile inflammation’, a process in which endogenous danger molecules or 
DAMPs bind to pattern recognition receptors (PRRs) expressed on 
hematopoietic, endothelial or parenchymal cells to trigger the innate immune 
system (Mori et al., 2014). Second, infections in transplant recipients can cause 




activation and inflammation (Alegre et al., 2014). Third, microbiota in the recipient 
and donor, in the case of colonized organ grafts, can result in inflammation 
negatively impacting graft survival (Jenq et al., 2012; Lei et al., 2016). Indeed, 
organs colonized with bacteria such as lungs and intestines are known to have 
worse outcomes than sterile organs such as heart and kidney (Colvin-Adams et 
al., 2014; Matas et al., 2014; Smith et al., 2014; Valapour et al., 2014). 
Inflammatory stimuli have also been shown to prevent tolerance induction 
by experimental costimulation blockade therapies in animal models of 
transplantation. Although some pathogens shorten graft survival by generating 
effector/memory T cells cross-reactive to alloantigens (heterologous immunity), 
others do so by activating innate immunity that then activates non-pathogen 
specific alloreactive T cells, a process termed ‘bystander activation’ (Miller et al., 
2008). PRR ligands such as LPS, poly(I:C), Pam3CysK4 and CpG prevent 
costimulation blockade mediated long-term graft acceptance by impairing 
deletion of alloreactive CD8 T cells (Chen et al., 2006; Thornley et al., 2006b).  
PRR ligands are used as adjuvants to boost CD8 T cell responses to 
peptide antigens (Melief et al., 2015). The regulation of cross-presentation of 
antigens by Toll-like receptor (TLR) ligands in vivo appears to depend on the 
cellular location of the TLRs. The plasma membrane TLRs TLR2 and TLR4 
suppress cross-priming (Brossart and Bevan, 1997; Mandraju et al., 2014) 
whereas the endosomal TLRs TLR3 and TLR9 enhance it (Jelinek et al., 2011; 




impact of TLR ligands on CD8 T cell responses has not been studied in the 
context of alloimmunity. Here I studied the effects of two TLR ligands LPS and 
poly(I:C) on alloreactive CD8 T cell responses using the KB5 TCR transgenic 
system. The alloreactive CD8 T cells in this system respond to the foreign MHC 
on the surface of C57BL/6 cells. This system thus permits us to investigate the 
effects of inflammatory stimuli on direct recognition by CD8 T cells. Both LPS and 
poly(I:C) generated higher numbers of effector CD8 T cells at the peak of the 
primary alloresponse; however only LPS generated higher numbers of memory 
CD8 T cells by inhibiting cell death during the contraction phase of the response. 
Although both LPS and poly(I:C) upregulated the early activation markers CD25 
and CD69 on exposure to DST, they had opposite effects on alloreactive CD8 T 
cell function. Poly(I:C) enhanced the frequency of IFN-γ producing and granzyme 
B producing effector CD8 T cells whereas LPS reduced the frequency of IFN-γ 
producers and cytolysis of allogeneic targets. Interestingly IL-6 induced by LPS in 
vivo was necessary for LPS mediated suppression of alloreactive CD8 T cell 
responses. This finding is intriguing given the pro-rejection effects of IL-6 
reported in the literature (Ahmed et al., 2011; Booth et al., 2011; Chen et al., 
2009b; Shen and Goldstein, 2009; Zhao et al., 2012) and highlights the 
pleiotropic nature of this cytokine.  
 






C57BL/6J (H-2b), BALB/cJ (H-2d), CBA/J (H-2k), C3H/HeJ (H-2k) and 
B6.B10ScN-Tlr4lps-del/JthJ (H-2b, abbreviated as Tlr4-/-) mice were obtained 
from The Jackson Laboratory (Bar Harbor, ME). (CBA/J X KB5.CBA) F1 CD8+ 
TCR-transgenic mice were bred at the animal facility of University of 
Massachusetts Medical School. The TCR transgene is expressed in CBA (H-2k) 
mice by CD8 T cells and specifically recognizes native H-2Kb (Schonrich et al., 
1991). Chimeras were generated as described in Chapter II.  
 
Processing of tissues and leukocyte isolation 
Peripheral blood was collected from mice by tail vein bleeding into tubes 
containing heparin. Spleen, inguinal and axillary lymph nodes were excised from 
mice and homogenized using frosted microscope slides. Lungs were perfused 
with cold PBS and then excised and homogenized to a single cell suspension. 
For bone marrow extraction, tibia and femurs from mice were excised and 
marrow was flushed with PBS. Red blood cells from all tissues were lysed with 
0.84% ammonium chloride solution. To isolate intraepithelial lymphocytes (IELs), 
small intestines were removed and the luminal contents were expelled. Peyer’s 
patches were dissected out, the intestines were opened longitudinally and 
chopped into 5mm pieces. The tissue fragments were digested in a solution of 
HEPES bicarbonate buffer supplemented with 10% FBS and 0.1mM EDTA for 30 
mins at 37°C. Cells were filtered, centrifuged, suspended in Histopaque (Sigma 




temperature. IELs were recovered from the Histopaque interface. Cells isolated 
from all tissues were washed, resuspended in flow cytometry buffer (PBS 
supplemented with 1% FBS and 0.1% sodium azide) and counted before 
subsequent use for flow cytometry.  
 
Reagents 
LPS Ultrapure from E.coli 0111:B4 and poly(I:C) (HMW) were obtained from 
InvivoGen (San Diego, CA) and injected i.p. into mice at 50 or 100 µg dose per 
mouse. IL-6 neutralizing antibody (MP5-20F3), IL-10R blocking antibody 
(1B1.3A) and IgG1 isotype control antibody (HRPN) were purchased from 
BioXCell (West Lebanon, NH) and administered i.p. to mice at a dose of 500 µg 
per mouse at the specified times. Recombinant mouse IL-6 obtained from 
BioLegend (San Diego, CA) was injected i.p. at a dose of 3 µg per mouse as 
indicated. The following antibodies were used for flow cytometry: CD8α (53-6.7), 
IgG2a (R19-15), active caspase-3 (C92-605), CD25 (PC61), CD69 (H1.2F3), 
CD44 (IM7), Eomes (Dan11mag), Ly6C (RB6-8C5), IFN-γ (XMG1.2), TNF-α 
(MP6-XT22), granzyme B (GB11), pY705 STAT3 (4/P-STAT3), purchased from 
BD Biosciences, EBioscience or BioLegend.   
 
Apoptosis assay 
RBC lysed splenocytes were stained for surface markers in flow cytometry buffer 




Biosciences) and stained for intracellular active caspase-3 as per the 
manufacturer’s instructions. Freshly stained samples were analyzed on LSRII 
flow cytometer (BD Biosciences) with the FlowJo software (Ashland, OR).  
 
Proliferation assay 
RBC lysed splenocytes from KB5 transgenic mice were labeled with 1 µM 
VPD450 (BD Biosciences) for 12 mins at 37°C. Cells were washed twice in PBS 
supplemented with 10% FBS, and splenocytes comprising 2 X 106 labeled DES+ 
CD8 T cells resuspended in PBS were injected i.v. into non-transgenic CBA 
mice.   
 
Intracellular cytokine staining 
For intracellular cytokine staining, 2X106 RBC lysed splenocytes from recipient 
mice were incubated with 1X106 LPS matured, irradiated syngeneic (H-2b) or 
allogeneic (H-2k) stimulator cells for 4 hrs in complete RPMI and monensin 
(eBioscience) and assessed for intracellular IFNγ production as described 
previously (Brehm et al., 2007). 
 
In vivo cytotoxicity assay 
The in vivo cytotoxicity assay was performed as described in Chapter II. 
  




Levels of cytokines IL-6, IL-10, MCP-1, IFNγ, TNF and IL-12p70 in the plasma of 
mice were determined by BD Cytometric Bead Array™ as per the manufacturer’s 
instructions. Levels of IFN-β were determined by ELISA. IFN-β antibody (7F-D3) 
(Santa Cruz Biotechnology) was used to coat wells of a flat-bottom 96-well plate 
overnight at 4°C. The plates were washed with wash buffer (PBS supplemented 
with 0.05% Tween 20) thrice and blocked with the blocking solution (PBS 
supplemented with 10% FBS) for 2 hours at 37°C. Plasma samples and IFN-β 
standards (PBL Assay Science) were added to the wells and incubated overnight 
at 4°C. The plates were washed and incubated with polyclonal rabbit anti-mouse 
IFN-β antibody (PBL Assay Science) for 90 mins at RT, followed by a secondary 
HRP-linked polyclonal anti-rabbit Ig antibody (Agilent Technologies) for 2 hours 
at RT. The plates were washed and TMB substrate (Bethyl Laboratories, 
Montgomery, TX) was added for 15 mins at RT. The reaction was quenched by 
adding ELISA stop solution containing 0.18M H2SO4 (Bethyl Laboratories) and 
IFN-β concentrations were determined using an EMax Endpoint ELISA 
Microplate Reader (Molecular Devices).  
 
Phospho-STAT3 (Tyr705) staining 
RBC-lysed splenocytes were resuspended in complete RPMI and plated at 1x106 
cells per well in 96 well round bottom plates. Cells were stimulated with 0.1 µg 
recombinant IL-6 for 30 mins at 37°C and then fixed with BD Cytofix (BD 




with Fc block™ (BD Biosciences) and stained for surface markers. After washing, 
cells were permeabilized with ice-cold BD Perm Buffer III (BD Biosciences) for 30 
mins at 4°C in dark. Splenocytes were washed and stained with fluorescently 
labeled anti-pSTAT3 antibody for 45 mins at RT in dark. Cells were washed, 
resuspended in flow cytometry buffer and analyzed on LSR II flow cytometer.  
 
Statistical analyses 
Statistical analyses were performed using GraphPad PRISM software (San 
Diego, CA). An upaired t-test was used to compare two means. Three or more 
means were compared using one-way ANOVA and Tukey’s multiple 




LPS and poly(I:C) generate distinct cytokine milieus 
 
 
To evaluate the cytokine environment generated by the TLR ligands LPS 
and poly(I:C) in response to alloantigen challenge, KB5 chimeras were 
administered a DST of C57BL/6 splenocytes (H-2Kb) with or without LPS or 
poly(I:C) and levels of cytokines were determined in the plasma. DST did not 
stimulate significant cytokine production over background levels (Fig. 4.1). Both 
LPS and DST+LPS treatments induced high levels of IL-6, IL-10, MCP-1, IFN-γ 
and TNF-α (Fig. 4.1A-4.1E) suggesting that DST does not contribute to the pool 




MCP-1 and IFN-β (Fig. 4.1C, 4.1G) although modest levels of IL-6 and TNF-α 
were also found in the plasma of these mice (Fig. 4.1A, 4.1E). These results 
indicate that LPS and poly(I:C) generate qualitatively and quantitatively distinct 





Fig. 4.1. LPS and poly(I:C) generate distinct cytokine milieus. 
 
 
Fig. 4.1. LPS and poly(I:C) generate distinct cytokine milieus. (A-G) KB5 chimeras were 
administered C57BL/6 DST alone or in combination with LPS or poly(I:C). Mice receiving 
LPS or poly(I:C) alone served as controls. Plasma samples were collected 9 hours post-
treatment and assessed for production of IL-6, IL-10, MCP-1, IFN-γ, TNF-α and IL-12p70 
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LPS promotes survival of activated alloreactive CD8 T cells 
 
It is well established that cytokines regulate the differentiation and function 
of activated CD8 T cells (Joshi et al., 2007). Since LPS and poly(I:C) generated  
distinct cytokine milieus, I hypothesized that these inflammatory stimuli would 
differentially regulate alloreactive CD8 T cell responses. To test this hypothesis, 
KB5 chimeras were injected with a DST of C57BL/6 splenocytes with or without 
LPS or poly(I:C) and alloreactive DES+ CD8 T cell population in the blood and  
spleen was monitored. DES+ CD8 T cells from all mice that received DST 
underwent attrition by 24 hours in the blood (Table 4.1). This early attrition 
occurred in the spleen as well; however it was less pronounced in mice that 
received LPS (Fig. 4.2A). This reduction in splenic DES+ CD8 T cell number in 
response to alloantigen could not be explained by trafficking to other sites such 
as lymph nodes, lungs, bone marrow and intestinal epithelium (Fig. 4.3). I 
speculated that this early loss of alloreactive CD8 T cells is a result of cell death. 
Indeed, I found increased frequencies of DES+ CD8 T cells staining positively for 
active caspase-3 in mice that received the alloantigen, relative to untreated 
controls (Fig. 4.2B). Interestingly, LPS significantly reduced the percentages of 
active caspase-3+ DES+ CD8 T cells (DST: 18.04±0.84%, DST+LPS: 
8.82±1.08%, DST+poly(I:C): 15.29±0.74%). No cell division had occurred in 
DST+LPS treated mice by 24 hours as indicated by the lack of VPD450 dilution 
(Fig. 4.4) and thus the reduced attrition of alloreactive CD8 T cells in the 




Table 4.1. LPS and poly(I:C) differentially regulate kinetics of CD8 T cells in 
















Untreated 6 4.53±0.06 4.67±0.41a 4.27±0.29 4.62±0.22 4.10±0.33 
DST 7 6.39±0.22 0.16±0.03 0.51±0.09b 14.64±2.44 4.06±0.46 
DST/LPS 7 6.70±0.16 0.44±0.15 9.67±1.19 16.63±1.96 8.19±0.49c 
DST/poly(I:C) 9 5.36±0.78 0.58±0.09 12.53±0.58 18.88±2.60 7.13±0.98 
LPS 6 5.05±0.65 4.05±.73a 5.17±1.02 5.08±0.87 5.30±1.11 
Poly(I:C) 3 2.83±0.18 ND ND 3.53±0.09 3.70±0.06 
 
 
KB5 chimeras were administered the indicated treatment and bled at the indicated times. 
The values indicate the percentage of DES+ CD8 T cells in the blood (gated on 
lymphocytes) and are expressed as mean ± SEM. Data are cumulative of two 
independent experiments.  a p<0.0001 vs all other groups, b p<0.0001 vs DST/LPS and 













Fig. 4.2. LPS enhances survival of alloreactive CD8 T cells in response to antigen 
challenge. KB5 chimeras were administered C57BL/6 DST alone or in combination with 
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recovered 24 hours post-treatment are shown. The graph shows the absolute number of 
DES+ CD8 T cells in the spleen. (B) Splenocytes harvested at 12 hours post-treatment 
were stained for active caspase-3. Representative plots of active caspase-3 staining on 
DES+ CD8 T cells are shown. (C) Representative plots of DES+ CD8+ T cells from the 
spleen recovered 3 days post-treatment are shown. The graph shows the absolute 
numbers of DES+ CD8 T cells in the spleen. (D) Splenocytes harvested on day 5 post-
treatment were stained for active caspase-3. Representative plots of active caspase-3 
staining on DES+ CD8 T cells are shown. Data are cumulative of at least two 






Fig. 4.3. Trafficking to other compartments does not account for the early loss of 




Fig. 4.3. Trafficking to other compartments does not account for the early loss of 
alloreactive CD8 T cells from the spleen in response to alloantigen. KB5 chimeras were 
administered C57BL/6 DST alone or in combination with LPS or poly(I:C). Inguinal and 
axillary lymph nodes, bone marrow, lungs and intestinal intraepithelial lymphocytes were 
Untreated DST DST+LPS DST+poly(I:C)
16.8 10.3 12.8 11.6
16.0 10.6 16.7 15.1
2.1 0.3 0.5 0.4
4.7 0.4 0.5 0.1
















harvested from the mice 24 hours post-treatment. Representative plots display the 







Fig. 4.4. LPS challenge does not induce division of alloreactive CD8 T cells within 
24 hours of alloantigen challenge. 
 
 
Fig. 4.4. LPS challenge does not induce division of alloreactive CD8 T cells within 24 
hours of alloantigen challenge. Splenocytes from KB5 transgenic mice were labeled with 
VPD450 and 2 x 106 VPD450 labeled DES+ CD8 T cells were adoptively transferred to 
CBA mice that were then treated with C57BL/6 DST alone or in combination with LPS or 
poly(I:C). Representative histogram depicts VPD450 profile of DES+ CD8 T cells in the 



















Alloantigen in the form of DST triggered expansion of the DES+ CD8 T cell 
population following the early death phase; however, co-administration of LPS or 
poly(I:C) accelerated the expansion and I found significantly higher percentages 
of DES+ CD8 T cells in the blood of mice that were exposed to the inflammatory 
agents on day 2 post-treatment (Table 4.1). The alloresponse peaked on day 3 
with LPS and poly(I:C) generating higher numbers of alloreactive CD8 T cells 
relative to DST alone (Fig. 4.2C). LPS slowed the contraction phase of the 
alloresponse (Table 4.1) and I found proportionately lower numbers of apoptotic 
active caspase-3+ DES+ CD8 T cells in the spleen of DST+LPS treated mice on 
day 5 post-treatment compared to mice that received DST with or without 
poly(I:C) (DST: 26.55±2.89), DST+LPS: 19.64±1.50, DST+poly(I:C): 24.1±1.85) 
(Fig. 4.2D). Consequently, LPS generated higher number of memory phenotype 
CD44hi DES+ CD8 T cells (Fig. 4.5). Inflammation alone (LPS or poly(I:C) 
treatment) did not induce expansion of alloreactive CD8 T cells (Table 4.1) 
suggesting the requirement for exposure to the alloantigen to initiate the 
alloresponse. Together, these data suggest that while both LPS and poly(I:C) 
generate higher numbers of effector alloreactive CD8 T cells at the peak of the 
primary alloresponse, LPS provides survival signals during contraction to 










Fig. 4.5. LPS challenge generates higher levels of memory alloreactive CD8 T cells. KB5 
chimeras were administered C57BL/6 DST alone or in combination with LPS or 
poly(I:C). The graph shows the absolute number of CD44hi DES+ CD8 T cells in the 
spleen 21 days post-treatment. Data are cumulative of two independent experiments. 








































LPS and poly(I:C) alter the phenotype of alloreactive CD8 T cells in 
response to the alloantigen 
 
 
Since inflammation altered the magnitude of the alloresponse, I hypothesized 
that inflammation would alter the phenotype or activation profile of alloreactive 
CD8 T cells. Indeed, LPS and poly(I:C) increased the frequency of DES+ CD8 T  
cells expressing the early activation markers CD25 (IL-2Rα) and CD69 in 
response to DST at 24 hours post-treatment (Fig. 4.6A). Interestingly, poly(I:C) 
enhanced the expression levels of CD25 and CD69 on DES+ CD8 T cells 
compared to LPS (Fig. 4.6B). Inflammation alone was not sufficient to upregulate 
CD25; however higher levels of CD69 were detected on DES+ CD8 T cells in 
response to both LPS and poly(I:C) relative to untreated controls (Fig. 4.6A, 
4.6B) in agreement with previous studies (Sun et al., 1998; Tough et al., 1997). 
Interestingly both LPS and poly(I:C) when administered with DST reduced the 
percentages of DES+ CD8 T cells expressing the activation marker CD44 and its 
expression levels relative to DST alone (Fig. 4.6A, 4.6B). A similar profile was 
observed for the T-box transcription factor family member Eomes with reduced 
expression levels upon exposure to inflammation at the peak of the alloresponse 
(Fig. 4.6A, 4.6B). Inflammation alone did not induce upregulation of CD44 and 
Eomes expression emphasizing the requirement for antigen encounter to induce 
the expression of these proteins. Finally, I examined the expression of Ly6C, a 
protein that was originally shown to have an accessory role in the cytolytic 




Fig. 4.6. LPS and poly(I:C) alter the phenotype of alloreactive CD8 T cells in 














































Fig. 4.6. LPS and poly(I:C) alter the phenotype of alloreactive CD8 T cells in response to 
antigen challenge. KB5 chimeras were administered C57BL/6 DST alone or in 
combination with LPS or poly(I:C). Mice were sacrificed one or three days later and 
splenocytes were stained for T cell activation markers. (A) Representative plots of CD25 
and CD69 expression on DES+ CD8 T cells at 24 hours post-treatment and CD44, 
Eomes and Ly6C expression at 3 days post-treatment are shown. (B) The graphs show 
the expression levels (MFIs) of each of the activation markers on DES+ CD8 T cells. 
Data are cumulative of at least two independent experiments. *p<0.05, **p<0.01, 







































































































































































 DST alone upregulated Ly6C expression on DES+ CD8 T cells relative to 
untreated controls (Fig. 4.6A, 4.6B). Inflammation alone was sufficient to induce 
Ly6C and coadministration with DST resulted in further increase in Ly6C 
expression. To summarize, LPS and poly(I:C) alter the phenotype of alloreactive 
CD8 T cells in response to the alloantigen.   
 
LPS suppresses alloreactive CD8 T cell IFN-γ production and cytotoxicity 
 
 
To investigate the impact of inflammation on alloreactive CD8 T cell 
function, KB5 chimeras were administered DST with or without LPS or poly(I:C) 
and the ability of DES+ CD8 T cells to produce IFN-γ upon ex vivo restimulation 
with allogeneic C57BL/6 cells was assessed. Poly(I:C) enhanced the frequency 
and numbers of IFN-γ producing DES+ CD8 T cells in response to DST (Fig. 
4.7A-4.7C). This observation was consistent with previous studies demonstrating 
the CD8 T cell enhancing effect of poly(I:C) (Coffman et al., 2010; Schulz et al., 
2005). Interestingly, LPS lowered the percentage of IFN-γ producing DES+ CD8 
T cells in response to DST (Fig. 4.7A, 4.7B). Although the numbers of IFN-γ+ 
DES+ CD8 T cells were lower in the DST+LPS group relative to DST (Fig. 4.7C), 
the difference was not statistically significant because of LPS generating higher 
numbers of DES+ CD8 T cells at the peak of the response (Fig. 4.2C). 
Inflammation alone did not stimulate significant IFN-γ production in DES+ CD8 T 
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Fig. 4.7. LPS suppresses alloreactive CD8 T cell function. (A) KB5 chimeras were 
administered C57BL/6 DST alone or in combination with LPS or poly(I:C). Splenocytes 
were harvested from mice 3 days post-treatment and stained for intracellular IFN-γ upon 
allogeneic (H-2b) stimulation. Representative plots of IFN-γ staining on DES+ CD8 T cells 
are shown. (B) The graphs show the percentages and total numbers of IFN-γ producing 
DES+ CD8 T cells. (C) C57BL/6 mice were administered CBA (H-2k) DST alone or in 
combination with LPS or poly(I:C). Splenocytes were harvested from mice 3 days post-
treatment and stained for intracellular IFN-γ upon allogeneic (H-2k) stimulation. The 
graph depicts the percentages of IFN-γ producing CD8+ T cells. (D) C57BL/6 mice were 
treated on day 0 with CBA DST alone or with LPS or poly(I:C). On day 3, CFSE labeled 
CBA (H-2k) and C57BL/6 (H-2b) splenocytes were transferred intravenously at equal 
proportions into the mice, and the survival of each population was determined 3 hours 
later. Survival of the CBA splenocytes is shown in the representative histograms and the 
graph shows percent specific lysis of CBA splenocytes. Data are cumulative of at least 3 







To test if the KB5 TCR transgenic system recapitulates the endogenous 
polyclonal alloresponse, I treated C57BL/6 mice (H-2b) with a DST of CBA 
splenocytes (H-2k) and tested the ability of CD8 T cells from the recipient mice to 
produce IFN-γ to ex vivo allogeneic restimulation at various time points post-
treatment. Our lab has previously demonstrated that effector alloreactive CD8 T 
cells produce IFN-γ upon antigen restimulation (Brehm et al., 2007). I found that 
DST priming generated highest frequencies of IFN-γ producing CD8 T cells on 
day 3 (Fig. 4.8), which coincides with the peak of the alloresponse in the KB5 
transgenic system. LPS treatment in conjunction with DST significantly reduced 
the percentage of endogenous IFN-γ producers relative to DST alone (Fig. 4.7C). 
However, I did not find an enhancement of the CD8 T cell response by poly(I:C) 
in C57BL/6 mice (Fig. 4.7C). Next I investigated the cytotoxic potential of 
alloreactive CD8 T cells in C57BL/6 mice using an in vivo cytotoxicity assay. 
Recipient mice were administered CBA (H-2k) DST with or without LPS or 
poly(I:C) and tested for their ability to reject allogeneic CBA splenocytes 3 days 
later. Mice treated with DST alone exhibited approximately 82% killing of 
allogeneic CBA targets indicating that alloreactive CD8 T cells in these mice are 
primed for cytolysis (Fig. 4.7D). LPS treatment significantly reduced the cytolysis 





Fig. 4.8. The endogenous alloreactive CD8 T cell kinetics are similar to those of 
the KB5 transgenic system.  
 
 
Fig. 4.8. The endogenous alloreactive CD8 T cell kinetics are similar to those of the KB5 
transgenic system. C57BL/6 mice were treated with CBA DST and sacrificed on days 1, 
3, 7 and 21 post-treatment. Splenocytes were stained for intracellular IFN-γ upon 
allogeneic (H-2k) stimulation. The graph shows the percentages of IFN-γ producing CD8 
T cells at each time point. Data are cumulative of two independent experiments. 

































This result is particularly interesting because the in vivo cytotoxicity assay 
measures the cytotoxic potential of the total CD8 T cell population and the 
reduction in cytolysis by LPS despite increased generation of effector CD8 T 
cells (Fig. 4.2C) must mean that LPS has a pronounced effect on cytotoxic 
potential on a per cell basis.  Cytolysis of allogeneic targets was increased by 
poly(I:C) challenge and was comparable to the DST group, although significantly 
higher levels of granzyme B producing alloreactive CD8 T cells could be detected 
upon poly(I:C) challenge at the peak of the alloresponse in KB5 chimeras (Fig. 
4.9). Inflammation alone did not result in cytolysis of targets above background 
levels (Fig. 4.7D). Together, these data indicate that LPS reduces the frequency 
of IFN-γ producing and cytolytic effector alloreactive CD8 T cells whereas 
poly(I:C) enhances the response when administered with the alloantigen. Also, 
these inflammatory stimuli fail to confer effector function on CD8 T cells in the 






Fig. 4.9. Poly(I:C) challenge enhances the levels of granzyme B producing 





Fig. 4.9. Poly(I:C) challenge enhances the levels of granzyme B producing effector 
alloreactive CD8 T cells. KB5 chimeras were administered C57BL/6 DST alone or in 
combination with LPS or poly(I:C). Splenocytes were harvested from mice 3 days post-
treatment and stained for intracellular granzyme B. Representative plots of granzyme B 
staining on DES+ CD8 T cells are shown. The graph shows the percentages and total 
numbers of granzyme B producing DES+ CD8 T cells in the spleen. Data are cumulative 





































































































LPS signaling through recipient and not donor cells is critical for 
suppression of alloreactive CD8 T cell function 
 
 
To test whether LPS signaling through recipient cells or donor cells (DST) 
is necessary for the suppression of alloreactive CD8 T cell response, I used 
TLR4 deficient mice as recipients or donors. Co-administration of LPS with wild 
type (WT) or Tlr4-/- C57BL/6 DST lowered the percentages of IFN-γ producing 
DES+ CD8 T cells in the KB5 chimeras to similar extent (Fig. 4.10A) suggesting 
that LPS signaling through TLR4 on donor cells is not necessary for LPS 
mediated suppression of the CD8 T cell response. In a converse experiment, WT 
or Tlr4-/- C57BL/6 recipients were administered CBA DST along with LPS. While 
LPS reduced the frequency of IFN-γ producing CD8 T cells in WT recipients as 
demonstrated previously (Fig. 4.7C), the opposite result was observed in Tlr4-/- 
recipients (Fig. 4.10B). To confirm the importance of LPS signaling through 
recipient cells, I employed C3H/HeJ mice (H-2k) that have a natural Tlr4 mutation 
making them resistant to LPS. C57BL/6 DST stimulated a small percentage of 
CD8 T cells to produce IFN-γ upon ex vivo restimulation (Fig. 4.10C), which 
could mean that C3H/HeJ cells do not respond well to ex vivo C57BL/6 
stimulation or the actual frequency of CD8 T cells reactive to H-2b cells in these 
mice is very low. Interestingly, administration of DST with LPS increased the 






Fig. 4.10. TLR4 expression on recipient cells is necessary for LPS mediated 
suppression of CD8 T cell function.  
 
 
Fig. 4.10. TLR4 expression on recipient cells is necessary for LPS mediated suppression 
of CD8 T cell function. (A) KB5 chimeras were administered WT or Tlr4-/- C57BL/6 DST 
alone or in combination with LPS. Splenocytes were harvested from the mice 3 days 
post-treatment and stained for intracellular IFN-γ upon allogeneic (H-2b) stimulation. 
Representative plots of IFN-γ staining on DES+ CD8 T cells are shown. The graph 
shows the percentages of IFN-γ producing DES+ CD8 T cells. (B) WT or Tlr4-/- C57BL/6 
mice were treated with CBA DST alone or in combination with LPS. Splenocytes were 
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allogeneic (H-2k) stimulation. Representative plots of IFN-γ staining on CD8 T cells are 
shown. The graph shows the percentages of IFN-γ producing CD8 T cells. (C) C3H-HeJ 
mice were treated with C57BL/6 DST alone or in combination with LPS. Splenocytes 
were harvested from the mice 3 days post-treatment and stained for intracellular IFN-γ 
upon allogeneic (H-2b) stimulation. Representative plots of IFN-γ staining on CD8 T cells 
are shown. The graph shows the percentages of IFN-γ producing CD8 T cells. Data are 







These data indicate that the presence of functional TLR4 is necessary on 
recipient cells for LPS to suppress alloreactive CD8 T cell responses.   
 
IL-6, and not IL-10, is necessary for LPS mediated suppression of 
alloreactive CD8 T cell function 
 
 
Cytokines secreted upon TLR engagement regulate CD8 T cell 
responses. Several studies have reported that IL-10 can suppress CD8 T cell 
responses in infection and cancer settings (Bogunovic et al., 2011; den Haan et 
al., 2007; Sun et al., 2011). Since LPS stimulated IL-10 secretion (Fig. 4.1B), I 
tested if IL-10 was important for the suppressive effects of LPS. KB5 chimeras 
were administered C57BL/6 DST with LPS with or without IL-10R blocking 
antibody and IFN-γ production by DES+ CD8 T cells upon ex vivo restimulation 
was assessed. Blocking IL-10 signaling did not increase the frequency of IFN-γ 
producers (Fig. 4.11) suggesting that IL-10 is not critical for LPS mediated 
suppression of alloreactive CD8 T cell responses. TLR ligand induced IL-6 was 
recently implicated in counter-regulating anti-viral CD8 T cell response during an 
acute retrovirus infection (Wu et al., 2015). To test the possible role of IL-6 in 
LPS mediated CD8 T cell suppression in my studies, I administered KB5 
chimeras with IL-6 neutralizing antibody or isotype control along with DST+LPS 





Fig. 4.11. IL-10 signaling is not necessary for LPS to suppress IFN-γ production 
by effector alloreactive CD8 T cells.  
 
 
Fig. 4.11. IL-10 signaling is not necessary for LPS to suppress IFN-γ production by 
effector alloreactive CD8 T cells. KB5 chimeras were administered C57BL/6 DST alone 
or in combination with LPS. Anti-IL10R antibody was injected 2 hrs before and 12 hrs 
after LPS treatment. Splenocytes were harvested from the mice 3 days post-treatment 
and stained for intracellular IFN-γ upon allogeneic (H-2b) stimulation. Representative 
plots of IFN-γ staining on DES+ CD8 T cells are shown. The graph shows the 
percentages of IFN-γ producing DES+ CD8 T cells. Data are cumulative of two 























































Administration of the neutralizing antibody rendered IL-6 in plasma undetectable, 
suggesting the efficacy of the antibody in vivo (Fig. 4.12A). Neutralizing IL-6 
increased expression of the early activation markers CD25 and CD69 on DES+ 
CD8 T cells in response to DST+LPS  (Fig. 4.12B, 4.12C). Interestingly, 
neutralizing IL-6 significantly increased the percentages and numbers of IFN-γ+ 
DES+ CD8 T cells in response to DST+LPS, relative to mice that received the 
isotype control (Fig. 4.12D). Similar results were obtained when I compared IFN-
γ production by endogenous alloreactive CD8 T cells (Fig. 4.12E). IL-6 
neutralization also elevated plasma levels of IFN-γ and IL-10 (Fig. 4.12A) early in 
the response suggesting that IL-6 regulates secretion of these cytokines by 
innate immune cells or non-hematopoietic cells. Moreover, neutralizing IL-6 
showed a modest but significant increase in cytolysis of target cells in mice 
treated with DST+LPS compared to mice that received the isotype control (Fig. 
4.12F). The cytotoxicity results correlated with the frequency of granzyme B 
producing DES+ CD8 T cells since IL-6 neutralization markedly elevated the 
levels of granzyme B producers (Fig. 4.12G). To test if IL-6 recapitulated the in 
vivo effects of LPS treatment, I injected KB5 chimeras with DST along with 
recombinant IL-6 and examined IFN-γ production by DES+ CD8 T cells to allo-
stimulation. Exogenous IL-6 did not decrease the frequency of IFN-γ producing 
DES+ CD8 T cells (Fig. 4.12H) suggesting that IL-6 is not sufficient to inhibit CD8 





Fig. 4.12. IL-6 is necessary but not sufficient for LPS mediated suppression of 
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Fig. 4.12. IL-6 is necessary but not sufficient for LPS mediated suppression of CD8 T 
cell function. (A) KB5 chimeras were administered C57BL/6 DST alone or in combination 
with LPS. Anti-IL-6 antibody was injected 2 hrs before and 12 hrs after LPS treatment 
Plasma samples were collected 9 hours post-treatment with DST and analyzed for levels 
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of IL-6, IL-10 and IFN-γ. (B) and (C) Representative plots of CD25 and CD69 expression 
on DES+ CD8 T cells at 24 hours post-treatment are shown. The graphs show the 
expression levels (MFIs) of the activation markers on DES+ CD8 T cells. (D) Splenocytes 
were harvested from mice 3 days post-treatment and stained for intracellular IFN-γ upon 
allogeneic (H-2b) stimulation. Representative plots of IFN-γ staining on DES+ CD8 T cells 
are shown. The graphs show the percentages and numbers of IFN-γ producing DES+ 
CD8 T cells. (E) C57BL/6 mice were treated with CBA DST alone or in combination with 
LPS and IL-6 neutralizing antibody or its isotype control. Splenocytes were harvested 
from mice 3 days post-treatment and stained for intracellular IFN-γ upon allogeneic (H-
2k) stimulation. Representative plots of IFN-γ staining on CD8 T cells are shown. The 
graph shows the percentages of IFN-γ producing CD8 T cells. (F) C57BL/6 mice were 
treated as in (E).  On day 3, CFSE labeled CBA (H-2k) and C57BL/6 (H-2b) splenocytes 
were transferred intravenously at equal proportions into the mice, and the survival of 
each population was determined 3 hours later. Survival of the CBA splenocytes is shown 
in the representative histograms and the graph shows percent specific lysis of CBA 
splenocytes. (G) KB5 chimeras were treated as in (A). Representative plots of granzyme 
B expression on DES+ CD8 T cells at 3 days post-treatment are shown. The graphs 
show the percentages and total numbers of granzyme B producing DES+ CD8 T cells.  
(H) KB5 chimeras were administered C57BL/6 DST alone or in combination with LPS or 
recombinant IL-6. Splenocytes were harvested from the mice 3 days post-treatment and 
stained for intracellular IFN-γ upon allogeneic (H-2k) stimulation. Representative plots of 
IFN-γ staining on DES+ CD8 T cells are shown. The graph shows the percentages of 
IFN-γ producing DES+ CD8 T cells. (I) Splenocytes were harvested from KB5 chimeras 
and stimulated with recombinant IL-6. Representative plot of pSTAT3 staining on CD8 T 
cells is shown. The graph shows the MFI of pSTAT3 on CD8 T cells. Data are 







It is well established that CD8 T cells express the IL-6 receptor (Teague et al., 
2000). Binding of IL-6 to its receptor triggers the activation of JAK-STAT pathway 
involving phosphorylation of STAT3. To test if IL-6 acts directly on CD8 T cells, I 
examined levels of phosphorylated STAT3 in response to ex vivo IL-6 
stimulation. IL-6 stimulation increased pSTAT3 levels in CD8 T cells suggesting 




The impact of PRR ligands on CD8 T cell responses to soluble protein 
antigens, peptide immunizations, DC vaccines and pathogens has been 
extensively studied (Cui et al., 2014; den Haan et al., 2007; Mandraju et al., 
2014; Melief et al., 2015). Here I studied the impact of PRR ligands LPS and 
poly(I:C) on CD8 T cell responses to alloantigens directly presented by DST. I 
performed a detailed assessment of the kinetics of the alloresponse, phenotype, 
and functionality of effector CD8 T cells generated upon exposure to these 
inflammatory stimuli. I found that while poly(I:C) elevated the expression of 
activation markers on alloreactive CD8 T cells and their primary effector function 
compared to LPS, LPS generated higher levels of memory CD8 T cells by 
providing survival signals during contraction phase of the alloresponse.  
Antigen-specific CD8 T cell responses have been extensively studied in 
the context of acute viral infections. The early stage of acute LCMV infection 
preceding the expansion of antigen-specific T and B cells is characterized by 




al., 2001). I observed a similar attrition of alloantigen specific DES+ CD8 T cells 
as early as 12 hours post DST administration (Fig. 4.2B). Both LPS and poly(I:C) 
are known to induce upregulation of costimulatory molecules required for T cell 
activation and survival (Hoebe et al., 2003). My finding that LPS, but not 
poly(I:C), inhibits this early cell death suggests that cell death at this stage is 
regulated by factors other than costimulation. I speculate that the distinct 
cytokine environment generated by LPS contributes to its anti-apoptotic effects. 
Indeed, TNF-α produced upon LPS challenge has been shown to rescue 
peripheral T cells from death induced by superantigens (Vella et al., 1995). The 
early cell death in viral infections was found to be dependent on type I interferons 
(Bahl et al., 2006; McNally et al., 2001). High amounts of IFN-β generated upon 
poly(I:C) challenge (Fig. 4.1G) might explain increased apoptosis of DES+ CD8 T 
cells compared to LPS treatment which did not generate significant levels of 
interferon. Following this first wave of CD8 T cell death, cells expanded and the 
response peaked on day 3. Since the DES+ TCR recognizes the native form of 
the alloantigen H-2Kb (Schonrich et al., 1991), my experimental setup tracks the 
CD8 T cells directly responding to the antigen and hence the kinetics of the CD8 
T cell response are faster than those of cells responding to a viral antigen or a 
minor alloantigen that undergo the processes of antigen processing and 
presentation by antigen presenting cells. The expansion was accelerated by LPS 
and poly(I:C) relative to DST alone (Table 4.1). Increased expression of the high 




make the alloreactive CD8 T cells more sensitive to IL-2 signals. IL-2 has been 
shown to have a prominent role in the primary expansion and accumulation of 
effector CD8 T cells after antigen challenge (Obar et al., 2010; Starbeck-Miller et 
al., 2014). It is conceivable that LPS and poly(I:C) by increasing the 
responsiveness of CD8 T cells to IL-2, accelerate expansion and the generation 
of higher numbers of DES+ CD8 T cells in the spleen at the peak of the response 
(Fig. 4.2C), although I cannot rule out the possible contribution of other cytokines 
produced upon exposure to these PRR ligands. The relative contribution of 
costimulation and cytokines to the adjuvant effect of LPS and poly(I:C) needs to 
be investigated.  
LPS was recently shown to accentuate the expression of pro-memory 
genes in KLRG1lo IL-7Rhi memory precursor effector CD8 T cells and promote 
their longevity following immunization culminating in larger numbers of memory 
CD8 T cells compared to other TLR agonists (Cui et al., 2014). Studies suggest 
that STAT3 dependent cytokines such as IL-6, IL-10 and IL-21 are critical for 
memory CD8 T cell differentiation (Castellino and Germain, 2007; Cui et al., 
2011; Foulds et al., 2006; Laidlaw et al., 2015). IL-10 and IL-21 have been shown 
to act together to promote memory CD8 T cell development and functional 
maturation after acute LCMV infection (Cui et al., 2011). These investigators 
further showed that IL-10 derived from CD4+ Tregs during the resolution phase of 
the response was necessary for memory CD8 T cell maturation (Laidlaw et al., 




monocytogenes infection (Foulds et al., 2006). IL-6 was demonstrated to 
contribute to the survival of activated CD8 T cells in the contraction phase of the 
immune response in a noninfectious vaccine model (Castellino and Germain, 
2007). Since LPS challenge generates higher levels of IL-6 and IL-10 relative to 
poly(I:C) challenge, it is possible that the combined effect of these two cytokines 
augments memory alloreactive CD8 T cell formation upon LPS exposure.  
Upon recognition by the cell surface receptor TLR4, LPS signals through 
the adaptor protein MyD88 to trigger signaling cascades culminating in 
production of pro-inflammatory cytokines IL-6, IL-1 and TNF-α. Besides LPS, 
TLR4 is known to recognize DAMPs such as high mobility group box 1 (HMGB1), 
hyaluronan, fibrinogen and heat shock proteins (Mori et al., 2014). In the context 
of transplantation, TLR4 can potentially be activated by these endogenous 
DAMPs upon ischemic tissue damage or by LPS from bacterial infections or 
translocation of microbiota. Studies employing TLR4 deficient mice or local 
knockdown of TLR4 on the allograft using short-hairpin RNA (shRNA) have 
demonstrated that inhibition of TLR4 signaling modestly prolongs survival and/or 
function of certain allografts (Goldberg et al., 2007; Hsieh et al., 2017; Krams et 
al., 2010; Kwan et al., 2016; Zhang et al., 2010). Moreover, genetic deficiency or 
gene silencing of MyD88 prolongs the survival of allografts and synergizes with 
costimulation blockade to promote long-term graft acceptance (Goldstein et al., 
2003; Lerret et al., 2015; Tesar et al., 2004; Walker et al., 2006; Zhang et al., 




and cytotoxicity of alloreactive CD8 T cells, is surprising because CTLs are 
crucial mediators of acute rejection. I speculate that the dose of LPS used in my 
studies is higher than the inflammation encountered during organ transplantation. 
Indeed, studies showed that endotoxin tolerance induced upon repeated 
injections of LPS or polymicrobial sepsis suppressed antigen-specific CD8 T cell 
IFN-γ production (De Wilde et al., 2009; Delano et al., 2007). The common 
theme emerging from these studies is that a CD11b+ Gr-1+ myeloid derived 
suppressor cell (MDSC) population expanding in endotoxin tolerant or septic 
mice suppresses the CD8 T cell response. Interestingly, endotoxin tolerance 
induced a significant delay in skin graft rejection in a minor antigen mismatch 
model (De Wilde et al., 2009). However, the rejection kinetics of a full MHC 
mismatched graft were not affected. Poly(I:C) elevated the levels of IFN-γ and 
granzyme B producing cytotoxic alloreactive CD8 T cells. Although poly(I:C) has 
not been widely studied in the context of transplantation, its CD8 T cell 
potentiating effects are known from vaccine, infection and cancer studies 
(Dowling and Mansell, 2016).  
LPS has been shown to suppress cross-presentation of soluble protein 
antigens to CD8 T cells (Brossart and Bevan, 1997; Mandraju et al., 2014). When 
the antigen and LPS were administered locally, LPS inhibited cross-priming by 
altering the composition of DCs in the draining lymph nodes (Mandraju et al., 
2014). Upon systemic administration, LPS induced IL-10 producing regulatory 




IL-10 dependent manner (den Haan et al., 2007). LPS mediated suppression of 
alloreactive CD8 T cell function was independent of IL-10 in my studies (Fig. 
4.11). Interestingly, IL-6 was necessary for this suppression (Fig. 4.12D, E). 
Originally discovered as a B cell growth factor, IL-6 is a pleiotropic cytokine 
regulating growth, differentiation, survival and function of immune cells (Hunter 
and Jones, 2015). Most studies on the impact of IL-6 on T cells have focused on 
the CD4 T cell subset. IL-6 promotes survival and proliferation of CD4 T cells, 
promotes differentiation of Th17 cells in conjunction with TGF-β and has an 
important role in memory CD4 T cell formation (Bettelli et al., 2006; Lotz et al., 
1988; Nish et al., 2014; Teague et al., 1997; Veldhoen et al., 2006). Moreover, 
IL-6 releases conventional CD4 T cells from Treg suppression by enhancing their 
responsiveness to IL-2 (Nish et al., 2014). Recently, it was demonstrated that IL-
6 in combination with IL-17 inhibits CTL function in a Theiler’s murine 
encephalomyelitis virus (TMEV) infection model and promotes viral persistence 
(Hou et al., 2014). Another study reported inhibition of effector CD8 T cell 
responses by IL-6 in a Friend retrovirus mouse model (Wu et al., 2015). 
Consistent with these studies, I find that IL-6 is critical for the suppression of 
effector alloreactive CD8 T cell function. This finding may appear paradoxical 
since IL-6 induced upon TLR activation or bacterial infection has been shown to 
play a central role in preventing costimulation blockade mediated long-term 
allograft acceptance (Ahmed et al., 2011; Chen et al., 2009b; Shen and 




blockade, systemic IL-6 deficiency or neutralization did not have a significant 
impact on allograft rejection (Booth et al., 2011; Zhao et al., 2012). Neutralizing 
IL-6 significantly delayed graft rejection in mice depleted of CD8 T cells 
suggesting that IL-6 is required for allograft rejection mediated by CD4 T cells 
(Booth et al., 2011). These mice exhibited a reversal of Th1/Th2 balance in favor 
of Th2 and a decrease in graft infiltrating cells. Thus, it appears that neutralizing 
IL-6 has a more dominant effect on CD4 T cells than CD8 T cells in a 
transplantation setting. Based on these reports, I speculate that an increase in 
effector CD8 T cell function upon IL-6 neutralization would be offset by a 
reduction in Th1 activity and infiltration of graft-damaging immune cells. Poly(I:C) 
challenge also stimulated IL-6 production; however poly(I:C) enhanced CD8 T 
cell effector function. Type I interferon signaling after or at the time of antigen 
recognition is known to act as signal 3 for CD8 T cell activation and promote the 
differentiation of highly cytolytic effector cells (Crouse et al., 2015). Poly(I:C) 
stimulated high levels of IFN-β (Fig. 4.1G). Therefore, it appears that the relative 
levels of cytokines, rather than absolute amounts, determine their impact on CD8 
T cell effector function.    
LPS signaling through recipient TLR4 was critical for the inhibition of 
alloreactive effector CD8 T cell function (Fig. 4.10). I speculate that in Tlr4-/- 
recipients that receive Tlr4+/+ DST, LPS signaling through TLR4 on the DST will 
not stimulate sufficient IL-6 and other cytokines to suppress the CD8 T cell 




binds IL-6 and the gp130 subunit that is involved in signal transduction. While 
gp130 is ubiquitously expressed on hematopoietic and non-hematopoietic cells, 
IL-6Rα is selectively expressed on leukocytes, megakaryocytes and hepatocytes 
(Hunter and Jones, 2015). I observed IL-6 signaling in CD8 T cells in vitro (Fig. 
4.12I); however it is unclear if IL-6 acts directly on CD8 T cells in vivo to mediate 
suppression or whether an intermediate cell type is involved. Wu et al. observed 
that IL-6 directly inhibited effector CD8 T cell activity by inducing the STAT3 
signaling pathway (Wu et al., 2015). IL-6 plays a major role in maintaining 
immature DCs and is required for suppression of LPS mediated DC maturation 
(Park et al., 2004). Our lab has previously demonstrated that LPS challenge 
upregulates costimulatory molecules CD80 and CD86 on cells in the DST (Miller 
et al., 2009). Therefore, IL-6 mediated inhibition of APC maturation resulting in 
reduced alloreactive CD8 T cell priming is unlikely. Recently TLR2 activation in 
skin resident cells was shown to trigger IL-6 that induced expansion of MDSCs, 
which were recruited to the skin and suppressed T cell mediated recall 
responses such as dermatitis (Skabytska et al., 2014). It is possible that LPS 
induced IL-6 expands MDSCs in the spleen that suppress alloreactive CD8 T cell 
function in response to DST. Using conditional knockout mice with cell type 
specific deletion of IL-6R would shed light on the cell type necessary for IL-6 
mediated inhibition of CD8 T cell function.      
To summarize, the two PRR ligands LPS and poly(I:C) differentially 




responding to a directly presented alloantigen by generating distinct cytokine 
profiles (Fig. 4.13). These studies highlight the complexity of regulation of 
different immune cell populations by cytokines and warrant caution when 






Fig. 4.13. Summary: LPS and poly(I:C) differentially regulate alloreactive CD8 T 
cell kinetics and function in response to donor alloantigen (DST). 
 
Fig. 4.13. Summary: LPS and poly(I:C) differentially regulate alloreactive CD8 T cell 
kinetics and function in response to donor alloantigen (DST). LPS inhibits the early 
deletion of alloreactive CD8 T cells induced by DST challenge. Following the early 
deletion, cells proliferate in all the groups. Both LPS and poly(I:C) generate higher 
numbers of alloreactive CD8 T cells at the peak of the response, day 3. LPS reduces the 
frequency of IFN-γ producing and cytolytic effector CD8 T cells, whereas poly(I:C) 
enhances it. By providing survival signals in the contraction phase of the response, LPS 



































 Improved B cell development in humanized 
NOD-scid IL2Rγnull mice transgenically 
expressing human stem cell factor, 
granulocyte-macrophage colony-stimulating 









Immunodeficient mice engrafted with human immune systems support 
studies of human hematopoiesis and the immune response to human-specific 
pathogens. A significant limitation of these humanized mouse models is, 
however, a severely restricted ability of human B cells to undergo class switching 
and produce antigen-specific IgG after infection or immunization. In this study, I 
have characterized the development and function of human B cells in NOD-scid 
IL2Rγnull (NSG) mice transgenically expressing human SCF, GM-CSF and IL-3 
(NSG-SGM3) following engraftment with human hematopoietic stem cells, 
autologous fetal liver and thymic tissues (bone marrow, liver, thymus or BLT 
model).  The NSG-SGM3 BLT mice engraft rapidly with human immune cells and 
develop T cells, B cells and myeloid cells. A higher proportion of human B cells 
developing in NSG-SGM3 BLT mice had a mature/naive phenotype with a 
corresponding decrease in immature/transitional human B cells as compared to 
NSG BLT mice. In addition, NSG-SGM3 BLT mice have higher basal levels of 
human IgM and IgG as compared with NSG BLT mice. Moreover, dengue virus 
infection of NSG-SGM3 BLT mice generated higher levels of antigen-specific IgM 
and IgG, a result not observed in NSG BLT mice. These studies suggest that 
NSG-SGM3 BLT mice show improved human B cell development and permit the 







 Humanized mice are increasingly being utilized to study human immunity 
as well as infections, autoimmunity, allergies, organ transplantation, vaccine 
development, and immune regulation (Shultz et al., 2012; Shultz et al., 2007). A 
key factor for the successful generation of humanized mice is the use of optimal 
mouse strains that enable the survival of engrafted human cells and tissues. 
Immunodeficient scid, Rag1null or Rag2null mice bearing mutations within the IL2 
receptor gamma chain (IL2rg) gene support the robust engraftment of human 
immune cells and tissues and the development of functional human immune 
systems (Brehm et al., 2010; Ito et al., 2002; Shultz et al., 2005; Traggiai et al., 
2004). 	
Current efforts to further enhance immune system development and 
function in humanized mouse models have focused on improving specific human 
immune cell populations. One major limitation of the existing humanized mouse 
models is the severely limited ability of human B cells in these mice to undergo 
class switching and affinity maturation in response to pathogens or immunization 
with protein antigens (Seung and Tager, 2013). Antigen-specific antibody 
responses are generated in these mice but they are largely of the IgM isotype 
with very low IgG titers, which suggests inefficient class switching (Biswas et al., 
2011; Jaiswal et al., 2015). The restricted B cell responses in humanized mice 
are an obstacle for studies of vaccine development and infectious diseases 
where humoral responses predominate. The limited ability of human B cells to 




including impaired T and B cell maturation, lack of secondary lymphoid structures 
in the peripheral lymphoid organs, poor reconstitution of myeloid antigen-
presenting cells (APCs), and insufficiency of human cytokines (Chen et al., 
2009c; Covassin et al., 2013; Matsumura et al., 2003; Vuyyuru et al., 2011; 
Watanabe et al., 2009). Examples of approaches to improve human B cell 
function include expression of HLA class II and expression or injection of human 
cytokines that facilitate hematopoiesis and lymphocyte differentiation. While 
these approaches have enabled improvements in B cell function, generation of 
high levels of antigen-specific IgG remains problematic. 
In this study I evaluated human B cell development and function in 
humanized NSG mice constitutively expressing SCF, GM-CSF and IL-3, also 
known as NSG-SGM3 mice. Previous studies have shown that NSG-SGM3 mice 
have significantly improved engraftment of human acute myeloid leukemia (AML) 
cells as well as long-term pre-leukemic myeloid cell cultures (Wunderlich et al., 
2010). Moreover, NSG-SGM3 mice engrafted with human CD34+ HSC have 
elevated levels of neutrophils (Miller et al., 2013) and other granulocytes 
(Coughlan et al., 2016), myeloid dendritic cells (mDCs) as well as CD4+ cells with 
a lineage skewing towards Tregs that were functionally and phenotypically 
equivalent to human Tregs (Billerbeck et al., 2011). To test the ability of NSG-
SGM3 mice to support human B cell development and function, these mice along 
with NSG mice were transplanted with human fetal thymic and liver tissues and 




NSG-SGM3 BLT mice have enhanced human B cell development, with higher 
levels of mature naïve B cells and lower levels of immature transitional and 
transitional B cells as compared with NSG BLT mice. NSG-SGM3 BLT mice also 
had higher basal levels of human IgM and IgG in the plasma as compared with 
control NSG BLT mice. Finally, infection of NSG-SGM3 BLT mice with dengue 
virus stimulated the generation of antigen-specific IgM and IgG responses at 
levels higher than NSG BLT mice. These results indicate that NSG-SGM3 mice 
support enhanced development and maturation of human B cells and will be a 
useful model to study human antigen-specific B cell responses.  
 
Materials and Methods 
 
Mice 
NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NOD-scid IL2rγnull, NSG) mice and NOD.Cg-
Prkdcscid Il2rgtm1Wjl Tg(CMV-IL3,CSF2,KITLG)1Eav/MloySzJ (NSG-SGM3 mice) 
were obtained from The Jackson Laboratory (Bar Harbor, ME, USA). All animals 
were housed in a specific pathogen free facility in microisolator cages, given 
autoclaved food and maintained on sulphamethoxazole-trimethoprim medicated 
water (Goldline Laboratories, Ft Lauderdale, FL, USA) and acidified autoclaved 
water on alternate weeks. All experiments were performed in accordance with 
the guidelines of the Institutional Animal Care and Use Committee of the 
University of Massachusetts Medical School and the recommendations in the 
Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal 





Generation of BLT mice 
Male and female NSG and NSG-SGM3 mice at 6-10 weeks of age were 
irradiated with 100 cGy and implanted with human fetal thymus and liver 
fragments under the kidney capsule. The fetal tissues (gestational age 16-20 
weeks) were obtained from Advanced Bioscience Resources (Alameda, CA, 
USA). The tissues were washed with RPMI supplemented with penicillin G 
(100U/ml), streptomycin (100mg/ml), fungizone (0.25ug/ml) and gentamycin 
(5ug/ml) and 1mm3 fragments of the fetal thymus and liver were implanted in the 
renal subcapsular space. Mice were injected subcutaneously with gentamycin 
(0.2 mg) and cefazolin (0.83 mg) post surgery. To obtain fetal HSC, fetal liver 
tissue was processed as described previously (Covassin et al., 2013), depleted 
of CD3+ T cells and a cell suspension containing 1 to 2x105  CD34+ fetal liver 
HSC was injected in the tail vein of mice between 4-6 h after irradiation.  
 
Antibodies and flow cytometry 
Fluorophore linked primary antibodies used for analysis of hematopoietic cell 
engraftment were purchased from BD Biosciences, Inc. (San Jose, CA, USA), 
eBiosciences (San Diego, CA, USA) or BioLegend (San Diego, CA, USA). The 
following antibodies (clones) were used: mouse CD45 (30-F11), human CD45 
(2D1), CD34 (581), CD3 (UCHT1), CD20 (2H7), CD33 (WM53), CD4 (RPA-T4), 




CD45RA (HI100), CD27 (M-T271), CD38 (HIT2), CD10 (HI10A), IgD (IAG-2), 
CD138 (MI15). Single cell suspensions of spleen and bone marrow (recovered 
from 1 femur) were prepared from mice and whole blood was collected in 
heparin. Single cell suspensions of 0.5-1 X 106 cells or 50-100ul of heparinized 
whole blood were washed with FACS buffer and incubated with rat anti-mouse 
CD16/CD32 (clone 2.4G2) for 5-7 mins at 4°C to block Fc binding. Cells were 
then incubated with antibodies for surface markers for 20 mins at 4°C in the dark. 
Stained samples were washed with FACS buffer and fixed with 1% 
paraformaldehyde for cell suspensions or treated with BD FACS lysing solution 
for whole blood to lyse red blood cells (RBCs) and fix the samples. To detect 
human Tregs, blood samples were stained for surface markers, lysed and fixed 
and then incubated with eBioscience fixation/permeabilization buffer for 60 mins. 
Cells were then stained with antibody against human Foxp3 in eBioscience 
permeabilization buffer for 60 mins. At least 50000 events were collected on 
LSRII flow cytometer (BD Biosciences) using the BD FACSDIVA software. 
FlowJo software  (Tree Star, Inc., Ashland, OR, USA) was used to analyze data.  
 
Infections and ELISAs 
Total human IgM and IgG concentrations were measured in the plasma of mice 
by ELISA as per the manufacturer’s instructions (Bethyl Laboratories, Inc., 
Montgomery, TX, USA) using an EMax Endpoint ELISA microplate reader 




antibody responses, mice were infected subcutaneously with approximately 106 
plaque forming units (PFUs) of dengue virus serotype-2 strain New Guinea C 
(DENV-2 NGC). The levels of dengue-specific IgM and IgG were determined 
using inactivated dengue-2 antigen lysates in ELISAs as described previously 
(Jaiswal et al., 2015). 
 
Statistical analyses 
Statistical analyses were performed using GraphPad PRISM software version 5 
(GraphPad, San Diego, CA, USA). An unpaired t-test was performed to 






NSG-SGM3 BLT mice show accelerated human cell chimerism as compared 
to NSG BLT mice 
 
 
BLT mice were generated on the NSG or NSG-SGM3 background and levels of 
human CD45+ hematopoietic cells were examined in the blood at 6, 9 and 12 
weeks post implantation and in spleen and bone marrow at week 12 (Fig. 5.1). 
Levels of human CD45+ hematopoietic cells were significantly higher in the 
peripheral blood of NSG-SGM3 mice at 6, 9 and 12 weeks as compared to NSG 
mice (Fig. 5.1A, 5.1B and 5.1C). The levels of circulating human CD45+ cells in 




35.3±3.3% at 9 weeks and 47.3±4.6% at 12 weeks). In contrast, CD45+ cell 
levels in the blood of NSG-SGM3 BLT mice reached maximal levels at 6 weeks 
and did not increase significantly beyond that time point (52.7±2.2% at 6 weeks, 
62.5±2.9% at 9 weeks and 64.2±3.3% at 12 weeks). In the spleen, the 
percentages and total numbers of human CD45+ cells were similar between NSG 
and NSG-SGM3 mice at 12 weeks post implantation (Fig. 5.1D and 5.1E). The 
percentages and total numbers of human CD45+ cells in the bone marrow were 
similar between NSG and NSG-SGM3 mice at 12 weeks post implantation (Fig. 
5.1F and 5.1G). Together these results indicated that NSG-SGM3 mice support 






Fig. 5.1. Human CD45+ cell engraftment kinetics in the peripheral blood, spleen 
and bone marrow of NSG BLT mice and NSG-SGM3 BLT mice.   
 
Fig. 5.1. Human CD45+ cell engraftment kinetics in the peripheral blood, spleen and 
bone marrow of NSG BLT mice and NSG-SGM3 BLT mice. NSG and NSG-SGM3 mice 
were irradiated with 100cGy and implanted with 1mm3 of human fetal thymus and liver in 
the renal subcapsular space. All mice were injected intravenously with 1x105 CD34+ 
hematopoietic stem cells (HSC) derived from autologous fetal liver. The peripheral blood 
of the recipient NSG BLT and NSG-SGM3 BLT mice was screened for total human 
hematopoietic CD45+ cell engraftment at the 6-week (A), 9-week (B) and 12-week (C) 
post-transplantation time points. The spleen (D,E) and bone marrow (F,G) of NSG BLT 
and NSG-SGM3 BLT mice were screened for total human CD45+ cell engraftment 12 
weeks after transplantation of human fetal tissues. Engraftment results are represented 
as a percentage of total cells or as total numbers in the spleen (D,E) and in the bone 
marrow (F,G). *p<0.05; **p<0.01; ****p<0.0001. The results for peripheral blood are from 


































































































































NSG-SGM3 BLT mice support human T cell development 
 
 A significant advantage of the BLT model is the efficient development of 
human T cells on autologous human thymic tissues. Human CD3+ T cell 
development in NSG-SGM3 BLT and NSG BLT mice was monitored in the blood 
at 6, 9 and 12 weeks post implantation and in spleen and bone marrow at week 
12 (Fig. 5.2). Levels of human T cells were significantly lower in the blood of 
NSG-SGM3 mice compared to NSG mice and the differences were significant 
over time (Fig. 5.2A, 5.2B, 5.2C). T cell engraftment improved with the age of 
mice in both groups. NSG-SGM3 mice had lower percentages of human T cells 
in the spleen compared to NSG mice at 12 weeks (Fig. 5.2D), but total numbers 
of T cells were similar (Fig. 5.2E). Human T cell levels were low in the bone 
marrow of both groups of mice, with significantly higher percentages (Fig. 5.2F) 
detected in NSG-SGM3 mice compared to NSG mice and similar numbers for 
each group (Fig. 5.2G).  
 
 
NSG-SGM3 BLT mice support human B cell development 
 
 
 Human CD20+ B cell development in NSG-SGM3 BLT and NSG BLT mice 
was monitored in the blood at 6, 9 and 12 weeks post implantation and in spleen 





Fig. 5.2. Human CD3+ T cell engraftment kinetics in the peripheral blood, spleen 
and bone marrow of NSG BLT mice and NSG-SGM3 BLT mice.  
 
 
Fig. 5.2. Human CD3+ T cell engraftment kinetics in the peripheral blood, spleen and 
bone marrow of NSG BLT mice and NSG-SGM3 BLT mice. The peripheral blood of the 
NSG BLT and NSG-SGM3 BLT mice was screened for total human CD3+ T cell 
engraftment at 6-week (A), 9-week (B) and 12-week (C) post-transplantation of human 
fetal tissues. The spleen (D,E) and bone marrow (F,G) of NSG BLT and NSG-SGM3 
BLT mice were screened for human CD3+ T cell engraftment 12 weeks after 
transplantation of human fetal tissues. Engraftment results are represented as a 
percentage of total human CD45+ cells or as total numbers in the spleen (D,E) and in the 
bone marrow (F,G). The results for peripheral blood are from 4 independent experiments 
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Levels of human B cells were significantly lower in the blood of NSG-SGM3 mice 
at week 6 compared to NSG mice but the levels were comparable at weeks 9 
and 12 (Fig. 5.3A, 5.3B, 5.3C). NSG-SGM3 and NSG mice had similar 
percentages and total numbers of human B cells in the spleen (Fig. 5.3D and 
5.3E) and bone marrow (Fig. 5.3F and 5.3G) at 12 weeks.  
 
NSG-SGM3 BLT mice support enhanced myeloid cell development 
compared to NSG BLT mice 
 
 
Previous studies have shown that NSG-SGM3 mice engrafted with human 
HSC have significantly improved myeloid cell development (Billerbeck et al., 
2011; Coughlan et al., 2016; Miller et al., 2013; Wunderlich et al., 2010). Human 
CD33+ myeloid cell development in NSG-SGM3 BLT and NSG BLT mice was 
monitored in the blood at 6, 9 and 12 weeks post implantation and in spleen and 
bone marrow at week 12 (Fig. 5.4). At all time points tested significantly higher 
levels of human CD33+ cells were detected in the blood of NSG-SGM3 BLT mice 
as compared to NSG BLT mice (Fig. 5.4A, 5.4B, 5.4C). In the spleen, the 
percentages and total numbers of human CD33+ cells were significantly higher in 
NSG-SGM3 mice at 12 weeks post implantation compared to NSG mice (Fig. 
5.4D and 5.4E). The percentages and total numbers of human CD45+ cells in the 
bone marrow were similar between NSG and NSG-SGM3 mice at 12 weeks (Fig. 




Fig. 5.3. Human CD20+ B cell engraftment kinetics in the peripheral blood, spleen 
and bone marrow of NSG BLT mice and NSG-SGM3 BLT mice. 
 
 
Figure 3. Human CD20+ B cell engraftment kinetics in the peripheral blood, spleen and 
bone marrow of NSG BLT mice and NSG-SGM3 BLT mice. The peripheral blood of the 
NSG BLT and NSG-SGM3 BLT mice was screened for total human CD20+ B cell 
engraftment at 6-week (A), 9-week (B) and 12-week (C) post-transplantation of human 
fetal tissues. The spleen (D,E) and bone marrow (F,G) of NSG BLT and NSG-SGM3 
BLT mice were screened for human CD20+ B cell engraftment 12 weeks after 
transplantation of human fetal tissues. Engraftment results are represented as a 
percentage of total human CD45+ cells or as total numbers in the spleen (D,E) and in the 
bone marrow (F,G). *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. The results for 
peripheral blood are from 4 independent experiments and for spleen and bone marrow 































































































































Fig. 5.4. Human CD33+ myeloid cell engraftment kinetics in the peripheral blood, 
spleen and bone marrow of NSG BLT mice and NSG-SGM3 BLT mice  
 
Fig. 5.4. Human CD33+ myeloid cell engraftment kinetics in the peripheral blood, spleen 
and bone marrow of NSG BLT mice and NSG-SGM3 BLT mice. The peripheral blood of 
the NSG BLT and NSG-SGM3 BLT mice was screened for total human CD33+ myeloid 
cell engraftment at 6-week (A), 9-week (B) and 12-week (C) post-transplantation of 
human fetal tissues. The spleen (D,E) and bone marrow (F,G) of NSG BLT and NSG-
SGM3 BLT mice were screened for human CD33+ myeloid cell engraftment 12 weeks 
after transplantation of human fetal tissues. Engraftment results are represented as a 
percentage of total human CD45+ cells or as total numbers in the spleen (D,E) and in the 
bone marrow (F,G). In Fig. B, data points shown for NSG-SGM3 BLT are a combination 
of 8 and 9 week time points. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. The results for 
peripheral blood are from 4 independent experiments and for spleen and bone marrow 











































































































































Together, these data show that NSG-SGM3 BLT mice show a heightened 
development of human myeloid development as has been found in HSC-
engrafted NSG-SGM3 mice (Billerbeck et al., 2011). 
 
NSG-SGM3 BLT mice show improved engraftment of CD4+ regulatory T 
cells as compared to NSG BLT mice 
 
 
 NSG-SGM3 mice engrafted with human HSC have previously been shown 
to have enhanced development of CD4+ human Tregs (Billerbeck et al., 2011). T-
cell subsets were characterized in NSG-SGM3 BLT mice, by comparing CD4+ to 
CD8+ T cell ratios, Treg levels and T cell phenotype in the blood of both groups 
of mice at 12 weeks post tissue implantation (Fig. 5.5).  The CD4+ to CD8+ ratio 
was approximately 5:1 in both strains of mice (Fig. 5.5A). Significantly higher 
levels of human CD4+CD25+CD127loFoxp3+ T regulatory cells were detected in 
the blood of NSG-SGM3 mice compared to NSG mice (Fig. 5.5B). Analysis of 
CD45RA expression levels by human CD4 and CD8 T cells showed a lower 
proportion of T cells expressing CD45RA in the blood of NSG-SGM3 mice 
compared to NSG mice (Fig. 5.5C and 5.5D). These data indicate that NSG-
SGM3 BLT mice have higher levels of CD4+ regulatory T cells, and lower levels 






Fig. 5.5. Characterization of human CD3+ T cells in the peripheral blood of NSG 





Fig. 5.5. Characterization of human CD3+ T cells in the peripheral blood of NSG BLT and 
NSG-SGM3 BLT mice at 12 week-post transplantation. The ratio of human CD4:CD8 T 
cells gated on CD3+ T cells is shown in (A). The proportion of CD25+CD127lowFoxp3+ 
regulatory T cells (Treg) gated on CD4+ T cells is shown in (B). The percentages of CD4+ 
and CD8+ T cells expressing naïve T cell marker CD45RA are shown in (C) and (D) 





























































































NSG-SGM3 BLT mice develop higher levels of mature naïve B cells 
compared to NSG BLT mice 
 
 
Previous studies have described a predominance of immature B cells in 
humanized mice (Biswas et al., 2011; Covassin et al., 2013; Matsumura et al., 
2003). To evaluate B cell development in NSG-SGM3 BLT mice, the phenotype 
of B cells in the periphery was examined (Fig. 5.6). B cells were categorized into 
5 groups based on their phenotypic markers; immature/transitional B cells (CD27-
CD10+), transitional B cells (CD27-CD10-CD38+), mature naïve B cells (CD27-
CD10-IgD+), memory B cells (CD27+CD10-) and plasma cells (CD138+). 
Immature/transitional B cells were present at comparable levels in the peripheral 
blood of NSG-SGM3 and NSG mice (Fig. 5.6A). NSG-SGM3 mice had lower 
levels of immature/transitional B cells in the spleen (Fig. 5.6B) and bone marrow 
(Fig. 5.6C). Transitional human B cells were significantly lower in blood (Fig. 
5.6D) and spleen (Fig. 5.6E) of NSG-SGM3 mice compared to NSG mice and 
levels were similar in the bone marrow (Fig. 5.6F). Mature/naïve B cells were 
significantly higher in the blood (Fig. 5.6G), spleen (Fig. 5.6H) and bone marrow 
(Fig. 5.6I) of NSG-SGM3 mice compared to control NSG mice. Healthy human 
adults have between 60-70% mature naïve B cells in the peripheral blood (Perez-
Andres et al., 2010).  Memory B cells were present at significantly higher levels in 
the blood of NSG-SGM3 mice compared to NSG mice (Fig. 5.6J) and similar in 




Fig. 5.6. Characterization of human CD20+ B cells in the peripheral blood, spleen 



































































































































































































































































































































Fig. 5.6. Characterization of human CD20+ B cells in the peripheral blood, spleen and 
bone marrow of NSG BLT and NSG-SGM3 BLT mice at 12 weeks post-transplantation. 
Human B cells were divided into 5 categories and expressed as a percentage of total 
human CD20+ B cells: CD20+CD27-CD10+ immature transitional B cells in blood (A), 
spleen (B), bone marrow (C); CD20+CD27-CD10-CD38+ transitional B cells in blood (D), 
spleen (E), bone marrow (F); CD20+CD27-CD10-IgD+ mature naïve B cells in blood (G), 
spleen (H), bone marrow (I); CD20+CD27+CD10- memory B cells in blood (J), spleen (K), 
bone marrow (L) and CD20+CD138+ plasma cells in blood (M), spleen (N), bone marrow 
(O). *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. The results for peripheral blood are 







Healthy human adults are reported to have 10-30% memory B cells circulating in 
blood (Perez-Andres et al., 2010). Plasma cells were present at very low levels in 
both groups of mice in all tissues (Fig. 5.6M, 5.6N, 5.6O). Together these data 
indicate that NSG-SGM3 BLT mice have lower levels of immature and 
transitional B cells and higher levels of mature naïve B cells relative to NSG BLT 
mice, suggesting that the NSG-SGM3 BLT mice have improved human B cell 
maturation.  
 
NSG-SGM3 BLT mice show an improved ability to generate IgG antibodies 
 
 A major limitation of humanized mice is their reduced ability to generate 
human IgG responses. The enhanced human B cell maturation observed in the 
NSG-SGM3 BLT mouse model (Fig. 5.6) suggested that these mice may have an 
increased ability to undergo Ig class switching. The basal levels of human IgM 
and IgG in the plasma of resting BLT mice were therefore evaluated at 12 weeks 
post tissue implant. NSG-SGM3 mice had 5.6 fold higher levels of human IgM 
compared to NSG mice (Fig. 5.7A). Human IgG levels were 4.5 fold higher in 
NSG-SGM3 mice compared to NSG mice (Fig. 5.7B). Next the mice were 
infected with DENV-2 (Dengue virus serotype-2) and the generation of DENV-2 
specific antibodies was assessed by sandwich ELISA 4 weeks post infection. 
The generation of IgM responses to the inactivated lysates of dengue antigen 
and the DENV-2 E (envelope) protein in NSG BLT mice but limited antigen-




Fig. 5.7. Evaluation of total antibody titers and dengue virus specific antibody 




Fig. 5.7. Evaluation of total antibody titers and dengue virus specific antibody responses 
in NSG BLT and NSG-SGM3 BLT mice. Mice were bled at 12 weeks post implantation of 
human tissues and total human IgM (A) and human IgG (B) levels (ng/ml) were 
determined in the plasma of these mice by ELISA. Mice were infected with DENV-2 and 
plasma samples were tested to determine DENV-2 specific IgM (C) and IgG (D) by 
sandwich ELISA. Each symbol indicates an individual BLT mouse. The results are from 


























































































NSG-SGM3 BLT mice infected with DENV-2 had significantly higher levels of 
DENV-2 specific IgM (Fig. 5.7C) and increased levels of DENV-2 specific IgG 
(Fig. 5.7D). These data indicate that transgenic expression of SCF, GM-CSF and 
IL-3 generates higher levels of total human IgM and IgG suggesting improved 




The BLT model enables the generation of humanized mice having a 
complete human immune system, including the development of both 
conventional and regulatory HLA-restricted T cells. Although B cells develop in 
BLT mice, the circulating antibody levels are significantly lower compared to adult 
humans. Moreover, the generation of antigen-specific antibody responses in BLT 
mice, specifically IgG responses, are weak, limiting their use in studying humoral 
responses to pathogens and testing candidate vaccines (Seung and Tager, 
2013). Two studies have demonstrated that the immunoglobulin gene repertoires 
of human B cells in humanized (HSC-engrafted) mice are similar to those of 
normal human peripheral B cells suggesting that humanized mice have the 
genetic potential to mount broad and high affinity antibody responses to diverse 
pathogens (Becker et al., 2010; Ippolito et al., 2012). The poor antigen-specific 
antibody responses are unlikely to be attributed to a genetic defect in the 
immunoglobulin repertoire. Studies have suggested that the contributing factors 




structures and an absence of human cytokines (Chen et al., 2009c; Covassin et 
al., 2013; Matsumura et al., 2003; Vuyyuru et al., 2011; Watanabe et al., 2009).  
Mature B cells that encounter their cognate antigen in lymphoid follicles 
and receive T cell help enter a germinal center where they undergo the 
processes of class switching, that generates different antibody isotypes, and 
somatic hypermutation, that diversifies their antibody repertoire (LeBien and 
Tedder, 2008). Activated B cells can then differentiate into plasmocytes and 
become antibody-secreting plasma cells or become long-lived memory B cells. 
Human B cells develop in NSG BLT mice and generate human immunoglobulins 
although at lower levels than in adult humans (Covassin et al., 2013). Human B 
cells in humanized mice have been shown to generate antigen-specific antibody 
responses to human immunodeficiency virus 1 (HIV-1) (Biswas et al., 2011; 
Brainard et al., 2009), West Nile virus (Biswas et al., 2011), dengue virus 
(Jaiswal et al., 2012) and Epstein-Barr virus (EBV) (Yajima et al., 2008). These 
antibody responses are predominantly of the IgM isotype with very little to no IgG 
responses. A few studies have demonstrated antigen-specific IgG responses in a 
small subset of mice infected with HIV-1 (Sato et al., 2010; Sun et al., 2007), 
albeit at low titers. The inability to efficiently generate antibody response to most 
antigens has necessitated the development of humanized mouse models with 
improved class-switching. 
The expression of human transgenes and inactivation of specific mouse 




of human signal regulatory protein alpha (SIRP alpha) in BALB/c-Rag2-/- IL2rgnull 
mice that were injected with human HSC significantly elevated the total levels of 
human IgG in the plasma, but could not elicit a strong IgG response to the 
protein antigen ovalbumin (OVA) (Strowig et al., 2011). However, transgenic 
expression of HLA-DR4 in NOD-Rag1-/- IL2rgnull mice engrafted with HLA-DR4+ 
HSC elicited an IgG response to tetanus toxoid vaccine as well as class 
switching to IgA, IgE and all subtypes of IgG (Danner et al., 2011). In addition 
HLA-DR4 expression in NOD Shi-scid IL2rgnull mice induced an anti-OVA IgG 
response (Suzuki et al., 2012). Expression of specific human cytokines has also 
improved the engraftment of human hematopoietic cells and enhanced the 
development and function of human immune cells, including B cells (Chen et al., 
2009c). Administration of the recombinant human cytokine BAFF (B cell 
activating factor, also called BLyS) to NOD-Rag1-/- Prf1-/- mice injected with 
human PBLs improved the engraftment of B cells, elevated serum 
immunoglobulin levels and generated an antibody response to thymus-
independent antigens in pneumovax vaccine (Schmidt et al., 2008). 
Hydrodynamic injection of human GM-CSF and IL-4 in HSC-engrafted NSG mice 
allowed the induction of tetanus toxoid specific IgG as well as neutralizing 
antibodies against H5N1 influenza virus upon immunization (Chen et al., 2012). 
While the approaches described above have improved human B cell functionality 
in humanized mice, further advancements are necessary to make these models 





In this study I have shown that NSG-SGM3 BLT mice that transgenically 
express human SCF (also called c-kit ligand or Steel factor), GM-CSF and IL-3 
show heightened human B cell engraftment consistent with the important role of 
these human hematopoietic growth factors in hematopoiesis as well as in 
proliferation and survival of HSC in vitro (Broudy, 1997). Three studies have 
described HSC-engrafted NSG mice transgenically expressing membrane bound 
SCF (Brehm et al., 2012; Coughlan et al., 2016; Takagi et al., 2012). In one 
study, transgenic expression of membrane bound SCF circumvented the need 
for irradiation and permitted high levels of engraftment of human CD45+ cells in 
HSC engrafted NSG mice (Brehm et al., 2012). Another study reported these 
mice to have an improved human myeloid cell compartment, specifically cells of 
the granulocytic lineage (Takagi et al., 2012). A recent study showed that the 
human myeloid cells in the SCF NSG mice migrated to the renal tissue to 
become resident dendritic cells and some of these mice could be used as a 
source of human bone marrow-derived macrophages (Coughlan et al., 2016). 
GM-CSF and IL-3 are important for the development and function of myeloid 
cells. Human IL-3/GM-CSF knock-in mice engrafted with human HSC were 
shown to have improved myeloid cell reconstitution in the lung and the engrafted 
human alveolar macrophages mounted an innate immune response to influenza 
virus showing that the myeloid cells were functionally responsive (Willinger et al., 




have been described previously (Billerbeck et al., 2011). These mice were shown 
to have elevated myeloid cell frequencies, specifically myeloid DCs, and CD4+ 
Foxp3+ regulatory T cells. NSG-SGM3 BLT mice have a similar increase in 
myeloid cell levels (Fig. 5.4) and Tregs (Fig. 5.5B).  
Interestingly, NSG-SGM3 BLT mice had significantly higher frequencies of 
mature naïve B cells and proportionately reduced frequencies of immature and 
transitional B cells compared to control NSG BLT mice (Fig. 5.6). Immature B 
cells develop from the lymphoid progenitors in the bone marrow by passing 
through the pro-B and pre-B cell stages. These immature B cells expressing 
surface IgM (sIgM) exit the bone marrow and enter into the periphery. The early 
bone marrow emigrants are called immature transitional B cells and they express 
the markers CD10 and CD38 (Kaminski et al., 2012). In the periphery, they 
develop into transitional B cells that can gain access to lymphoid follicles in the 
spleen and become more sensitive to T cell help. Upon receiving appropriate 
cytokine signals and positive signals through the B-cell receptor, they become 
mature B cells that repopulate the periphery (Chung et al., 2003). Successful 
differentiation from the transitional to mature B cell stage is governed by the 
cytokine BAFF (Mackay et al., 2003). BAFF is a member of the TNF (tumor 
necrosis factor) family and is secreted mainly by myeloid cells such as 
neutrophils, monocytes, macrophages and dendritic cells (Mackay and 
Schneider, 2009). BAFF is also shown to be produced by activated T cells to 




B cell maturation observed in NSG-SGM3 BLT mice. Firstly, the increased 
frequencies of activated T cells characterized as CD45RA- (Fig. 5.5C, 5.5D) 
could facilitate B cell maturation in NSG-SGM3 mice. Recently, Lang et al. 
demonstrated a requirement of T cells for human B cell maturation in BALB/c-
Rag2-/- IL2rgnull mice engrafted with CD34+ HSC (Lang et al., 2013). The study 
showed that adoptive transfer of autologous T cells elevated mature B cell 
frequencies, whereas T cell depletion diminished mature B cell levels.  T cell 
activation, characterized by the expression of CD45RO, HLA-DR and CD49d, 
correlated with B cell maturation suggesting T cell activation might be important 
for B cell maturation. I did not find increased numbers of T cells in NSG-SGM3 
BLT mice relative to NSG BLT mice (Fig. 5.2). However, the increased 
frequencies of CD45RA- activated T cells (Fig. 5.5C, 5.5D) in NSG-SGM3 BLT 
mice could possibly explain the improved B cell maturation in these mice. 
Secondly, the well engrafted human myeloid cell compartment in the NSG-SGM3 
mice (Fig. 5.4) could secrete increasing amounts of human BAFF that binds the 
BAFF-R on transitional B cells rescuing them from death and easing them into 
the mature B cell stage. Also consistent with its role of a ‘survival cytokine’, BAFF 
would bind BAFF-R on mature B cells mediating their longevity and thus 
elevating the mature B cell frequencies.  
Since improved B cell maturation contributes to enhanced B cell 
functionality in terms of antigen-specific antibody responses, I tested the 




generate antigen-specific antibody responses. Previously our lab has 
demonstrated that NSG BLT mice can elicit DENV-2 antigen-specific antibody 
responses that are predominantly of the IgM class (Jaiswal et al., 2012). NSG-
SGM3 BLT mice elicited significantly stronger IgM as well as IgG responses to 
inactivated DENV-2 lysates relative to NSG BLT mice. I propose that improved B 
cell maturation in these mice contributes to the enhanced levels of human 
immunoglobulins and antigen-specific antibody responses. The histology 
sections of spleens of NSG and NSG-SGM3 BLT mice upon dengue infection 
showed similarly disorganized architecture ruling out the formation of organized 
secondary lymphoid structures in NSG-SGM3 mice. However, I cannot rule out 
other mechanisms for enhanced antibody responses in these mice.  
To summarize, transgenic expression of SCF, GM-CSF and IL-3 in NSG 
BLT mice resulted in improved human myeloid cell reconstitution, enhanced B 
cell maturation and antigen-specific antibody responses to dengue virus 
infection. Thus, NSG-SGM3 BLT mice prove to be a useful tool to study antibody 
responses to viral infections. Further improvements in B cell development, such 
as the development of secondary lymphoid structures to support class switching, 
engraftment of human follicular dendritic cells and enhanced B and T cell 





















In this thesis, I examined the role of costimulation and inflammation on the 
generation of alloreactive CD8 T cell responses. In Chapter II, I demonstrated 
that blocking CD40-CD154 interactions using an antagonistic CD40 antibody 
prolonged skin allograft survival and suppressed donor-specific CD8 T cell 
responses predominantly by impairing expansion of the CD8 T cell population. 
The pro-apoptotic proteins Fas and Bim functioned together to promote graft 
acceptance by CD154 costimulation blockade (Chapter III). In Chapter IV, I 
examined the impact of inflammatory stimuli LPS and poly(I:C) on CD8 T cell 
responses to the donor alloantigen DST and found that LPS and poly(I:C) 
differentially regulated the kinetics of the response, phenotype and functionality 
of alloreactive CD8 T cells. In Chapter V, I showed that transgenic expression of 
human cytokines SCF, GM-CSF and IL-3 in humanized NSG mice promoted B 
cell maturation and development of antibody responses. 
Achieving transplantation tolerance clinically has been the ‘Holy Grail’ for 
transplantation immunologists for over two decades. Costimulation blockade has 
emerged to be a promising strategy to achieve this goal. Considering the central 
role of the CD40-CD154 pathway in the generation of adaptive immune 
responses, targeting this pathway is highly desirable. Using a stringent skin 
transplantation model of complete MHC mismatch, I showed that CD40 targeting 
antibodies can replace CD154 targeting antibodies to promote graft acceptance. 
This study supports the need to develop CD40 blocking reagents for clinical 




benefits in models of several autoimmune diseases (Peters et al., 2009). CD40 
antagonists will potentially be efficacious in halting progression of autoimmunity. 
The absence of thromboembolism or other serious adverse events in phase 1 
clinical trials of the CD40 antagonist ASKP1240 provides a ray of hope that 
targeting the promising CD40-CD154 pathway could become a reality in clinical 
transplantation and autoimmunity (Goldwater et al., 2013).  
 Although I showed that CD4+CD25+Foxp3+ Tregs were necessary for 
DST/anti-CD40 mediated long-term allograft acceptance, I did not examine 
whether Tregs were induced by this treatment. Peripheral induction of Tregs is a 
feature of DST/anti-CD154 therapy (Ferrer et al., 2011). Although the exact 
mechanism of Treg induction by blocking CD154 is not known, the favored 
hypothesis is that DST/anti-CD154 inhibits production of cytokines such as IL-6 
(Ferrer et al., 2012a) that are critical inhibitors of Treg differentiation. To test if 
DST/anti-CD40 induces Tregs, OT-II T cells can be adoptively transferred into 
congenic recipient mice receiving DST/anti-CD40 treatment and a skin graft 
expressing ovalbumin (OVA) followed by counting CD25+Foxp3+ OT-II T cells in 
the draining lymph nodes a week after transplantation. I hypothesize that 
DST/anti-CD40 treatment would promote iTreg differentiation. Also I expect a 
higher Treg: Teff ratio within the graft after DST/anti-CD40 treatment relative to 
DST/isotype control treatment. A combination therapy of anti-CD154 mAb and 
CTLA4-Ig induces modest prolongation of allograft survival in the BALB/c -> B6 




resistant to CD28/CD154 blockade (Trambley et al., 1999); hence testing 
DST/anti-CD40 in a less stringent model such as BALB/c -> C3H will reveal if the 
anti-CD40 mAb can synergize with CTLA4-Ig to prolong allograft survival. 
Combination therapy of CD40 antagonist and belatacept in clinical 
transplantation might provide greater therapeutic benefit compared to belatacept 
monotherapy due to the Treg-promoting effects of blocking CD40 signaling.   
 DST/anti-CD40 treatment reduced IFN-γ production by alloreactive DES+ 
CD8 T cells at the peak of the primary response (day 3) and by endogenous 
donor-reactive CD8 T cells in the skin-grafted mice at a late time-point (day 42) 
suggesting that CD8 T cells that survive the deletion might be anergic. However, 
I did not pursue the ‘anergy’ aspect in my project. A recent study reported anergy 
in CD8 T cells that survived CD3 antibody mediated depletion (Baas et al., 2016). 
In this study, the graft-infiltrating CD8 T cells co-expressed PD-1, PD-L1 and 
produced TGF-β and neutralizing either of these molecules abrogated anti-CD3 
antibody-induced tolerance. It would be interesting to examine if similar 
mechanisms exist to maintain tolerance by DST/anti-CD40 costimulation 
blockade. Moreover, to test if the alloreactive CD8 T cells surviving DST/anti-
CD40 mediated deletion are functionally competent, these cells can be sorted 
from tolerant mice and tested for their ability to reject established allografts in 
Rag-/- mice. Another interesting avenue would be to test the requirement of 




although the lack of specific depleting agents for these populations will confound 
interpretations of data from these experiments. 
 Memory T cells present a formidable barrier to long-term graft survival in 
clinical transplantation. Since memory T cells are resistant to tolerization by 
DST/anti-CD154 treatment, it is reasonable to expect that they will be resistant to 
DST/anti-CD40 treatment. Combining OX40 blockade with DST/anti-CD40 might 
overcome the barrier imposed by memory T cells generated by homeostatic 
proliferation or previous priming (Vu et al., 2006).  
 In Chapter III, I found that loss of Bim made mice partially resistant to 
tolerance induction by DST/anti-CD154. Combined deficiency of Fas and Bim 
completely abrogated tolerance induction. Donor-reactive CD4 and CD8 T cells 
and B cells are deleted in the context of DST/anti-CD154 costimulation blockade. 
TUNEL or annexin V staining on cells in the skin draining lymph nodes should 
reveal which of the cell subsets was rescued from death by Fas/Bim deficiency. 
Fas and Bim double deficient mice have elevated numbers of T and B cells as 
well as macrophages and dendritic cells (Hutcheson et al., 2008). Hence the 
precursor frequency of T and B lymphocytes capable of mediating graft rejection 
would be higher in these mice than in normal mice. Since the feasibility of 
tolerizing cells is inversely proportional to their frequency, Bcl2l11-/-Faslpr/lpr mice 
have an inherent limitation to tolerization. Downregulating Fas and Bim mediated 
apoptotic signaling in normal mice with Fas ligand decoy receptors (Connolly et 




time of transplantation would be an approach to overcome the limitation of 
abnormally high lymphocyte counts in Bcl2l11-/-Faslpr/lpr mice. My data suggest 
that in the absence of Bim, apoptotic signaling through Fas (or other apoptotic 
proteins) is not sufficient to delete alloreactive cells and promote long-term graft 
acceptance by DST/anti-CD154 costimulation blockade. It would be interesting to 
test the requirement of Bim in a minor antigen mismatch model such as 
transplanting male (H-Y expressing) skin on female mice. In this case, the minor 
antigen will be indirectly presented by host APCs. Alloreactive T cells with 
indirect specificity are present at significantly lower frequencies than direct 
specificity alloreactive T cells. It is possible that Fas-mediated apoptosis can 
effectively delete this smaller pool of alloreactive T cells in the absence of Bim 
and hence Bim deficient female mice exhibit prolonged survival of male grafts in 
response to DST/anti-CD154 costimulation blockade. 
   In Chapter IV, I found that TLR agonists LPS and poly(I:C), that signal 
through different pathways, differentially regulate CD8 T cell responses to MHC 





Fig. 6.1. Model 
 
  
Fig. 6.1. Model 
LPS signals through TLR4 on recipient cells and stimulates production of IL-6. IL-6 
inhibits the generation of IFN-γ and granzyme producing alloreactive CD8 T cells in 
response to DST. Poly(I:C) signals through TLR3/MDA5 and promotes generation of 




























My skin-grafting experiments in Chapter II revealed that DST in the absence of 
CD40/CD154 blockade was not tolerogenic and the grafts were rapidly rejected. 
Moreover, my studies in Chapter IV illustrated that DST could induce an antigen-
specific CD8 T cell response characterized by proliferation of cells and IFN-γ 
production and cytolysis of targets. However, CD8 T cell responses to a skin 
graft will vary from CD8 T cell responses to DST since DST is systemically 
administered whereas skin transplantation is local (Chai et al., 2015). I found that 
LPS reduced the frequency of IFN-γ producing alloreactive CD8 T cells and their 
cytotoxic ability. Future studies should test if LPS-mediated inhibition of 
alloreactive CD8 T cell function translates to delaying skin graft rejection if LPS is 
administered at the time of transplantation. It is possible that LPS delays graft 
rejection when the mismatch is in a minor, but not a major histocompatibility 
antigen.  
 I focused my studies on primary effector responses of alloreactive CD8 T 
cells.  LPS challenge generated higher levels of CD44hi memory-like alloreactive 
CD8 T cells relative to poly(I:C). This finding poses several questions: Do LPS 
and poly(I:C) differentially regulate the proportion of KLRG1hiIL-7Rαlo short-lived 
effector cells (SLECs) and KLRG1loIL-7Rαhi memory precursor effector cells 
(MPECs)? Are the gene expression profiles of fate determining transcription 
factors such as T-bet, Blimp-1, Bcl-6, Id2, Id3 different in CD8 T cells from mice 
treated with the two TLR agonists? Understanding how LPS and poly(I:C) 




inflammation in the transplant recipient resulting from infectious or non-infectious 
sources prior to receiving the graft. To test memory responses, KB5 chimeric 
mice primed with DST and LPS or poly(I:C) can be challenged with a second 
dose of DST 4 weeks after the initial treatment and expansion of DES+ CD8 T 
cells monitored in response to the second challenge.  
  Poly(I:C) challenge has been shown to promote the generation of highly 
cytotoxic CD8 T cells. I observed higher frequencies of granzyme B producing 
and IFN-γ producing effector alloreactive CD8 T cells in poly(I:C) treated mice. Is 
type I interferon generated upon poly(I:C) challenge necessary and sufficient to 
potentiate the CD8 T cell response? If it is so, then is direct type I interferon 
signaling into CD8 T cells sufficient to enhance the CD8 T cell effector function? 
Our lab has previously demonstrated that poly(I:C) can abrogate DST/anti-
CD154 mediated tolerance induction by promoting alloreactive effector CD8 T 
cell responses in a type I interferon dependent and TLR3 independent manner  
(Thornley et al., 2007a). Does poly(I:C) then require the cytosolic MDA5 receptor 
to enhance the alloreactive CD8 T cell response? Mice with genetic deficiency of 
type I interferon receptor, MDA5, TLR3 would be required to answer these 
questions. The CBA background of KB5 mice is not amenable to generating 
knockouts limiting their usefulness. Instead 2C TCR transgenic mice on the 
C57BL/6 background with allospecificity for H-2Ld would facilitate conducting 




 Inhibition of alloreactive CD8 T cell function by LPS is an interesting 
finding. Future experiments should test if TLR4 activation by infection with Gram 
negative bacteria such as Salmonella typhimurium induces a similar response as 
LPS challenge. My experiments demonstrated a requirement for IL-6 in LPS 
mediated suppression of CD8 T cell function. TLR2 activation is known to 
generate high levels of IL-6 (Skabytska et al., 2014) and no type I interferon. I 
hypothesize that the relative amounts of IL-6 and type I interferons determine the 
impact of TLR stimulation on CD8 T cell function. I would thus speculate that 
challenge with TLR2 agonists would suppress CD8 T cell function, perhaps more 
than LPS. Also, neutralizing IL-6 in poly(I:C) treated mice should further enhance 
CD8 T cell function.  
 IL-6 was necessary, but not sufficient to inhibit CD8 T cell function.  Future 
studies should address the involvement of other cytokines that might be acting in 
concert with IL-6 to regulate alloreactive effector CD8 T cell function. Multiplex 
cytokine assays would reveal differences in cytokines not investigated in this 
study. The finding that IL-6 can suppress CD8 T cell function brings to the 
forefront the pleiotropic nature of this cytokine. ‘Classical’ IL-6 signaling occurs in 
cells that express membrane-bound IL-6R subunit along with gp130. IL-6 can 
bind soluble IL-6Rα and signal into gp130 expressing cells in a process termed 
‘trans signaling’. The signaling subunit gp130 is shared with membrane-bound 
receptors for other cytokines such as IL-11, IL-27, LIF (leukemia inhibitory 




1 (cardiotrophin-1) and OSM (oncostatin M) (Jones et al., 2011). The anti-IL-6R 
antibody tocilizumab for rheumatoid arthritis inhibits both modes of signaling (Kim 
et al., 2015). The general consensus in the IL-6 field appears to be that classical 
signaling regulates homeostatic or regenerative properties of this cytokine 
whereas trans-signaling drives its pro-inflammatory activities (Hunter and Jones, 
2015). A recent study showed that a subset of naïve CD8 T cells expresses 
membrane-bound IL-6Rα and in vitro TCR activation in the presence of 
exogenous IL-6 differentiates CD8 T cells to effector cells that produce less IFN-γ 
and more IL-21 (Yang et al., 2016). This in vitro study suggests that IL-6 
mediated suppression of IFN-γ production by CD8 T cells is a result of classical 
IL-6 signaling. However, both modes of IL-6 signaling will occur in vivo in naïve 
CD8 T cells because of the presence of soluble IL-6Rα (sIL-6Rα) in addition to 
the membrane-bound form. To determine which of the modes of IL-6 signaling is 
responsible for suppressing CD8 T cell function in vivo, reagents that selectively 
block classical vs trans-signaling should be used. A natural soluble form of gp130 
(sgp130) binds the IL-6/sIL-6Rα complex and selectively inhibits trans-signaling. 
Recombinant sgp130-Fc fusion protein has been used in several studies to 
delineate the role of trans-signaling in inflammation (Jones et al., 2011). 
Likewise, antibodies selectively targeting sIL-6Rα have been generated (Lissilaa 
et al., 2010). Another interesting finding by Yang et al. is that TCR activation 
downregulates IL-6Rα expression on CD8 T cell surface within 24 hours. In an in 




classical signaling. This raises an interesting question: if IL-6 is encountered 
during the effector phase of the CD8 T cell response, will it affect CD8 T cell 
function and in what manner? 
 The finding that TLR4 induced IL-6 can suppress CD8 T cell function has 
vast implications. TLR4 is expressed on tumors from a wide variety of tissues 
(Huang et al., 2005). Endogenous TLR4 ligands released by tumor cells (Huang 
et al., 2008) may activate TLR4 signaling triggering secretion of IL-6 by tumors. 
Indeed, IL-6 is a component of microenvironments of many tumors. Also STAT3 
is found to be constitutively activated in tumors and tumor infiltrating immune 
cells and contributes to immunosuppression (Yu et al., 2007). It is possible that 
IL-6 signaling into tumor infiltrating CD8 T cells inhibits their function contributing 
to immune evasion by the tumor. TLR4 signaling is thus a double-edged sword. 
While TLR4 agonists such as MPLA (monophosphoryl lipid A) are used as 
vaccine adjuvants because of their ability to enhance costimulation and cytokine 
production, my data adds to the body of literature showing that TLR4 signaling 
can be immunosuppressive.   
 In Chapter V, I found that transgenic expression of human SCF, 
GM-CSF and IL-3 in humanized NSG mice improved B cell maturation and 
facilitated generation of dengue antigen-specific antibody responses. Future 
studies should investigate the mechanisms by which these cytokines promote B 
cell maturation.  Plasma levels of the B cell maturation factor BAFF in these mice 




responses to human-specific viruses. In the future, supplementation of 
humanized mice with human ‘survival cytokines’ like BAFF and IL-7 by 
hydrodynamic injection or transgene expression might be a positive step in 
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